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β- and γ- thiol analogs into native amino acids after ligation in the presence of thioamides. We further
demonstrated that selective deselenization could be achieved in the presence of both Cys residues and
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Cys. Finally, we showed that hemiselenide protected selenocysteines (Sec) can be incorporated onto the
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handles. Further developments are underway in our laboratory to expand the AaT substrate scope for β- and
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thioamide probes into full-length protein, which enabled the application of this minimalist probe in protein
misfolding studies.
Degree Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Graduate Group
Chemistry
First Advisor
E. James Petersson
Keywords
Chemical biology, Parkinson's disease, Protein engineering, Protein semi-synthesis, Synuclein, Thioamide
Subject Categories
Biochemistry | Chemistry
This dissertation is available at ScholarlyCommons: http://repository.upenn.edu/edissertations/2082
 
 
CHEMICAL MODIFICATION METHODS FOR  
PROTEIN MISFOLDING STUDIES  
 
 
Yanxin Wang 
A DISSERTATION 
in 
Chemistry 
Presented to the Faculties of the University of Pennsylvania 
in 
Partial Fulfillment of the Requirements for the 
Degree of Doctor of Philosophy 
2015 
 
Supervisor of Dissertation 
________________________ 
E. James Petersson 
Associate Professor of Chemistry 
 
Graduate Group Chairperson 
________________________ 
Gary A. Molander, Hirschmann-Makineni Professor of Chemistry 
 
Dissertation Committee 
Tobias Baumgart, Associate Professor of Chemistry 
Donna Huryn, Adjunct Professor of Chemistry 
Jeffery G. Saven, Professor of Chemistry 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHEMICAL MODIFICATION METHODS FOR PROTEIN MISFOLDING STUDIES  
COPYRIGHT 
2015 
Yanxin Wang 
iii 
 
 
 
 
 
 
 
 
 
For my parents and mentors 
 
 
 
 
 
 
 
 
 
 
 
  
iv 
 
ACKNOWLEDGMENT 
 
First and foremost, I would like to thank Professor E. James Petersson for allowing 
me to join his laboratory and for his generous guidance throughout my graduate career. 
He has been a very knowledgeable and supportive mentor, who introduced me to the field 
of chemical biology and helped me develop my professional skills as a scientist. He gave 
me much freedom in intellectual exploration, while always making himself available for 
feedback and discussions. I would not have been where I am without his support. I would 
also like to thank my dissertation committee members − Professors Tobias Baumgart, 
Donna Huryn and Jeffery G. Saven – for consistently providing useful suggestions and 
fresh perspectives that helped me improve my research. 
 
I am fortunate to have worked with the many members and alumni of the Petersson 
group, who have been great colleagues, collaborators, and friends: Dr. Tomohiro Tanaka, 
Dr. Yun Huang, Dr. Conor Haney, Dr. Jacob Goldberg, Dr. Anne Wagner, Dr. John 
Warner, Dr. Lee Speight, Dr. Solongo Batjargal, Dr. Rebecca Wissner, Mark Fegley, 
Christopher Walters, X. Stella Chen, John J. Ferrie, D. Miklos Szantai-Kis, Itthipol Sung-
weinwong, Christina Cleveland, J. M. Vicky Jun, Eileen Moison, Colin Fadzen, Anand 
Muthusamy, E. Keith Keenan, Eileen Hoang, and Jimin Yoon. We worked together to 
keep the instruments functional, the supplies well-stocked, and the everyday life exciting. 
I am particularly appreciative of Dr. Jacob Goldberg, Dr. Anne Wagner and Dr. Solongo 
Batjargal for their invaluable inputs on my research, and for getting me started in the lab. 
v 
 
I owe my gratitude for the many people in and outside the department for helping me 
obtain good quality data and for maintaining a care-free research environment: Dr. 
Rakesh Kohli for mass spectrometry, Dr. George Furst and Dr. Jun Gu for NMR 
spectroscopy, Dr. Patrick Carroll for X-ray crystallography, Dr. Christopher Lanci for 
biological chemistry instrumentation, Dr. Dewight Williams for electron microscopy, Dr. 
Dustin Covell for cell culture, Judith N. Currano for the numerous times that she helped 
me find references and information, Mandy Swope and Kristen Muscat for watching my 
back on administrative business, and all other staff of the chemistry department. 
 
Finally, I would like to express my sincere appreciation for my family and friends. 
With me being the only child, my parents made tremendous sacrifices by allowing me to 
study here half way across the globe for five years. I owe my achievements and growth to 
their continuous inspiration, cultivation and unconditional support. I am also thankful for 
having a group of caring and supportive friends; we had much fun together and helped 
each other maintain our sanity in graduate school. 
 
  
vi 
 
ABSTRACT 
 
CHEMICAL MODIFICATION METHODS FOR PROTEIN MISFOLDING STUDIES  
Yanxin Wang 
E. James Petersson 
 
Protein misfolding is the basis of various human diseases, including Parkinson’s 
disease, Alzheimer’s disease and Type 2 diabetes.  When a protein misfolds, it adopts the 
wrong three dimensional structures that are dysfunctional and sometime pathological. 
Little structural details are known about this misfolding phenomenon due to the lack of 
characterization tools. Our group previously demonstrated that a thioamide, a single atom 
substitution of the peptide bond, could serve as a minimalist fluorescence quencher. In 
the current study, we showed the development of protein semi-synthesis strategies for the 
incorporation of thioamides into full-length proteins for misfolding studies.  
 
We adopted the native chemical ligation (NCL) method between a C-terminal 
thioester fragment and an N-terminal Cys fragment. We first devised strategies for the 
synthesis of thioamide-containing peptide thioesters as NCL substrates, and demonstrated 
their applications in generating a thioamide/Trp-dually labeled α-synuclein (αS), which 
was subsequently used in a proof-of-concept misfolding study. To remove the constraint 
of a Cys at the ligation site, we explored traceless ligation methods that desulfurized Cys 
into Ala, or β- and γ- thiol analogs into native amino acids after ligation in the presence 
of thioamides. We further demonstrated that selective deselenization could be achieved in 
vii 
 
the presence of both Cys residues and thioamides, expanding the scope of thioamide 
incorporation through traceless ligation to proteins with native Cys. Finally, we showed 
that hemiselenide protected selenocysteines (Sec) can be incorporated onto the protein N-
terminus through chemoenzymatic modification by aminoacyl transferase (AaT) as 
ligation handles. Further developments are underway in our laboratory to expand the AaT 
substrate scope for β- and γ- thiol amino acid analogs. In summary, we developed a set of 
methods that allowed the incorporation of thioamide probes into full-length protein, 
which enabled the application of this minimalist probe in protein misfolding studies. 
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Chapter 1 .  Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of the content in this chapter was originally published in Organic & Biomolecular Chemistry. It is 
adapted here with permission from the publisher: 
 
Reprinted and adapted with permission from Wang, Y. J.; Szantai-Kis, D. M.; Petersson, E. J., Semi-
Synthesis of Thioamide Containing Proteins. Org. Biomol. Chem. 2015, 13, 5074−5081. Copyright 2015 
Royal Society of Chemistry. 
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1.1  Protein Misfolding and Human Diseases 
Protein Misfolding    Proteins are an important class of biological macromolecules, 
and key building blocks of life
1
. They are responsible for the majority of cellular 
activities in living organisms, from maintaining cell morphology and catalyzing 
metabolic reactions, to signaling and homeostasis
2
. All proteins are constructed from a 
simple scaffold of linear chains of amino acids that are joined together through peptide 
bonds
3. The classic view − as represented by the “central dogma”4 and the Anfinsen 
hypothesis
5
 − states that the structures and functions of proteins are largely encoded by 
their amino acid sequences; a defined sequence is transcribed from genetic information 
stored in DNA into RNA, which is in turn translated into a protein that folds into a 
defined three-dimensional structure to serve a set of defined biological functions. 
 
With the emergence of the “energy landscape” theory for protein folding6 and 
empirical characterization of protein dynamics
7,8,9
, we now understand that proteins may 
assume a variety of conformations and that the amino acid sequence per se is not suffi-
cient to determine its three-dimensional structure. For many proteins, their biologically 
active conformations are not the “global energy minimum”, but rather a “local energy 
minimum” that is either stabilized by a binding partner or trapped by kinetic barriers to 
the next available conformation (Figure 1-1)
10
. As proteins sample various energy 
minima on their folding energy landscapes, they can also “misfold” into wrong 
conformations that are dysfunctional and sometimes pathological. In our laboratory, we 
strive to construct chemical tools for the characterization of this misfolding phenomenon.  
3 
 
 
Figure 1-1.  A Unified View of Protein Folding and Misfolding. 
Various folding states on a protein energy landscape. Graphics adapted from Stefani
10
. 
 
Protein Misfolding Diseases    Protein misfolding is of great significance to human 
health, particularly in the context of aging-associated diseases. The majority of “degene-
rative diseases” (including Alzheimer’s disease (AD), Parkinson’s disease (PD) and Type 
2 diabetes) involve toxic loss-of-function or gain-of-function in particular tissues, which 
at the molecular level, can be attributed to protein misfolding
11,12,13
. Table 1-1 
summarizes some of the most well-studied protein misfolding diseases
14,15
; it is worth-
noting that many of these diseases are sporadic rather than hereditary – the misfolded 
protein originates from a normally folded, functional protein that becomes pathological 
(or accumulates to a critical amount that overwhelms the cell’s ability to clear misfolded 
proteins) at the onset of the disease
16
. The accumulation of misfolded proteins leads to a 
4 
 
variety of consequences such as oxidative stress and cell deformation, which ultimately 
results in cell death and thus the “degenerative” symptoms (Figure 1-2)14. 
 
Table 1-1.  Selected Protein Misfolding Diseases in Human. 
Human Disease Associated Protein(s) Affected Tissue 
   
Neurodegenerative Diseases   
Alzheimer’s disease (AD) Amyloid β, tau Brain 
Parkinson’s disease (PD) α-Synuclein, tau Brain 
Lewy-body dementia (DLB) α-Synuclein Brain 
Huntington’s disease (HD) Hungtintin Brain 
Frontotemporal dementia (FTD) Tau Brain 
Amyotrophic lateral sclerosis (ALS) Superoxide dismutase 1 Brain 
   
Other Aging-Related Diseases   
Primary systemic amyloidosis (PSA) Ig light chain Systemic 
Senile systemic amyloidosis (SSA) Transthyretin Microvasculature 
Atherosclerosis Low-density lipoprotein (LDL) Arteries 
Cataract Crystallin Eye 
Type 2 diabetes (T2D) Amylin Pancreas 
   
* Adapted from Christensen et al.
14
 and Gebbink et al.
15
 
 
 
Figure 1-2.  Cellular Consequences of Pathological Protein Misfolding. 
Graphics adapted from Christensen et al.
14
 
5 
 
At the molecular level, the most common type of pathological protein misfolding is 
aggregation – in particular, the transformation of a natively folded or unfolded protein 
into β-sheet rich aggregates known as “amyloids”17. Due to the nature of the β-sheet 
secondary structure, these aggregates have unsatisfied backbone hydrogen bond donors 
and acceptors on either ends of the β-sheets, and have a tendency to propagate by 
recruiting additional proteins and templating their folding into β-sheets (Figure 1-3)15,18. 
Once a small population of misfolded monomers and/or oligomers is formed, a vicious 
self-propagation cycle is initiated
18
. Additionally, amyloids are more resistant to 
proteolytic degradation than their natively folded or unfolded counterparts
19
, making it 
difficult to reverse the misfolding. This amyloidosis phenomenon is the basis for many of 
the most infamous aging-related diseases, including AD and PD
12,18
.  
 
Figure 1-3.  Generalized Scheme: the Molecular Basis of Amyloid Formation. 
Graphics adapted from Gebbink et al.
15
 
 
α-Synuclein (αS) Misfolding and Parkinson’s Disease    PD is the second most 
common neurodegenerative disorder that affects approximately 7 million people 
worldwide
20
. It was first described by British doctor James Parkinson in 1817 as a 
6 
 
“shaking palsy”21, and later fully characterized as a progressive degenerative disorder 
with motor impairments as the initial symptoms
22
. The physiological basis of PD was 
discovered in the 1960s, where loss of dopaminergic neurons in the substantia nigra were 
observed by post-mortem analyses of PD patients, leading to the introduction of levodopa 
as a dopamine supplement (which is still the “gold standard” for PD treatment today)23. 
In 1912, Lewy body inclusions were found as the “pathological hallmark” of PD24; in 
1997, αS was characterized as the major component of Lewy body inclusions, and the 
first familial PD mutation A53T was identified.
25
 Since its initial discovery, the central 
role of αS in PD pathogenesis has been extensively studied – currently, the extent of 
“synucleopathy” is commonly recognized as the most important parameter for PD 
diagnosis and disease stage classification
26,27
. 
 
αS is a 140 residue protein that is abundantly expressed in pre-synaptic terminals, and 
is estimated to “comprise 1% of total cytosolic proteins in the brain”28. Its physiological 
function has not been fully characterized, but current evidences suggest that it is involved 
in synaptic transmission
29
 – in one study, fluorescently labeled αS was observed to 
dissociate from synaptic vesicles upon neuronal firing, and then gradually re-associate 
with newly formed vesicles during resting
30. The sequence of αS consists of three 
different regions (Figure 1-4) – an N-terminal region (residues 1−60) that contains seven 
imperfect repeats of lipid-binding KTKEGV motifs and confers α-helical propensity, a 
central hydrophobic region (residues 61−95) known as the non-amyloid β component 
(NAC) domain that has β-sheet formation potential, and a highly acidic C-terminal region 
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(residues 96-140) that is largely disordered under physiological pH
31
. Known mutations 
that result in early onset of PD include A30P
32
, E46K
33
, H50Q
34
, G51D
35
 and A53T
25
. 
 
 
Figure 1-4.  Amino Acid Sequence of Human αS. 
Graphics adapted from Lee et al.
31
 
 
αS can adopt three distinct types of structures depending on its environment − it is α-
helical when bound to micelles or vesicles
36
, disordered when in aqueous solution
37
, and 
β-sheet rich during in vitro or in vivo aggregation38. In its micelle bound form, αS adopts 
a well-defined helical structure that has been characterized by both nuclear magnetic 
resonance (NMR) spectroscopy and electron paramagnetic resonance (EPR) spectrscopy, 
where two helices (residues 1−41 and 45−94) and a disordered C-terminal region were 
observed (Figure 1-5)
36,39
. When bound of unilamellar vesicles, the two helices has been 
shown to stretch into an extended helical conformation in response to membrane 
curvature by single molecule Förster resonance energy transfer (smFRET) studies from 
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the Rhoades group
40. Additional studies using truncated αS fragments determined that the 
first 25 residues in the N-terminal domain were most crucial for membrane binding
41
.  
 
 
Figure 1-5.  Membrane Bound Structure of αS as Determined by NMR (PDB 1XQ8)
36
. 
 
In comparison, the structures of lipid-free αS monomer and fibrils are not nearly as 
defined. αS monomers are largely unstructured as determined by circular dichroism 
spectroscopy (CD) and Fourier transform infrared spectroscopy (FT-IR)
37. However, αS 
does exhibit some level of compaction as evidenced by the smaller radius of gyration 
than that expected of a fully unfolded conformation (40 vs. 55 Å)
42
. Other studies also 
suggested the potential for transient tertiary contacts between the N- and C-terminal 
regions, which were postulated to be protective against αS aggregation.43,44,45  
 
The overall morphology of αS fibrils has been well-documented, but their molecular 
details are poorly understood. Transmission electron microscopy (TEM) studies showed 
that both patient-derived and in vitro aggregated αS fibrils exhibited long, unbranched 
morphology with a uniform width of 5−10 nm46,38; two fibril strands may further 
assemble into “mature fibrils” with a straight or twisted orientation47. At the molecular 
level, various secondary structure assignments have been proposed by different group 
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using NMR methods, but a clear three-dimensional structure model has yet to be 
constructed (Figure 1-6)
47,48,49,50
. Recently, Eisenberg et al. used an innovative micro-
electron diffraction method and obtained structures of fibrillized αS-derived peptides.51  
 
 
 
Figure 1-6.  Proposed Secondary Structures for αS Fibrils. 
Graphics adapted from Bennati et al.
52
 
 
In terms of the αS aggregation process where monomers convert into pathological 
fibrils, even fewer structural details are known. Most studies of αS aggregation were 
based on global monitoring of the “extent of aggregation”, where fibril-binding dyes or 
band intensities on SDS-PAGE gels were used to quantify monomer/fibril concen-
trations
46,53
. The most commonly used dye is thioflavin T (ThT) – it consists of two 
aromatic rings, and exhibits turn-on fluorescence when the relative rotations of the two 
rings are restricted, preventing, internal charge transfer, as it binds to hydrophobic 
surfaces on amyloid fibrils
54
. Data from these crude global monitoring methods revealed 
that αS aggregation was a nucleation-elongation process: it exhibits a lag phase that 
10 
 
corresponds to the formation of nuclei, followed by a rapid growth phase where β-sheet 
propagation takes place (Figure 1-7)
55,28
. Additional studies showed the significance of 
seeding and fibril fragmentation, which could significantly accelerate aggregation
56,57
. 
The aggregation process is also dependent on salts and buffer conditions
58
, and most 
intriguingly, it was found that dopamine itself may interact with αS oligomers/fibrils and 
contribute to their cytotoxicity
59,60,61
 – the current standard of care with levodopa may 
actually exacerbate PD progression, while temporarily compensating for the diminished 
neuronal function
62
.  
 
 
Figure 1-7.  αS Aggregation Process as Characterized by Thioflavin T (ThT) Monitoring. 
Graphics adapted from Jucker et al.
18
 
 
Last but not least, αS fibrils were found to transmit from cell to cell, and propagate in 
the brain in a “spatiotemporal manner”63,64,65. In particular, two conformational “strains” 
of αS fibrils were identified, where strain B evolved from strain A after 6~7 rounds of 
fibril propagation and gained the ability to cross-seed tau aggregation,
 
without exhibiting 
11 
 
much difference in conventional CD or FT-IR characterizations
66
.
 
To date, neither the 
structures nor the formation processes of these strains are known. 
 
Challenges in Protein Misfolding Studies    Obtaining clear structural information 
on protein misfolding is extremely challenging because of the polymorphism, or hetero-
geneity, in amyloid structures and formation processes
48,67
. As summarized in Eisenberg 
et al.
53
, there are eight possible structure elements in β-sheet rich aggregates, depending 
on the parallel/antiparallel nature within one β-sheet and the relative orientations of 
different layers of β-sheets (Figure 1-8). For most misfolded proteins such as αS, there 
are multiple β-strand segments in the sequences, giving rise to various possible combina-
tions of the structural elements, and thus different fibril conformations
 
(see Figure 1-6). 
Therefore, it is very difficult to determine fibril structures by conventional structural 
biology methods such as X-ray crystallography and NMR spectroscopy, which frequently 
require the preparation of a homogenous material
68
.  
 
In comparison, fluorescence spectroscopy, particularly single molecule fluorescence 
spectroscopy, is a much more powerful tool in the context of protein misfolding studies
69
: 
1) it has nanosecond temporal resolution, and can be conducted in real time to capture the 
dynamic conformational changes in the aggregation process; 2) using Förster resonance 
energy transfer (FRET, see next section) between a fluorescence donor and an acceptor/ 
quencher, the distance between the two labels can be accurately extrapolated, yielding 
structural information about aggregation intermediates and the final fibrils; 3) in addition 
to the most common steady state fluorescence intensity measurements, one could also 
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utilize florescence life-time measurements, fluorescence correlation spectroscopy (FCS), 
fluorescence anisotropy, and fluorescence imaging techniques to obtain in vitro and in 
vivo properties of the target protein at various stages of aggregation; 4) it is amenable to 
single molecule measurements, where a heterogeneous ensemble of conformations can be 
each accounted for as distinct populations in fluorescence spectroscopy. In fact, some of 
the most useful information about αS monomers and oligomers were obtained through 
single molecule fluorescence studies
70,71
.  
 
 
Figure 1-8.  Structural Elements of β-Sheet Rich Fibrils. 
Adapted from Eisenberg et al.
53
 and Gebbink et al.
15
 
 
Our challenge was to identify and incorporate the appropriate chromophores to 
realize our vision of characterizing the molecular details behind the protein misfolding 
phenomenon using fluorescence spectroscopy (we use the term “chromophore” to include 
both fluorophores and quenchers). In addition to the photophysics and stability require-
13 
 
ments, our chosen chromophores must also be amenable to positional scanning, i.e. it 
should be minimally perturbing when incorporated at any desired position, including the 
β-sheet rich fibril core. Traditional chromophores such as fluorescent proteins (FPs) and 
organic fluorophores/quenchers are too bulky for such applications
72
. Therefore, our 
group set out to investigate a novel fluorescence quencher, a thioamide. 
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1.2  Thioamides as a Minimalist Probes 
Properties of the Thioamide Bond    A thioamide is a single-atom substitution of 
the standard amide functional group (herein referred to as “oxoamide”), where the 
carbonyl oxygen is replaced with a sulfur. It is nearly isosteric to the amide group, while 
exhibiting different physical and chemical properties (Table 1-2)
73,74
. The sulfur atom is 
slightly larger than the oxygen atom (van der Waals radii 1.85 Å vs. 1.40 Å)
75
, and the 
C=S bond is slightly longer than the C=O bond (1.71 Å vs. 1.23 Å)
76
. Due to the 
additional electron shell in sulfur vs. oxygen, the overlap is less strong with carbon 2sp
2
 
and 2p orbitals, therefore the C=S bond is weaker than the C=O bond (average bond 
energy 130 kcal/mol vs. 170 kcal/mol)
77
 and more polar (5.07 D vs. 3.79 D)
78
. The 
rotation energy barrier for thioamide cis-trans isomerization is greater that of oxoamides 
(22−25 kcal/mol vs. 20 kcal/mol) due to “a considerable transfer of charge density from 
N to S” that elevates energies of the transition states as characterized by Wiberg,79 which 
is also reflective of the less electronegative nature of sulfur than oxygen (2.58 vs 3.44)
80
.  
 
Thioamides are stronger hydrogen bond donors than oxoamides, but weaker 
acceptors. Based on experimental studies
81,82
 and theoretical modeling
83
 from various 
groups, the C=S ∙∙∙ H−N hydrogen bond has been characterized as 0.6 Å longer and 2 
kcal/mol weaker than its oxoamide counterpart, due to the larger van der Waals radius of 
sulfur, as well as the less effective orbital overlap between the sulfur 3sp
2
 orbital (as 
compared to the 2sp
2
 orbital of oxygen) and the hydrogen 1s orbital. In contrast, the 
CSN−H ∙∙∙ O=C bond is approximately 1 kcal/mol more favorable, due to more polarized 
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N−H bond in the thioamide, which is also reflected in its lower pKa (18.5 vs. 25.5).
84
 In 
addition, the presence of a sulfur atom gives the thioamide higher nucleophilicity
85
 as 
well as greater affinity for soft metals
86
 in terms of chemical reactivity. 
 
Of particular interest to our group is the π–π* absorption and oxidation potential of 
thioamides. The thioamide absorption is red-shifted as compared to that of an oxoamide 
(270 nm vs. 200 nm)
87
, allowing the selective excitation of thioamide in a background of 
oxoamides. Similarly, a thioamide is easier to oxidize than an oxoamide (1.21 V vs. 3.29 
V)
84
, allowing the specific oxidation of thioamide when the reduction potential of the 
electron acceptor is carefully controlled. The exact photophysical applications of these 
properties will be discussed in later sections. In early studies of thioamide-containing 
peptides, the stability of the thioamide group in aqueous buffer was well-established.
88,89
  
Overall, thioamides are excellent isosteric replacements for the natural oxoamides in 
peptides and proteins, where one could leverage their unique chemical and physical 
properties without major concerns on steric perturbation or stability. 
  
Table 1-2.  Selected Properties of Thioamides. 
Property Oxo Thio 
Van der Waals radius (Å)  1.40 1.85 
C=X bond length (Å)  1.23 1.71 
Electronegativity 3.44 2.58 
C=X∙∙∙H–N bond dissociation energy (kcal mol-1)  6.1 4.8 
π–π* absorption (nm)  200 270 
EOx (V vs. S.H.E.)  3.29 1.21 
* S.H.E. = Standard hydrogen electrode 
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Thioamides in Nature and in Medicinal Chemistry    In nature, thioamides are 
found in small molecules and at least one folded protein. To our knowledge, there are 
five natural products with thioamide bonds, namely cycasthioamide from the seeds of 
Cycas revoluta
90
, (4-methoxyphenyl)-N-methyl-2-oxothioacetamide from Polycarpa 
aurata
91
, apo-methanobactin from Methylosinus trichosporium
92
, thioviridamide from 
Streptomyces olivoviridis
93
, and closthioamide from Clostridium cellulolyticum
94
. Among 
these compounds, closthioamide has been most thoroughly characterized (Figure 1-9)
94,95
 
– it has six thioamide bonds and exhibits strong antibiotic activity against S. aureus; the 
compound was fully inactive when all thioamides were substituted with oxoamides, and a 
significant reduction in potency was observed even with a single thio-to-oxo substitution. 
A recent study showed that the biological activity of closthioamide was related to its 
copper binding ability, which explained the importance of the thioamides
96
. The only 
known protein with a thioamide bond is methyl-coenzyme M reductase, an enzyme 
involved in archeal methane formation
97
. It was shown to possess a thioglycine residue 
near its active site by X-ray crystallography and mass spectrometry, which presumably 
facilitates the oxidation and reduction of cofactor and substrate.  
 
 
Figure 1-9.  Chemical Structure of Closthioamide. 
 
17 
 
In medicinal chemistry, thioamides are frequently used as an amide bond derivative 
for structure-activity relationship (SAR) studies of natural products; they may also be 
subsequently derivatized into thiazoles, thiazolines, thiazines, or amidines to expand the 
candidate library
98
. Representative examples include thioamide derivatization of oxytocin 
by du Vigneaud and coworkers
99
, of leucine enkephalin by Lawesson and colleagues
100
, 
and of vancomycin by the Boger group
101
. Interestingly, in the case of leucine enke-
phalin, thioamide substitution at Tyr1 completely eliminated its biological activity, while 
substitution at Gly2 enhanced its activity by 3−14 fold100. There are several approved 
drugs that contain thioamides, the most notable of which is 6-n-propyl-2-thiouracil (PTU) 
that derives its anti-hyperthyroidism activity from the thioamide moiety
102
. 
 
Early Applications of Thioamides in Peptides and Proteins    An early example for 
applying thioamides to studying peptides and proteins was a carboxypeptidase A kinetic 
analysis, where thioamide-modified short peptide substrates were evaluated for their 
enzymatic activity.
103
 With a thioalanine or thiophenylalanine (Ala
S
 or Phe
S
; we use a 
superscript “S” to denote thioamide-containing residues) at the scissile bond, the authors 
demonstrated that thioamides can function as effective substrates. More interestingly, 
utilizing the affinity of sulfur to soft metals, they were able to identify cadmium as a 
more effective metal cofactor as compared to the native zinc, where the kcat/Km was 2.4–
9.7 fold higher for the Cd(II) carboxypeptidase than for the Zn(II) carboxypeptidase 
when thioamide-containing peptides were used as substrates. 
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More recently, Raines et al. have utilized the differences in the electronic properties 
of C=S and C=O bonds to study the n-π* interactions between two adjacent peptide 
bonds.
104
 The n-π* interaction is characterized as the donation of one of the non-bonding 
lone pairs (n) of a carbonyl into the antibonding orbital (π*) of an adjacent carbonyl. 
Since sulfur is a better electron donor, the n-π* interaction is proved to be stronger for 
thioamides (Figure 1-10). Based on these data, the authors argued that n-π* interactions 
were a protein stabilizing force that were complimentary to hydrogen bonds
105
. 
 
       
Figure 1-10.  Strength of n-π* Interactions as Measured in cis-trans Equilibrium
106
. 
 
Several direct studies on the effects of thioamides in protein secondary structures 
have also been conducted, where thioamides were incorporated into different model 
peptides for conformational studies. Reiner et al. incorporated a thioamide near the N-
terminus of an α-helical peptide, and demonstrated its structural similarity to the 
oxoamide peptide using NMR spectroscopy, as well as a 1.6 kcal/mol stabilization to the 
oxopeptide
88
. Miwa et al. conducted a similar study with a thioamide near the C-terminus 
of a model α-helical peptide, and reached the same conclusion that the thiopeptide 
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exhibited a nearly identical structure to the oxopeptide
89
. The same group also tested the 
compatibility of thioamides with β-sheets, by incorporating a thioglycine (GlyS) at the β-
turn in a β-hairpin model peptide, and showed structural compatibility107. As a follow-up, 
Culik et al. incorporated thioamides into other positions in a β-hairpin tryptophan zipper, 
and showed that the substitution was well-tolerated except when it was placed directly 
next to the β-turn108. Most recently, Raines et al. incorporated thioamides into the 
collagen triple helix and observed minimal perturbation to its structural stability; in fact, 
the authors noted that the thioamide was “the first in the collagen backbone that does not 
compromise thermostability”109. These studies showed that while thioamides may subtly 
affect folding pathways, they are generally well-tolerated in these secondary structures.  
 
Thioamide as a Minimalist Fluorescence Quencher    Thioamides are particularly 
appealing modifications for our vision of using a “minimalist” chromophore to monitor 
protein misfolding. With the abundance of peptide bonds and side chain oxoamides in 
peptides and proteins, one could envision placing thioamides at any residue along the 
protein sequence as probes for mechanistic and/or structural studies. Earlier experiments 
showed that thioamides exhibit unique
 
circular dichroism signature around 272 nm
89
 and 
can be selectively photo-isomerized
110
 in a background of oxoamides. In our own group, 
we have extensively explored the utility of thioamides as fluorescence quenchers through 
FRET or photo-induced electron transfer (PET). 
 
FRET is a non-radiative energy transfer phenomenon, where the excited state of a 
donor fluorophore transfers its energy to a ground state acceptor fluorophore; as a result 
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of this process, the donor will relax back to ground state, while the acceptor enters an 
excited state and subsequently relaxes back either through release of a photon or through 
thermal or collisional relaxation (see Figure 1-11)
69
. The energy transfer efficiency (EQ) 
is distance dependent, and can be described by the following equations: 
𝐸Q =
1
1 + (
𝑅
𝑅0
)
6 = 1 −
𝐹
𝐹0
 
𝑅0
6 =
9000(𝑙𝑛10)𝜅2Φ𝐷𝐽
128𝜋5𝑛4𝑁𝐴
 
where R is the distance between acceptor and donor fluorophores, and R0 is the 
Förster distance at which the transfer efficiency is 50%. R0 can be experimentally 
determined from EQ or theoretically calculated – experimentally, EQ can be measured 
from donor fluorescence in the presence (F) or absence (F0) of the acceptor chromophore, 
and fitted to the Förster equation; theoretically, the parameters needed include the 
spectral overlap integral between donor emission and acceptor absorption (J), an 
orientation factor to describe the interaction of the transition dipoles of the donor and the 
acceptor (κ2), the quantum yield of the donor (ΦD), index of refraction of the solvent (n), 
and Avogadro’s number (NA). 
 
UV wavelength dyes, such as p-cyanophenylalanine (Cnf) and the natural amino acid 
Tyr, are quenched by thioamides through a FRET mechanism, where the emission spectra 
of these chromophores exhibit overlap with the absorption spectra of thioamides. 
111,112
 
Using rigid “polyproline rulers”, we determined the empirical Föster distances (R0) to be 
16.5 Å for Cnf, and 16.2 Å for Tyr (Figure 1-11). These R0 values translate for an 
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effective monitoring distance of 10−25 Å (where EQ is approximately between 10% and 
90%), a very useful scale to monitor protein conformational changes at the secondary or 
tertiary structure level, as well as tight protein-protein binding interactions. As proof-of-
concept examples, we also demonstrated the application of the Cnf-thioamide 
fluorophore-quencher pair to monitoring thermal denaturation of a 35-residue model 
peptide through intramolecular quenching
111
, and the utilization of the Tyr-thioamide pair 
in quantifying protein-peptide binding through intermolecular quenching
112
. 
 
                
Figure 1-11.  Thioamide Quenching of Fluorescence through FRET. 
Left: distance dependent quenching as measured by “proline ruler”. Right: Jablonski diagram 
showing the FRET process. Graphics adapted from Goldberg et al.
111-112
 and Olympus Inc. 
 
PET is also a distance-dependent non-radiative energy transfer phenomenon, but is 
achieved through electron transfers between the excited state donor and the ground state 
acceptor chromophore
69
. For two chromophores to be a PET pair, they must have 
matching oxidation/reduction potentials, and be present in sufficient proximity to enable 
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the physical transfer of an electron. PET favorability can be determined by the Gibbs free 
energy in the Rehm-Weller model
113
 with the following equation: 
Δ𝐺𝐸𝑇 = 𝐹[𝐸𝑜𝑥(𝐷) − 𝐸𝑟𝑒𝑑(𝐴) − 𝐸0,0] + 𝐶 
where F is the Faraday constant; Eox(D) and Ered(A) are the fround state oxidation and 
reduction potentials of the electron donor and acceptor (the fluorescence donor can be 
either the electron donor or the electron acceptor), respectively; E0,0 is the zero 
vibrational electronic excitation energy of the fluorophore, calculated as the average 
energy of the absorption and emission; and C is a term for Coulombic interactions that 
are typically assumed to be negligible in aqueous solutions. In the case of fluorescence 
quenching by a thioamide, the fluorophore is typically the electron acceptor, and the 
thioamide is the electron donor. With an oxidation potential of 1.21 V (vs. S.H.E.), 
thioamides were found to quench a number of near UV and visible wavelength 
fluorophores (Figure 1-12), including commonly used dyes such as Alexa Fluor 488 
(ΔGET = - 0.86 eV) and BODIPY FL (ΔGET = - 0.37 eV)
114,115
. As a proof-of-concept 
example, we synthesized short peptides that were dually labeled with a fluorophore and a 
thioamide, and showed that they were effective substrates for proteases such as calpain 
both in vitro and in cell lysate
116
. Work is underway in our group to further pursue this 
strategy as a tool to construct minimally-perturbing protease sensors. 
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Figure 1-12.  Thioamide Quenching of Fluorescence through PET. 
Graphic adapted from Goldberg et al.
114,115,116
 and Petersson et al.
74
 
 
In the context of protein misfolding, we envision using thioamide as a minimalist 
label for “protein motion capture” (Figure 1-13). The target protein can be labeled with 
fluorophore-thioamide pairs at various positions, and then fluorescence changes can be 
monitored throughout the aggregation process and in the mature fibrils. The quenching 
efficiencies observed will then be converted into distances, and by combining results 
from various combinations of labeling positions, we can reconstruct the conformational 
24 
 
changes that underlie the misfolding process. The fact that the thioamide is a nearly 
isosteric substitution of the native amide bond is extremely important to the successful 
application of this strategy − we can move the thioamide across the peptide backbone in a 
“positional scanning” manner while keeping the fluorophore at a relatively non-
perturbing position, which would not be possible with any other organic fluorophores or 
fluorescent proteins (FPs). 
 
 
Figure 1-13.  A Conceptual Representation of “Protein Motion Capture”. 
Analogous to motion capture in movie making, proteins can be tagged with fluorophore-
quencher pairs at various positions, and then subject to in vitro or in vivo misfolding. The 
distances between the fluorophore and the quencher can be monitored throughout the 
process by fluorescence quenching; results from all labeling positions can be combined to 
recapitulate the “motions”, or conformational changes, involved in the misfolding process.  
 
 
Thioamide Incorporation into Small Molecules and Peptides    In order to utilize 
the thioamide as a minimalist chromophore, we must first be able to introduce it into the 
peptide or protein of interest. Prior to our work (as shown in Chapters 2 to 4), thioamides 
could only be incorporated into small molecules by solution phase thionation, or into 
short peptides by solid phase peptide synthesis (SPPS).  
25 
 
 
To our knowledge, the first synthetic thioamide-containing compound was prepared 
by Gay-Lussac in 1815 from cyanogen and hydrogen sulfide
117
. In modern organic 
synthesis, thioamides can be prepared from a variety of precursors including amides, 
aldehydes, ketones and isothiocyanates, which has been extensively reviewed by several 
authors
118,119
. The most applicable type of transformation for our studies is the direct 
conversion of an oxoamide into thioamide. The two commonly used reagents are 
phosphorous pentasulfide (P2S5 or P4S10)
120,121
 and Lawesson’s reagent122,123 − both 
reactions involve a concerted sulfur transfer in a Wittig-type intermediate (Figure 1-14). 
P2S5 can be used at lower temperature than Lawesson’s reagent (which typically requires 
reflux for activation), but is also more difficult to remove by flash chromatography
119
.  
 
 
Figure 1-14.  Structures and Mechanisms of Common Thionating Reagents. 
Adapted from Ozturk et al.
120
 and Jesberger et al.
123
 
 
While thionation by P2S5 or Lawesson’s reagent is applicable to short peptides, it will 
indiscriminately convert all oxoamides into thioamides (or in some cases, result in a 
mixture of peptides with various degrees of thionation)
119
.  To site-selectively incorporate 
thioamides into peptides, one would need to adopt SPPS, where a preactivated thioamide 
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precursor is first synthesized and then coupled to the growing peptide chain through 
carbonyl substitution reactions (Figure 1-15). Rapoport et al. pioneered the synthesis of 
N-Boc (Boc = t- butyloxycarbonyl) protected thioamide precursors, where 19 out of the 
20 natural amino acids (except Gly) were successfully prepared
124
. More recently, 
Chatterjee et al. systematically evaluated the preparation of N-Fmoc (Fmoc = 
fluorenylmethyloxy-carbonyl) protected thioamide precursors and their coupling 
conditions, where they synthesized 12 thoiamide precursors for D- and L-amino acids and 
identified CH2Cl2 as the preferred solvent for thioamide coupling in SPPS
125
. In our own 
group, we have successfully prepared 12 thioamide precursors using a similar strategy. 
 
 
Figure 1-15.  General Scheme for Thioamide Incorporation through SPPS. 
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1.3  Protein Semi-Synthesis Methods 
Protein semi-synthesis is the chemoselective condensation of two or more peptides/ 
proteins fragments. It has been a tremendously useful tool in incorporating synthetic 
moieties that would otherwise not be accessible through cellular expression or single-
chain SPPS, for the structural and functional studies of long peptides and full-length 
proteins
126
. In the context of thioamide-containing protein preparation, we will focus on 
methods that result in an amide bond at the ligation junction in the following discussions. 
Overview of other methods − including thioether ligation, oxime ligation, and azide-
alkyne cycloaddition – can be found in a detailed review by Verzele and Madder127. 
 
Native Chemical Ligation (NCL)    NCL was first introduced by Kent et al.
128
 in 
1994, and quickly become the most widely adopted protein semi-synthesis method in the 
last two decades. It utilized two unprotected peptide fragments in aqueous buffer − one 
with a C-terminal thioester, the other with an N-terminal Cys. The thiol side chain of Cys 
first undergoes a transthioesterification with the thioester fragment, and then an S-to-N 
acyl shift takes place to form a native amide bond at the junction (Figure 1-16). The mild 
reaction conditions are compatible with chemically sensitive groups such as glycosylated, 
phosphorylated, or ubiquitinated side chains
129
. The most common applications for NCL 
are
130
: 1) accessing long peptide sequences that are not possible to construct in a single-
chain SPPS; 2) incorporation of unnatural modification into peptides and proteins, that 
would otherwise not be accessible through cellular expression; 3) studying the properties 
and functions of peptides/proteins with natural or unnatural substitutions at specific sites, 
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which would otherwise be obtained as a mixture either in cell extract or through other 
derivatization methods; 4) preparation of cyclized peptides and peptide analogs through 
head-to-tail NCL reactions for activity screening. Even for short peptides that can be 
synthesized directly through SPPS, NCL still offers two levels of benefits: 1) for 
chemically sensitive groups, one could reduce the exposure of the peptide to harsh 
synthesis conditions (e.g. trifluoroacetic acid, or TFA) by synthesizing shorter fragments 
that can be rapidly deprotected; 2) for peptides that are functionalized at more than one 
site, one could use combinatorial synthesis for the efficient generation of peptide 
libraries. A notable example of NCL applications is the total chemical synthesis of αS by 
Lashuel et al. − after establishing the feasibility of αS total synthesis by NCL131, they 
further elucidated the effects of site-specific αS phosphorylation132, ubiquitination133, and 
nitration
134
 on αS aggregation by synthesizing the corresponding “post-translationally” 
modified αS. Another exemplary work was from Muir et al., where they synthesized 
large libraries of modified histones via NCL and studied their biological functions
135
. 
 
 
Figure 1-16.  Mechanism of Native Chemical Ligation (NCL). 
In practice, NCL is frequently catalyzed by thiol additives. A systematic study by Kent et al.
136
 
characterized the reactivity of various thiols, and identified that aromatic thiols such as 4-
mercaptophenylacetic acid (MPAA) as the most effective catalyst.   
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Extended NCL Strategies    Major extensions of the NCL method include tandem 
ligation, expressed protein ligation (EPL) and reverse native chemical ligation. Tandem 
ligation was developed by Kent et al.
137
 using thiazolidine (Thz) as a masked Cys. The 
middle fragment of the target protein was synthesized with an N-terminal Thz and C-
terminal thioester to prevent self-ligation, and then joined to the C-terminal fragment. 
After the first ligation, the Thz group was deprotected using MeONH2∙HCl, and then 
subjected to another round of ligation with the N-terminal fragment. The tandem ligation 
can be repeated to combine more than three fragments, and is frequently used in the 
synthesis of large proteins
135
. 
 
Expressed protein ligation (EPL) takes advantage of naturally-existing inteins to 
generate protein thioesters, and greatly expands the ligation scope − prior to EPL, ligation 
sites were largely restricted to the N-terminal region, as the thioester fragment could only 
be chemically synthesized
130
. An intein is a protein fragment that exhibits self-splicing 
properties – in nature, a protein sequence can be expressed with exteins and inteins 
(similar to the exons and introns of nucleic acids), after which the inteins would self-
excise, leaving just the exteins in the final protein
138
. The process starts with an N-to-S 
acyl transfer at the N-terminal Cys of the intein fragment, followed by a transthio-
esterification that joins the N-terminal extein with the C-terminal extein; the final step is 
the formation of a succinimide at the C-terminus of intein to release the α-nitrogen of the 
C-terminal extein (Figure 1-17)
139
. Muir et al. first reported the use of intein-mediated 
EPL in 1998; without a C-terminal extein, the intein would remain as a thioester and 
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serve as a substrate for subsequent ligation to a synthetic peptide
140
. Additional 
developments using naturally existing
141
 or evolved split inteins
142
 allowed the extension 
of EPL into in vivo systems; for example, a cell surface receptor can be expressed with 
one intein fragment, and then treated with a fluorescent protein fused to the other intein 
fragment, to achieve selective labeling on the cell surface (in comparison, traditional 
fusion protein expression will result in high background fluorescence from mis-trafficked 
proteins in the cytosol)
143
. 
 
 
Figure 1-17.  Intein-Mediate Protein Splicing and Expressed Protein Ligation. 
Picture courtesy of Solongo Batjargal. 
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Finally, reverse native chemical ligation is a similar technique to NCL, but uses a 
thioacid and a side chain alkylhalide as the ligation handles instead. In the first step, a 
thioester is formed by nucleophilic substitution on the alkylhalide, which subsequently 
rearranges through standard S-to-N acyl shift to generate the amide bond, leaving a Cys 
at the junction. Since both ligation handles are not accessible through cellular expression, 
this method is primarily used for conjugating peptides
127
. 
 
Traceless Staudinger Ligation    While NCL is limited to an N-terminal Cys (or 
thiol surrogates as discussed in later sections) as the nucleophile, traceless Staudinger 
ligation has no inherent limit on the N-terminal residue of the C-terminal fragment. 
Developed by Raines and Bertozzi
144,145,146
, it utilizes the well-known Staudinger reaction 
where an azide reacts with a phosphine to form an iminophosphorane. In the first step, a 
phosphinothioester is generated in situ from a thioester; the azide then reacts with the 
phosphine moiety to generate  an iminophosphorane, which then undergoes 
intramolecular carbonyl substitution to form the final product (Figure 1-18). While 
 
 
Figure 1-18.  Traceless Staudinger Ligation. 
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chemically elegant, this method suffers from several drawbacks including facile air 
oxidation of the phosphine and the necessity to generate the azide-containing fragment 
through chemical synthesis.  
 
Thioacid-Azide Ligation    A thioacid can directly react with an azide to form an 
amide bond through a thiatriazoline intermediate (Figure 1-19)
147
.  Recent studies showed 
that this reaction can be performed in various organic solvents as well as in water, and 
can be successfully applied to the synthesis of β-glycosylamides from glycosyl 
azides
148,149
. While no applications in peptides have been shown, it has been proposed as 
a phosphine-free alternative to traceless Staudinger ligation
130
. Interestingly, this reaction 
can also be utilized in the synthesis of thioamides; however, the reaction conditions needs 
to be carefully controlled to suppress competing oxoamide formation 
150
. 
 
 
Figure 1-19.  Mechanism of Thioacid-Azide Ligation. 
 
α-Ketoacid–Hydroxylamine Amide-Forming (KAHA) Ligation    Bode et al. 
devised another amide-bond-forming ligation method by conjugating an α-ketoacid to an 
N-alkylhydroxylamine
151
. Mechanistic studies revealed that the reaction started with a 
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nucleophilic attack of the N-alkylhydroxylamine nitrogen on the α-ketoacid α-carbonyl, 
followed by a transfer of its hydroxyl (or benzylhydroxy) group on to the carbonyl 
carbon. The formation of the amide bond was then achieved through collapse of the 
tetrahedral intermediate with release of a CO2 (Figure 1-20)
152
. KAHA reactions can be 
classified into two types – Type I utilizes an unsubstituted hydroxylamine and is 
conducted in organic solvents, while Type II uses an O-benzyl hydroxylamine and can be 
performed under aqueous conditions
151
. Recent studies from the Bode group also showed 
the feasibility of using 5-oxaproline and oxazetidine as the source of the hydroxylamine, 
which would result in a homoserine or serine, respectively, at the ligation site
153,154
. 
Similar to the traceless Staudinger ligation, this method has limited application in full-
length proteins because the ligation handles need to be chemically incorporated. 
 
 
Figure 1-20.  Mechanism for α-Ketoacid–Hydroxylamine Amide-Forming (KAHA) Ligtaion. 
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1.4  Methods for Peptide Thioester Synthesis  
Thioester Synthesis by PyBOP Activation    Thioesters are typically synthesized by 
carbonyl substitution reactions from a more reactive precursor, such as an activated 
amide, ester or anhydride
155
. In peptide chemistry, this can be achieved through 
activating the C-terminal carboxylic acid in situ with benzotriazol-1-yl-oxytripyrroli-
dinophosphonium hexafluorophosphate (PyBOP), and then performing nucleophilic 
substitution with a free thiol (Figure 1-21).
156
 Due to the harsh reaction conditions, the 
reaction needs to be conducted on a fully protected peptide – in particular, all carboxylic 
acid moieties and nucleophiles must be fully protected to avoid side reactions. In a 
typical procedure, a peptide is synthesized on 2-chlorotritylchloride resin and then 
cleaved under mild acidic conditions with 10% acetic acid or 1% TFA to preserve all the 
protecting groups. The resulting protected peptide is very hydrophobic and poorly 
soluble, which greatly limits the reaction efficiency and hinders its application to long 
sequences. In addition, this activation method frequently results in epimerization – the 
activation group also serves as a good leaving group for intramolecular cyclization, 
which subsequently tautomerizes and results in steric scrambling of the α-carbon. 
Although PyBOP has been identified as the least epimerizing reagent (as compared to 
other coupling reagents such as HBTU, HCTU)
157
, it still exhibits 5% epimerization in 
short peptides, which can be exacerbated with longer reaction time or difficult sequences.  
 
SPPS Methods using Unmasked Thioesters    Early on-resin syntheses of peptide 
thioesters was achieved using Boc-based SPPS, where successive cycles of coupling and  
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Figure 1-21.  Peptide Thioester Synthesis by PyBOP Activation. 
Adapted from Nagalingam et al.
157
 and von Eggelkraut-Gottanka et al.
156
 
 
TFA Boc removal were used to elongate the peptide. The thioester moiety is sufficiently 
stable under acid conditions to allow the direct elongation of peptide on a thioester 
linkage (Figure 1-22A)
158
. However, the requirement of harsh hydrofluoric acid 
cleavages at the end of the synthesis precludes its application to chemically sensitive 
groups such as thioamides. On the other hand, thioesters are not stable under the basic 
conditions used in Fmoc-based SPPS, particularly in the presence of nucleophilic bases 
such as piperidine used in the Fmoc deprotection steps. Recently, Rademann et al. 
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attempted to use a tertiary thiol linker, hypothesizing that the steric constraints around the 
thioester bond would reduce the rate of its degradation (Figure 1-22B)
159
. With a t1/2 of 
6.5 days for the thioester in this method, it was proven successful on model peptides, but 
did not fully resolve the degradation issue. 
 
 
Figure 1-22.  SPPS Methods using Unmasked Thioester Linkages. 
Adapted from Kent et al.
158
 and Radmann et al.
159
 
 
“Safety-Catch” Type Linkers    The “safety-catch” method was first introduced by 
Pessi et al. for their strategy of anchoring the growing peptide chain to the resin via a 
non-cleavable linkage such as a sulfonamide, and then activating the linkage at the end of 
synthesis to form a good leaving group, which can subsequently undergo thiolysis to 
yield a thioester 
160
. Various types of linkers have been developed under this principle as 
summarized in Figure 1-23. In Pessi et al., a sulfonamide linkage was used, which was 
subsequently alkylated by trimethylsilyldiazomethane or iodoacetonitrile to yield an N-
alkyl-peptidylsulfonamide as a good leaving group for thiolysis
160
. Jensen et al. used an 
orthogonally protected Glu residue, which was selectively deprotected at the end of 
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synthesis and cyclized to the adjacent amide using harsh PyBrOP activation
161
. Dawson 
et al. introduced 3,4-diaminobenzoic acid (Dbz)
162
 – only the meta-amine was acylated 
for peptide elongation under standard SPPS conditions; the para-amine was suppressed 
due to the electron-withdrawing effect of the amide group on the aromatic ring. Upon 
completion of SPPS, the para-amine was acylated by p-nitrocholoroformate, leading to a 
spontaneous ring closure to form an N-acyl benzimidazolinone that was labile towards 
thiolysis. Two mdified versions of Dbz were also prepared – one by Mahto et al., where 
the para-amine was protected by an allyl orthogonal protecting group that can be 
selectively removed prior to the final acylation
163
, the other by Dawson et al. where 
methylation was used to lower the para-amine nucleophilicity
164
. Finally, Ficht et al. 
took a slightly different approach and utilized side-chain anchoring instead of post-SPPS 
thiolysis. Rather than being anchored to the resin through the peptide C-terminus, the 
desired peptide was attached to the resin through a Glu side chain. At the end of 
synthesis, the C-terminal carboxylic acid was selectively deprotected, thioesterified by 
PyBOP, and then globally cleaved to yield the peptide thioester
165,166
. While it is possible 
to attach additional amino acids/thioesters to the C-terminus, a Glu residue is still needed 
either as the C-terminal residue or one residue away from the C-terminus. 
 
All these strategies are clever in by-passing the thioester stability problem, but they 
invariably suffer from low yields due to reactive site accessibility
167
 – since the activation 
is performed at the end of SPPS, reagents have to diffuse through a “crowded” resin 
decorated with protected peptide in order to reach the C-terminus. Due to the harsh 
conditions used for linker activation, these methods also require the N-terminus to be 
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acetylated to prevent side reactions, which is not always desirable since the N-terminal 
acetylation of proteins has been shown to affect their properties
168
. In the context of 
thioamide incorporation, since the harsh linker activation chemistry will take place after 
installation of the nucleophilic thioamide moiety into the peptide, these methods are not 
as desirable as the latent thioester strategies that will be discussed next. 
 
 
Figure 1-23.  Selected “Safety Catch” Type Linkers. 
 
N-to-S Latent Thioester Linkers    Taking inspiration from intein-mediated 
thioester formation in nature, various groups have designed linkers that utilize an amide 
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bond as the resin anchor, which is then activated in situ through a spontaneous or assisted 
N-to-S acyl transfer for conversion into a thioester (Figure 1-24A). Due to the reversible 
nature of N-to-S acyl shift, various auxiliaries are frequently necessary to promote the 
formation of thioester (Figure 1-25).  
 
 
Figure 1-24.  General Mechanism for N-to-S and O-to-S Latent Thioester Linkers. 
Protecting groups are designated as “PG” or grey triangles. 
 
Aimoto et al. developed a 2-mercapto-4,5-dimethoxybenzyl (Dmmb) auxiliary, where 
the tertiary amide nitrogen served as the leaving group, and an adjacent aromatic thiol 
was the attacking thiol
169
. It has been applied in several systems, where the longest 
thioester made was a 41 residue thioester
170
. The same group also developed a Cys-Pro 
ester (CPE) linker, where the N-to-S acyl shift is promoted by the irreversible formation 
of a diketopiperazine (DKP) moiety
171,172,173
. Hojo et al. designed a mercaptoprolyl-
prolyl ester motif and successfully synthesized a 25 residue thioester; the method was 
originally designed to promote DKP formation, but was found to proceed through a 
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simple N-to-S acyl shift instead
174
. As a follow-up, they were able to remove the second 
Pro, and obtained comparable N-to-S acyl shift efficiency; notably, they also 
demonstrated the compatibility of this particular linker with microwave assisted 
synthesis
174
. Nakahara et al. showed the use of a simple N-alkylated Cys as a latent 
thioester, and identified that an ethyl substitution was most effective in promoting the 
thioester formation (34%)
175
. Otaka et al. identified acyl oxazolidinone as a potential 
linker
176
, and later optimized it into an N-substituted aniline linker, where the aniline 
served as an even better leaving group
177,178
. Using the second method, a short nine 
reisude phosphopeptide was synthesized in 67% yield
177
.  
 
Melnyk et al. explored bis(2-sulfanylethyl)amido (SEA) as a tunable linker, where 
the N-to-S acyl shift can be turned off and on simply by the oxidation or reduction of the 
di-thiol moiety
179. Offer et al. showed the utility of α-methylcysteine in accelerating the 
N-to-S acyl shift; the extra methyl group on the Cys α-carbon favored the necessary 
cyclic transition state through a Thorpe-Ingold effect
180
, enriching the population of the 
molecule that was in the Burgi-Dunitz trajectory
181
. Liu et al. further synthesized alkene 
analogs of Cys, and showed that it was also a viable linker
182
. Recently, Aucagne et al. 
constructed a self-catalyzing linker with a side chain hydroxyl group that mimicked the 
natural intein; this linker was also shown to be compatible with microwave assisted 
SPPS
183
. Finally, Macmillan et al. demonstrated the similar application of selenocysteine 
in the N-to-Se acyl shift, which was more effective at lower temperature due to the higher 
reactivity of the selenol
184
. For our initial study in thioamide-containing peptide thioester 
synthesis, we chose the CPE linker
171
 because of its synthetic accessibility. 
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Figure 1-25.  Overview of N-to-S Latent Thioester Linkers. 
An N-to-Se linker from Macmillan et al.
184
 is also included for comparison. 
 
O-to-S Latent Thioester Linkers    Similar to their N-to-S counterparts, O-to-S 
latent thioester linkers utilize an ester bond to anchor the growing peptide to the resin, 
which is activated in situ through O-to-S acyl transfer (Figure 1-24B). The ester bond is 
less stable than the amide bond in N-to-S linkers; therefore, O-to-S linkers are less robust 
for long sequences that require repeated exposure to nucleophilic base in SPPS, but are 
also faster in generating an active thioester through O-to-S acyl shift.  
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Figure 1-26.  Overview of O-to-S Latent Thioester Linkers. 
 
There are four O-to-S scaffolds introduced to date, namely α-hydroxycysteine, β-
mercaptoethanol, thioglycerol and hydroxythiophenol (Figure 1-26). Botti et al. first 
synthesized the α-hydroxycysteine linker by hydroxylation of cysteine on resin, and 
successfully ligated two model peptide fragments using this method
185
; while it was a 
great proof-of-concept demonstration, the method required a water-compatible PEG-
based resin, which was fragile and difficult to handle for routine SPPS. Muir et al. 
subsequently improved the synthesis and introduced a protected precursor (which we 
termed TBS-ChB-OH), where the thiol was capped with a t-butylthio group and the α-
hydroxyl was protected by a silyl group
186
. Liu et al. used a different route and prepared 
trityl protected α-hydroxycysteine monomer through ring opening of an epoxide187. The 
β-mercaptoethanol scaffold was explored by Hoeg-Jensen et al., where it was introduced 
as its dimer, dithiodiethanol, and activated in situ with reducing agents
188
. The 
thioglycerol moiety was identified by Liu et al. after screening a variety of O-to-S linkers 
for rate of NCL over hydrolysis
189
.  The hydroxythiophenol scaffold was introduced by 
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Danishefsky et al., where it was conjugated to the last residue in its protected form, and 
then attached to the rest of a 5-residue peptide through solution phase coupling
190
. While 
this linker was not directly conjugated to the resin in this particular case, one could easily 
foresee its adaptation to SPPS by introducing a carboxylic handle on the phenyl ring as a 
resin anchor. For our initial trial, we chose to adapt the α-hydroxycysteine scaffold with 
the protected precursor approach by Muir et al.
186
 
 
Hydrazide as a Thioester Precursor   In 2011, Liu et al. introduced a different 
approach to synthesizing latent thioesters by using a hydrazide linkage
191
. The hydrazide 
linkage can be conveniently introduced by treating 2-chlorotrityl chloride resin with 
hydrazine, after which the peptide can be elongated using standard SPPS procedures. 
After isolating the purified hydrazide peptide, it is activated in situ through NaNO2 
treatment and immediately thiolyzed to generate an active thioester (Figure 1-27). This 
method has been shown to be compatible with the majority of natural amino acids (except 
Asn, Asp, and Gln) as the C-terminal reisdue, and has been successfully applied to the 
semi-synthesis of αS192. 
 
 
Figure 1-27.  Hydrazides as Thioester Precursors.  
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1.5  Traceless Ligation Methods 
Masking Methods    The residual Cys after NCL can be further derivatized into 
analogs of Lys, Glu and Gln through nucleophilic substitution (Figure 1-28). Treatment 
of Cys with aziridine or 2-bromoethylamine results in S-alkylation to form an isosteric 
Lys analog.
193
 Similarly, treatment with iodoacetamide
194
 or iodoacetic acid
195
 yielded a 
Gln or Glu analog, respectively, with thioether insertion in the side chains. While these 
methods are straight-forward to implement (i.e. they do not require synthetic ligation 
handles), they result in modified side chains with thioether linkages, and are not truly 
“traceless”. One of the first synthetic ligation handles to result in a native amino acid is 
homocysteine (Hcs), which yields a native Met upon alkylation with methyl iodide or 
methyl p-nitrobenzenesulfonate
196
. Interestingly, Roelfes and Hilvert applied the same 
strategy to selenohomocysteine, and successfully generated a selenomethionine in a 
peptide hormone analog through NCL followed by alkylation
197
. 
 
 
Figure 1-28.  Masking Methods for Traceless Ligation. 
 
Desulfurization Methods    An on-going paradigm shift in NCL is the introduction 
of thiol-bearing amino acid analogs as ligation handles
198
. The thiol serves as the 
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nucleophile for NCL, which is removed after ligation to generate a native amino acid. 
The first desulfurization was reported by Dawson et al. in 2001 for the conversion of Cys 
into Ala using Raney nickel
199
. Using this approach, they were able to synthesize a 110-
amino acid ribonuclease, barnase. However, the Raney nickel method per se is not 
translatable to other amino acids due to the lack of selectivity (for example, hydro-
genation of the Trp indole and demethythiolation of Met are two known complications 
with Raney nickel)
198
. In 2007, Danishefsky et al. used radical initiated desulfurization 
by a water soluble organic initiator VA-044 as an alternative approach.
200
 In the same 
year, Crich et al. synthesized the first β-thiol amino acid analog, β-mercaptophenyl-
alanine, and successfully demonstrated its desulfurization
201
. Since then, a number of 
thiol analogs have been introduced for 12 out of all 20 natural amino acids (Figure 1-29). 
 
In 2008, Danishefky et al. and Seitz et al. independently prepared two types of valine 
analogs, γ-mercaptovaline202 and β-mercaptovaline203. Two types of Lys analogs were 
also synthesized by two different groups, namely γ-mercaptolysine by Liu et al. in 
2007
204, and δ-mercaptolysine by Brik et al. in 2009205. Interestingly, these Lys analogs 
were designed with orthogonal protecting groups for the side chain amine so that they can 
be used for multiple ligations to elongate the backbone and introduce ubiquitin on the 
side chain − the N-terminal amine was first ligated to one thioester fragment, after which 
the side chain amine was revealed through selective deprotection and then conjugated to 
another thioester; finally the thiol auxiliary was removed through desulfurization to yield 
a native Lys at the branching site. In 2010, three additional analogs were introduced by 
the Danishefsky group, namely β-mercaptoleucine206, γ-mercaptothreonine207, and γ-
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mercaptoproline
208
. In 2012, Brik et al. followed up with a report on the synthesis of γ-
mercaptoglutamine
209
. Most recently, the Payne group has made much contribution to the 
analog repertoire by adding five additional analogs, namely β-mercaptoarginine210, β-
mercaptoglutamic acid
211, β-mercaptoaspartic acid212, β-mercaptoasparagine213, and a Trp 
analog with thiol on its indole ring
214
. With the success of these 14 analogs for 12 amino 
acids, the β- and γ-thiol strategy can conceivably be extended to 19 out of all 20 amino 
acids (except for Gly that does not have a β-carbon, which would require an α-thiol and 
four-membered ring transition state in NCL), which is corroborated by a computational 
study on the desulfurization reaction
215
.  
 
 
Figure 1-29.  Summary of Thiol Analogs of Natural Amino Acids. 
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Deselenization Methods    Similar to thiols, selenols may undergo radical initiated 
deselenization reactions, which can be utilized in traceless NCL methods with β-selenol 
amino acid analogs. The selenium-carbon bond is weaker than the sulfur-carbon bond 
due to less effective orbital overlap, which makes the deselenization reaction easier. In 
the first demonstration of traceless NCL through deselenization, Dawson et al. showed 
that deselenization could be initiated by spontaneous homolytic bond cleavage of a 
diselenide or hemiselenide, which then proceeded to severe the C−Se bond with the 
assistance of tris(2-carboxyethyl)phosphine (TCEP)
216
. Under these mild conditions, Cys 
residues in the peptide sequence remained intact, allowing the traceless ligation of 
peptides and proteins that contain native Cys residues in their sequence. In addition to the 
naturally existing selenocysteine, there are two synthetic selenol amino acids analogs 
reported thus far (Figure 1-30), namely γ-selenoproline by Danishefsky et al.217 and β-
selenophenyl-alanine by Payne et al.
218
. Due to the reactive nature of the selenol, peptides 
containing these analogs were typically isolated as dimers with intermolecular Se−Se 
bond, and then activated in situ by reduction
219
. 
 
 
Figure 1-30.  Post-ligation Deselenization of Selenocysteine (Sec) and Selenol Analogs. 
 
A unique property of selenols is that they can be directly converted into hydroxyls 
under oxidative conditions
220
. This allows the post-ligation conversion of Sec into Ser, 
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adding one additional amino acid as potential ligation sites. The first demonstration of its 
application to peptide ligation was recently conducted by Payne et al., where they 
constructed a glycol-peptide by Sec ligation and subsequent conversion to Ser
221
. A 
recent mechanistic study also confirmed the “dual personality” of selenol – when treated 
with TCEP under anaerobic conditions, Sec was predominantly converted into Ala; when 
oxygen or ozone was supplemented, however, the alaninyl radical could be quenched by 
oxygen instead, generating Ser-containing peptide as the major product (Figure 1-31)
222
.  
 
 
Figure 1-31.  Proposed Mechanism of Oxidative Conversion of Sec into Ser. 
Graphics adapted from Metanis et al.
222
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1.6  Selenocysteine 
Properties of Selenocysteine    Similar to the relationship between thioamides and 
oxoamides, selenocysteine (Sec) is nearly isosteric to Cys, but exhibits very different 
properties (Table 1-3)
223
. With an additional shell of electrons, selenium is slightly larger 
than sulfur (1.90 Å vs. 1.85 Å);
75
 the C−Se bond is slightly longer (1.96 Å vs. 1.80 Å)224 
and weaker (bond dissociation energy 56 kcal mol
-1
 vs. 65 kcal mol
-1
)
77
 than the C−S 
bond. The Sec side chain pKa is much lower than that of Cys (5.2 vs. 8.3)
225
 – at 
physiological pH, the majority of selenol will exist in the ionized form of selenoate. The 
diselenide/hemeselenide exchange reaction is also faster
226
 – the reaction rate constant of 
RS−SR exchange with thiol is 3.6 M-1 s-1, while that of RS−SeR is three times faster at 11 
M
-1
 s
-1; the corresponding reaction for RSe−SeR is 105 faster at 1.3 × 105 M-1 s-1. Finally, 
although selenium and sulfur have similar electronegativity (2.58 vs. 2.55)
80
, diselenides 
are much easier to reduce than disulfides (Ered -0.233 V vs. -0.488 V)
227
.  
 
Table 1-3.  Selected Properties of Cysteine and Selenocysteine. 
Property 
Cys 
(X = S) 
Sec 
(X = Se) 
Van der Waals radius of X (Å)  1.85 1.90 
C−X bond length (Å)  1.80 1.96 
C−X bond dissociation energy (kcal∙mol-1) 65 56 
−XH pKa 8.3 5.2 
RS−XR exchange rate constant (M-1 S-1) 3.6 11 
Ered for RX–XR (V vs. S.H.E.) -0.488 -0.233 
* S.H.E. = Standard hydrogen electrode 
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With these properties, Sec is a much more reactive amino acid than Cys; as 
exemplified in the mutagenesis study of thioredoxin reductase, when the native Cys-Sec 
catalytic motif of the enzyme was replaced with a Cys-Cys motif, a 20-fold reduction in 
catalytic efficiency was observed (kcat/Km 1.3 × 10
7
 vs. 6.0 × 10
5
 M
-1
 s
-1
)
228
. While the 
majority of the reactions that Sec participates in are analogous to those of Cys, Sec 
undergoes a unique reaction that is termed “glutathione peroxidase (GPx) like activity” –
when a selenol is oxidized into hydroxyselenol, it can be reversed simply by the addition 
of a thiol (Figure 1-32)
220
. This reactivity has been observed both in selenol-containing 
small molecules and in Sec-containing enzymes
229
; when handling Sec-containing 
peptides, we typically add excess thiol to protect the selenol side chain against oxidation. 
 
 
Figure 1-32.  Glutathione Peroxidase (GPx) Like Activity of Selenols. 
Graphics adapted from Derek et al.
220
 
 
Selected Applications of Selenocysteine    Selenocysteine is a useful tool in protein 
mechanistic studies and in biotechnology
230
. First of all, Sec is a unique reaction handle 
both for NCL and for other conjugation chemistry. Its reactivity in NCL was rigorously 
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characterized by Raines et al. in 2001, where they discovered that due to the low pKa of 
Sec, the ligation reaction can be conducted at pH ranges between 5 and 8, as compared to 
pH 7−8 for Cys NCL231. They also found that the reaction rates were generally 3 times 
faster, with a second order reaction rate of 9.5 × 10
2
 M
-1
s
-1
 for Sec as compared 3.7 x 10
2
 
M
-1
 s
-1
 for Cys at neutral pH. Sec has been incorporated into a variety of target proteins 
through NCL, including into full-length proteins by EPL
232
. A most representative 
example is the semi-synthetic azurin studies by van der Donk et al.,
233
 where they 
incorporated Sec as a replacement of the native Cys112 through EPL, and used it as a 
probe to elucidate the active site copper coordination geometry. 
 
With its distinct redox properties compared to natural amino acids, Sec can also be 
used as a site-specific label to study oxidative folding
234,227
. Moroder et al. used Sec to 
elucidate the structure of apamin, an 18 residue bee venom toxin
235
. With four Cys in its 
sequence, apamin can adopt a variety of conformations with different disulfide bond 
combinations; the authors systematically replaced Cys pairs with Sec pairs to isolate each 
conformation (Sec will preferentially form diselenide with another Sec before forming a 
hemiselenide with Cys), and solved the NMR structure of each disulfide/diselenide 
combination. In another example, Bulaj et al. replaced a disulfide bonded Cys pair with a 
diselenide bonded Sec pair in a background of six Cys on conotoxin; the other four Cys 
then correctly folded into a single, functional conformation rather than forming a mixture 
of various disulfides due to the templating effect of the first diselenide
236
. 
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Another widely explored application of Sec is 
77
Se NMR spectroscopy. Selenium has 
six stable natural isotopes, the most abundant of which are the NMR inactive 
78
Se and 
80
Se. The NMR active 
77
Se has a natural abundance of 7.63%, and can be enriched for 
NMR spectroscopy
220
. Early studies used 
77
Se-6,6’-diselenobis(3-nitrobenzoic acid), the 
selenium version of Ellman’s reagent, to covalently label Cys residues of the desired 
proteins
237,238
. Hilvert et al. prepared semi-synthetic 
77
Se-enriched subtilisin, and directly 
observed the formation of selenide (−Se-), hydroxyselenol (−Se−OH) and selenoic acid 
(−SeOOH) as intermediates of its catalytic cycle239. Recently, Rozovsky et al. developed 
a metabolic replacement method, where a target Cys containing protein was expressed in 
E. coli in media with minimal sulfates and 
77
Se selenite supplements
240
. Up to 80% 
77
Se 
enrichment can be achieved with this method. 
 
Selenocysteine Incorporation in SPPS    Sec-containing peptides can be synthesized 
by SPPS from protected Sec amino acids. The most commonly used protecting groups are 
phenyl, p-methoxybenzyl (Pmb), xanthyl and trityl groups.
241,242
 Due to the reactive 
nature of selenols, cleavage from the resin is typically performed in the presence of 
thiols, most commonly 2,2′-dithiobis(5-nitropyridine) (DTNP), to form a hemiselenide 
bond as a side chain protection for selenol
243
. The hemiselenide can then be reduced in 
situ by treatment with dithiothreitol (DTT). 
 
Selenoprotein Biosynthesis    Sec is known as “the 21st amino acid” and can be co-
translationally inserted through special cellular machinery
244
. Sec is encoded by the stop 
codon, UGA, which is repurposed for Sec using a set of special mRNA recognition  
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Figure 1-33.  Translational Machinery for Selenocysteine Incoporation. 
A) Biosynthesis of Sec-tRNA
UCA
; B) Machinery for co-translational insertion of Sec and 
structure of SECIS element. SerS = seryl-tRNA synthetase; PSTK = O-phosphoseryl-tRNA 
kinase; PSer = phosphoserine; SecS = selenocysteine synthetase; SPS2 = selenophosphate 
synthetase 2; SECIS = selenocysteine insertion sequence; SBP2 = SECIS-binding protein 2; 
EFsec = special elongation factor. Graphics adapted from Hatfield et al.
245
 
 
elements, elongation factors and tRNAUCA (Figure 1-33)
245
. The Sec-tRNA is synthesized 
from Ser-tRNA; the Ser is first phosphorylated, and then the phosphate is β-eliminated to 
form dehydroalanine, which is subsequently attacked by selenophosphate to generate 
selenocysteine on the tRNA
246
. The Sec-tRNA is then transported to the ribosome by a 
B) 
A) 
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special elongation factor EFsec
247
. The decoding of the UGA codon is achieved through a 
selenocysteine insertion sequence (SECIS) in the non-coding region near the 3’-end of 
peptide coding sequence; SECIS binding protein 2 (SBP2) binds to the SECIS element 
and then recruits the Sec-tRNAUCA/EFsec complex to insert the Sec into the growing 
peptide chain
248
. The process is in competition with chain termination through release 
factor (RF) binding; therefore, the UGA codon and SECIS element must be in spatial 
proximity and able to bend into a certain geometry to allow the efficient binding of EFsec 
and SBP2 for the incorporation of Sec
249
. The human proteome contains 25 naturally 
existing selenoproteins, most of which are redox enzymes
250,251
; due to the reactive nature 
of the selenol side chain, all these proteins contain a Cys near the Sec residue, to 
sequester the Sec as a intramolecular hemiselenide.  
 
Although recombinant expression of proteins with a Sec insertion has been achieved, 
it is at a very early stage of development. Gladyshev et al. were able to express the Sec 
mutant of a mammalian glutathione peroxidase in E coli. by grafting a UGA codon and a 
SECIS element into the protein-coding plasmid, but predominantly observed Trp mis-
incorporation (the Trp codon is UGG, which is similarly to the UGA codon) instead of 
the desired Sec-containing protein
252
. A handful of other examples have been 
reported
253,254,255
; in all cases, Sec incorporation was limited to the C-terminal region of 
the target protein due to the spatial proximity requirement of the UGA codon and SECIS 
element. To our knowledge, there has not been any demonstration on Sec incorporation 
into proteins other than redox enzymes, which contain native Cys-Cys motifs that can be 
mutated into Sec-Cys.  
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1.7  Aminoacyl Transferase (AaT) 
Structure and Biological Function of AaT    AaT is a key component of the N-end 
degradation pathway in E. coli
256
. The N-end pathway is a cellular mechanism to regulate 
protein half-life through N-terminal “destabilizing” amino acids known as “degrons”. In 
E. coli, the primary degron is an Arg or Lys (these residues are rarely exposed at the N-
terminus of a well-folded protein). The positively charged Arg or Lys is recognized by 
AaT, which installs a secondary degron of Leu or Phe onto the N-terminus of the protein. 
The L/F-R/K motif is then recognized by a “carrier protein” ClpS, which transports the 
tagged protein to a proteolytic complex, ClpA/P, for degradation (Figure 1-34). 
 
 
Figure 1-34.  Aminoacyl Transferase (AaT) and E. coli N-End Degradation Pathway. 
Adapted from Bukau et al.
256
 Picture courtesy of Anne M. Wagner. 
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The first observation of AaT activity was made in 1965 by Kaji et al., where the 
incorporation of radiolabeled leucine and phenylalanine was observed in cell extracts of 
E. coli
257
. The AaT enzyme was later isolated in 1970 by Leibowitz and Soffer
258
. They 
also characterized the basic functional properties of AaT, including the equal preference 
for its natural substrates Leu and Phe, the requirement of a monovalent cation source 
such as KCl, and the optimal pH of 8. Subsequent research established that the substrates 
of AaT are protein N-termini nearing a Lys or Arg, and linked its biological function to 
the N-end degradation pathway
259,260
. A crystal structure was solved in 2007 by Suto et 
al.
261
; it revealed two distinct binding pockets – a hydrophobic amino acid binding pocket 
that consists of Met144, Met158, Leu170 and Ile185, and a negatively charged Lys/Arg 
binding pocket that is formed by Tyr42, Tyr120, Glu156 and Gln188 (Figure 1-35). The 
catalytic mechanism seems to be a simple “induced fit” model262; Gln188 was proposed 
to be catalytic in initial studies
261
, but was later proved to be unnecessary for the catalytic 
process as an Ala mutation can be made at this site without loss of activity
262
. 
 
 
Figure 1-35.  Crystal Structure of E. coli Aminoacyl Transferase (AaT). 
Adatped from Suto et al. (PDB 2Z3N)
261
. Binding pockets highlighted in orange and purple. 
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AaT as a Protein N-Terminal Modification Tool    In 1996, Abramochkin et al. 
determined that the aminoacyl-tRNA anticodon was not necessary for AaT recognition 
using mutant tRNAs
263
. It was later confirmed in the crystal structure that only the last 
adenosine on the acceptor stem was involved in AaT binding
261
. Pioneering studies by 
Sisido and Tirrell established the feasibility of using AaT for protein N-terminal 
modification. Tirrell et al. took a fully enzymatic approach, where mutant synthetases 
were used to charge their corresponding tRNAs with unnatural amino acids; the 
aminoacyl-tRNAs were then subjected to activity screening with AaT
264
. Sisido et al. 
showed that truncated nucleotides with from 2 to 20 bases were also tolerated as AaT 
substrates
265,266,267
. In our own group, we were able to further minimize the substrate to 
aminoacylated adenosine donors
268
, and used this method to identify novel AaT 
substrates such as disulfide protected homocysteines (Figure 1-36)
269
.  Known substrates 
of AaT from these studies are summarized in Figure 1-37. 
 
 
Figure 1-36.  Aminoacyl Transferase as a Tool to Incorporate Homocysteine. 
Graphics adapted from Tanaka et al.
269
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Figure 1-37.  Known Substrates of Aminoacyl Transferase. 
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1.8  Summary 
Protein misfolding is the molecular basis of various human diseases, including AD, 
PD and Type 2 diabetes. However, little information is known about either the structural 
details of the misfolded species or the conformational changes that are involved in the 
misfolding process, which greatly restricts our ability to develop effective therapies for 
these diseases. We propose to study the misfolding phenomenon using thioamides as 
minimalist fluorescence quenchers. Previous work in our group has established the 
photophysics of fluorescence quenching by thioamides. In the current work, we will 
explore methods to incorporate thioamides into full-length proteins, a prerequisite for 
using fluorophore/thioamide dually labeled proteins for misfolding studies. 
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Chapter 2 .  Latent Peptide Thioester Strategies for Incorporation of Thioamides 
into Full-length Proteins via Native Chemical Ligation 
 
 
 
 
 
 
 
 
 
 
 
 
The C
b
PGo linker and full-length αS studies in this chapter was originally published in the Journal of the 
American Chemical Society. It is adapted here with permission from the publisher: 
 
Reprinted and adapted with permission from Batjargal, S.; Wang, Y. J.; Goldberg, J. M.; Wissner, R. F.; 
Petersson, E. J., Native Chemical Ligation of Thioamide-Containing Peptides: Development and 
Application to the Synthesis of Labeled Alpha-Synuclein for Misfolding Studies. J. Am. Chem. Soc. 2012, 
134, 9172-9182. Copyright 2012 American Chemical Society. 
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2.1  Introduction 
Having demonstrated the utility of the thioamide as a minimalist fluorescence 
quencher in previous work from our group
115
, we were faced with a major chemistry 
challenge: as a backbone modification, thioamides can only be installed onto small 
molecules through solution phase thionation, or short peptides by Fmoc-based (Fmoc = 
fluorenylmethyloxycarbonyl) solid phase peptide synthesis (Figure 2-1). To the best of 
our knowledge, the longest thioamide-containing peptides previously synthesized were 
two 35-residue peptides, one by Miwa et al.
89
 and one by our group
115
. In order to utilize 
thioamide as a probe for misfolding studies, we needed to first devise a method to 
incorporate it into full-length proteins reliably and site-specifically. 
 
 
 
Figure 2-1.  Thioamide Incorporation into Small Molecules and Peptides. 
For small molecules and dipeptides, solution phase thionation can be used to convert an oxo-
amide precrusor into thioamide; this would not be applicable to peptides with more than two 
residues due to the lack of site-specificity. Solid phase peptide synthesis (SPPS) using 
activated thioacyl benzotriazole precursors can be used for site-specific thioamide install-
ation; however, SPPS has an inherent length limit of ~70 residues
270
, beyond which cleavage 
and purification would become extremely difficult. 
 
There are four general strategies to incorporate synthetic moieties into proteins: post-
translational chemical derivatization
271
, unnatural amino acid (Uaa) mutagenesis
272
, in 
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vitro translation from chemically synthesized tRNA
273
, and protein semi-synthesis
130
. The 
first two are primarily used for side chain derivatization, and would be difficult to adapt 
for backbone thioamide incorporation. With chemically synthesized tRNA, it is possible 
to incorporate a dipeptide substrate
 
(a direct thioacid linkage to tRNA would be unstable); 
however, extensive synthetic efforts and directed evolution of the translational machinery 
are necessary for each Xaa-Yaa dipeptide combination
274
, which is not desirable for our 
goal of thioamide incorporation at any position. Among available strategies, protein 
semi-synthesis, particularly native chemical ligation (NCL), is most promising for our 
applications – a small thioamide-containing peptide fragment can be chemically synthe-
sized via SPPS, and then joined to the rest of the target protein produced by cellular 
expression, yielding a full-length target protein with a site-specific thioamide label. 
 
 
Figure 2-2.  Native Chemical Ligation (NCL) as a Strategy for Thioamide Incorporation. 
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Native chemical ligation (NCL), as pioneered by Kent et al.
128
, utilizes the trans-
thioesterification between two unprotected peptide fragments − one with a C-terminal 
thioester and another with an N-terminal Cys – and generates a native amide bond after 
S-to-N acyl shift (Figure 2-2). The reaction takes place under mild aqueous conditions, 
and has been successfully applied to the semi-synthesis of chemically sensitive peptide 
derivatives such as glycopeptides
275
. In our preliminary trials, we were delighted to find 
that the thioamide was compatible with the NCL method; the real challenge, however, 
was to synthesize the peptide fragments, particularly the thioester fragment, for ligation. 
 
 
Figure 2-3.  Challenges in the Synthesis of Thioamide-Containing Peptide Thioesters.   
 
In standard SPPS methods, thioesters are synthesized using Boc-based SPPS (Boc = 
t-butyloxycarbonyl), as they are not stable towards the basic conditions in Fmoc-based 
SPPS; on the contrary, the thioamide is not stable towards the highly acidic conditions in 
Boc-based SPPS, and requires the Fmoc method for successful incorporation (Figure 
2-3). In fact, this apparent mismatch has led to the speculation that NCL of thioamide-
containing peptides was “not suitable because the presence of [thioamide] bonds is not 
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compatible with the subsequent synthesis of the thioester moiety”.110 We hypothesized 
that we could find a compromise by adopting Fmoc-based SPPS for the synthesis of 
thioamide-containing peptides, and then identify a viable method to either generate the 
thioester off-resin or synthesize it on-resin as a latent thioester that is activated in situ. 
 
Upon a survey of the literature, we identified three main strategies for thioester 
synthesis in the context of Fmoc-based SPPS (Figure 2-4). Solution phase PyBOP 
activation
130
 is performed on the free carboxylic acid terminus of a peptide; due to the 
harsh reaction conditions, it requires side chains of the peptide to be fully protected, 
which greatly affects its solubility and thus lowers reaction efficiency. Nbz and other 
“safety-catch” type linkers276,277 utilize non-labile amide linkages to anchor the growing 
peptide to the resin; the linkers are activated at the end of the synthesis (typically by N-
acylation) and converted to thioesters by thiolysis. Latent thioester linkers
278,171
 are 
synthesized and purified as ester or amide using standard SPPS; they are only activated in 
situ through O-to-S or N-to-S acyl shift to generate an active thioester in aqueous buffer.  
 
We chose to investigate the latent thioester strategy for thioamide incorporation 
because of its various advantages: 1) while the other methods require additional derivati-
zation after thioamide installation, all harsh reactions in the latent thioester strategy are 
completed at the linker synthesis stage, ensuring maximal compatibility with chemically 
sensitive functional groups such as thioamide; 2) from a practical point of view, latent 
thioesters are purified and stored as esters or amides until the final NCL, which are much 
more stable and easier to handle than an actual thioester. 
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Figure 2-4.  Thioesterification Strategies for Fmoc-based SPPS. 
Due to the diversity of “safety-catch” type linkers, Nbz linker is shown here as an example. 
Triangles indicate side chain protecting groups on peptides. TFA = trifluoroacetic acid; PG = 
protecting group  SPPS = solid phase peptide synthesis; Nbz = N-acyl-benzimidazolinone. 
 
The two main sub-types of latent thioester linkers are O-to-S and N-to-S linkers. As 
the names suggest, O-to-S linkers are joined to the peptide through an ester bond and are 
subsequently activated by O-to-S acyl shift, while N-to-S linkers are the amide bond 
counterparts. Rather than choosing one type over the other, we decided to explore both 
strategies because they have complementary advantages: 1) due to the higher stability of 
amide bond as compared to ester bond, N-to-S linkers are more stable than O-to-S linkers 
in synthesis and handling, but would also be slower in in situ thioester formation; 2) for 
the same reason, O-to-S acyl shifts are typically conducted in mildly acidic conditions 
(pH 6.8 ~ 7.0) to avoid ester hydrolysis, whereas N-to-S acyl shifts can be conducted at 
much higher pH (7.4 ~ 8.4) to accelerate the reaction. Exploring both types gave us 
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access to a wide range of reactivity and reactions conditions, which would be beneficial 
in fine-tuning synthetic procedures for different target proteins.  
 
Figure 2-5.  ChB Latent Thioester Linker utilizing O-to-S Acyl Shift. 
 
The O-to-S linker we chose to adapt for the thioamide is ChB, an α-hydroxyl analog 
of Cys, as developed by Botti et al.
278
 (Figure 2-5). It was initially synthesized by on-
resin hydroxylation of Cys, and subsequently refined by Muir et al. into a monomer 
building block that can be directly incorporated by SPPS
186
. The N-to-S linker we chose 
was CPGo, a Cys-Pro-Gla motif, as developed by Aimoto et al.
171
 (Figure 2-6). Pro is a 
well-known substrate for diketopiperazine (DKP) formation; glycolic acid promotes this 
cyclization by serving as a good leaving group, which in turn shifts the N-to-S acyl shift 
equilibrium towards the thioester. In our design of C
b
PGo, we would added a tBuS− 
protecting group on Cys to avoid complications from dimerization and aggregation. 
 
Figure 2-6.  CPGo Latent Thioester Linker utilizing N-to-S Acyl Shift.  
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2.2  Results and Discussion 
We began by exploring the O-to-S latent thioester linker ChB. It can be synthesized 
in its protected form TBS-ChB-OH (6) in five steps from 1-thioglycerol (Figure 2-7) 
based on a route developed by Muir et al.
186
, where successive oxidations were used to 
obtain the carboxylic acid functionality. (We note that all synthetic routes from Cys or 
cystine proved unfruitful as summarized in Figure 2-15.) The precursor can then be used 
as a building block for incorporation by SPPS – 6 is first coupled onto Rink amide resin, 
and deprotected to reveal the hydroxyl group; the next amino acid is installed using in 
situ carbodiimide activation, after which the rest of the sequence can be assembled using 
standard SPPS (Figure 2-8).  
 
To test the compatibility of the ChB thioester linker with a thioamide, we synthesized 
model peptide 7 with thioleucine (Leu
S
) in the sequence. As expected, the latent ester 
strategy was a sufficiently small deviation from standard SPPS that 7 could be readily 
synthesized and purified without complications. When subjected to a test ligation with N-
terminal Cys peptide 8, the latent thioester was rapidly converted into the desired product 
9c within 10 min (Figure 2-9). Intermediates 9a and 9b could be observed early in the 
reaction, which corresponded to the O-linked and S-linked isomers as latent or active 
thioesters. The UV-Vis absorption profile of 9c clearly demonstrated the presence of two 
7-methoxycoumarin chromophores and the integrity of thioamide, giving us confidence 
that the ChB linker is compatible with the synthesis of thioamide-containing thioesters. 
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We next investigated the N-to-S latent thioester linker C
b
PGo. The synthesis was 
much more straight-forward, where the only precursor necessary was an Fmoc-Xaa-Csb-
OH dipeptide (10) to pre-load the C-terminal residue in order to avoid spontaneous 
diketo-piperazine (DKP) ester formation
171
 (Figure 2-18). 10 can be readily derivatized 
from Fmoc-protected amino acids in one step by isobutylchloroformate (IBCF)  
 
 
Figure 2-7.  Synthesis of TBS-ChB-OH Precursor.    
Conditions: a) tBuSH, I2, EtOH, 89%; b) TBS-Cl, imidazole, DMAP, DMF, 99%; c) 1:1:5 
TFA/H2O/THF, 0 ˚C, 61%; d) Dess-Martin periodinane, CH2Cl2, 65%; e) NaClO2, NaH2PO4, 2-
methyl-2-butene, 4:9 H2O/tBuOH, 31%. TBS = t-butyldimethylsilyl; DMAP = 4-dimethylamino-
pyridine; DMF = N,N-dimethylformamide;  TFA = trifluoroacetic acid;  THF = tetrahydrofuran. 
 
 
Figure 2-8.  Synthesis Scheme for Thioamide-Containing Peptide-ChB Thioester.    
We note that the symmetric anhydride intermediate from carbodiimide acitivation method was 
necessary for successful ester bond; uronium reagents such as HBTU were much less 
effective. TBAF = tetra-n-butylammonium fluoride; Fmoc-AA-OH = Fmoc protected amino 
acid building block; DCC = dicyclohexylcarbodiimide. 
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Figure 2-9.  Ligation of Thioamide-Containing Peptide-ChB Thioester with CA-Mcm-NH2.    
A) Schematic representation of the test reaction. B) HPLC chromatograms monitored at 325 
nm. Ligation was conducted using 1:10 Peptide-ChB 7/Cys-Peptide 8 for a 10 min reaction; 
intermediates were isolated using 1:1 Peptide-ChB 7/Cys-Peptide 8 for a 30 sec reaction. 
Excess 8 eluted at 18.5 min; it is omitted in these graphics for clarity. MALDI MS: [7+H]
+
, 
expected 939.37, found 939.23; [9a+H]
+
, expected 851.34, found 851.22; [9b+H]
+
, expected 
851.34, found 851.21, [9c+H]
+
, expected 1166.46, found 1166.30. 9a was positive towards 
Ellman’s reagent, while 9b was negative. C) UV-Vis absorption profiles of reactants and 
product, showing the integrity of thioamide and two Mcm chromophores in the product. 
Conditions: 0.5 mM 7, 0.5 or 5 mM 8, 20 mM TCEP, 200 mM Na2HPO4, pH 6.8. 
(7) 
(9a) 
7 
9a 
(9b) 
(9c) 
(8) 
9b 
9c 
7 9c 8 
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activation, a common amide bond formation method that is compatible with all 20 natural 
amino acids
124
. To construct the C
b
PGo linker, we devised an efficient synthesis from 
bromoacetic acid (Figure 2-10) – after its coupling onto the resin, an SN2 reaction was 
used to form the Pro-Gla ester bond, and then 10 was installed by PyBOP; standard SPPS 
was then used to complete subsequent synthesis and purification. 
 
 
Figure 2-10.  Synthesis Scheme for Thioamide-Containing Peptide-C
b
PGo Thioester. 
We note that BrCH2COOH loading must be conducted at neutral to acidic conditions without 
catalytic DMAP to avoid glycolic acid polymer formation. Synthesis of Fmoc-Xaa-Csb-OH 10 
is detailed in Materials and Methods. DCC = dicyclohexylcarbodiimide; DMAP = 4-dimethyl-
aminopyridine; DIPEA = N,N-diisopropylethylamine. 
 
Model peptide 11, analogous to peptide 7, was synthesized and evaluated in a test 
ligation with Cys (Figure 2-11). Upon treatment with reducing agent tris(2-carboxyethyl) 
phosphine (TCEP), 11 was rapidly reduced to the Cys form 11a in 10 min; the 
subsequent N-to-S acyl shift took place gradually and approached completion after 6 h. 
The reaction rate was much slower than that of the latent ChB thioester, presumably due 
to the higher stability of the amide bond in the N-to-S acyl shift than the ester bond in the  
(10) 
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Figure 2-11.  Ligation Thioamide-Containing Peptide-C
b
PGo Thioester with Cys. 
A) Schematic representation of the test reaction. B) HPLC chromatogram monitored at 325 
nm, and UV-Vis absorption spectra of isolated peptides. MALDI MS: [11 + H]
+
, expected 
1093.34, found 1093.46; [11a + H]
+
, expected 1005.41, found 1005.37; [12 + H]
+
, expected 
851.34, found 851.16. Star sign indicates thioamide absorption at 272 nm. See Materials and 
Methods for DKP intermediate characterization. Conditions: 1 mM peptide-C
b
PGo 11, 10 mM 
Cys, 50 mM TCEP, 200 mM Na2HPO4, pH 8.4. 
  
(11) 
(11a) 
11 
(12) 
11a 
12 
12 
11 
11a 
12 
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O-to-S acyl shift. Using a large excess of Cys, we were able to achieve a pseudo first-
order reaction with respect to 11, from which a second-order reaction constant (1.53 ± 
0.06) × 10
-2
 M
-1∙s-1 was obtained,with an empirical half-life of 75 ± 1 min (Figure 2-12). 
As a further validation, we showed that the thioamide was fully intact in the final 
product, and that DKP thioester intermediate could be observed at a very low substrate 
concentration in the absence of Cys (Figure 2-19). Lastly, we showed that both ChB and 
C
b
PGo latent thioesters were tolerant of denaturants – ligation rates were slower, but 
otherwise no additional complications were observed (Figure 2-17, Figure 2-20).  
 
 
Figure 2-12.  Triplicated Ligation Kinetics between C
b
PGo Thioester and Cys.    
Side products were defined as all products other than the desired product 12. See Material 
and Methods for detailed descriptions of quantification and data fitting methods. 
 
Having validated both ChB and C
b
PGo latent thioester strategies in the context of 
thioamide incorporation, we were eager to find out if these methods would be applicable 
to a full-length protein. Our chosen target was α-synuclein (αS), a 140 residue protein 
that is implicated in Parkinson’s disease (PD) 279. αS is a small pre-synaptic protein that 
Reduced 11a 
Product 12 
Side Products 
All Products 
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is ubiquitously expressed in the brain; upon conformational changes, it aggregates into 
oligomers and fibrils, leading to neuronal death and thus the degenerative symptoms in 
PD. By incorporating a Trp/thioamide fluorophore-quencher pair into αS, we would be 
able to track the relative movements of the two labels during aggregation using 
fluorescence spectroscopy, and then reconstruct the conformational changes involved. 
 
We chose the C
b
PGo linker for this particular application because of its ease of 
synthesis. Using an improved procedure, we synthesized Ac-αS1-8V
S
3-C
b
PGo 13 and 
ligated it to the other fragment αS9-140C9 that was expressed in E. coli. The ligation 
proceeded smoothly, yielding full-length Ac-αSVS3C9 as the desired product (Figure 
2-13). The integrity of thioamide can be confirmed by trypsin digest, as well as UV-Vis 
absorption (Figure 2-23). To generate the Trp/thioamide dually labeled protein, αSC9W94 
was use as the C-terminal fragment instead, which also proceeded without complications 
to yield Ac-αSVS3C9W94 (Figure 2-22). 
 
As a proof-of-concept experiment to demonstrate the utility of thioamide in protein 
misfolding studies, we subjected our semi-synthetic doubly labeled Ac-αSVS3C9W94 to in 
vitro aggregation and monitored the Trp fluorescence change over time (Figure 2-14). 
There is no native Trp in the αS sequence, therefore selective excitation of Trp can be 
achieved with 295 nm incident light. To account for the environmental effects on Trp 
emission, all fluorescence data were compared to an oxoamide control, where αSW94 
with no thioamide in its sequence was aggregated side by side with the thioamide-labeled 
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Figure 2-13.  Synthesis of Thioamide-Containing Full-length αS using C
b
PGo Linker. 
C-Terminal fragment of αS9-140 with an N-terminal His tag, an S9C mutation, and IEGR 
cleavage sequence was expressed and purified on Ni-NTA resin. After Factor Xa cleavage to 
generate an N-terminal Cys (αS9-140C9), the protein fragment is ligated Ac-αS1-8V
S
3-C
b
PGo 
latent thioester. Top Right: PAGE gel analysis of ligation. Far Right: MALDI-TOF MS of full 
length (calcd m/z 14,536) or trypsinized Ac-αSV
S
3C9 (Ac-αS1-5V
S
3, calcd m/z 828.4). No 
desulfurized oxopeptide (calcd m/z 812.4) was observed. With Solongo Batjargal.  
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samples. To isolate intramolecular misfolding events, we carried out our aggregation 
using 1:30 doubly labeled Ac-αSVS3C9W94 in WT αS, so that statistically there should not 
be intermolecular Trp/thioamide interactions within 30 Å (the contact quenching distance 
for Trp/thioamide pair
280
). Finally, with a residual Cys in our semi-synthetic construct, 
we conducted our aggregation in the presence of β-mercaptoethanol (BME) to prevent 
disulfide bond formation that may interfere with the aggregation process.  
 
We were excited to find that as aggregation proceeded, Trp fluorescence quenching 
was clearly observed, which corresponded to compaction between the Trp and thioamide 
labels as one would expect in oligomer and fibril formation. Comparing to aggregation 
progress as monitored by thioflavin T (ThT) fluorescence, Trp fluorescence quenching 
took place before the rise of ThT fluorescence (ThT preferentially binds to fibrils
54
), 
indicating that our Trp/thioamide dual labeling method revealed conformational changes 
at the early oligomer formation stage (< 24 h), which had been a difficult target in prior 
efforts
281
. While an extensive data set from various labeling positions is certainly 
necessary to draw definitive conclusions about the exact conformations involved, these 
studies clearly demonstrated the feasibility of thioamide incorporation into full-length 
proteins via NCL, as well as their great potential as minimalist probes in studying the 
misfolding of pathogenic proteins. 
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Figure 2-14.  Monitoring αS Misfolding Using Thioamide Fluorescence Quenching. 
Monomeric Ac-αS1-140V
S
3C9W94 was mixed in a 1:30 ratio with WT αS, and shaken at 37 °C 
for several days. Samples were taken at defined intervals and Trp fluorescence were 
measured at 295 nm. Thioflavin T (ThT) was used as a secondary assay to confirm fibril 
formation. See Materials and Methods for detailed description. With Rebecca F. Wissner. 
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2.3  Conclusion 
We have established two efficient thioesterification methods for the incorporation of 
thioamide into full-length proteins by NCL. ChB, an O-to-S latent thioester linker, 
functions at mildly acidic pH and exhibits rapid reaction kinetics, while C
b
PGo, an N-to-S 
latent thioester, utilizes mildly basic reaction conditions and is more stable toward 
purification and storage. Both methods are fully compatible with thioamide, giving a 
wide range of conditions for protein-specific optimization.  
 
As a proof-of-concept example, we successfully extended the thioesterification and 
NCL method to synthesizing a thioamide-labeled variant of αS, a protein implicated in 
Parkinson’s disease. We demonstrated the utility of the thioamide as a minimalist 
fluorescence quencher probe in an aggregation study with a Trp/thioamide dually labeled 
αS construct; conformational compaction was observed at the oligomer stage determined 
by Trp fluorescence quenching by the thioamide. Our semi-synthesis method has enabled 
the site-specific incorporation of thioamide into full-length proteins, greatly expanding its 
potential applications as a minimalist probe in protein misfolding studies. 
 
  
78 
 
2.4  Materials and Methods 
General Information    Fmoc protected amino acids and peptide synthesis reagents 
were purchased from EMD Millipore (Billerica, MA). All other reagents and solvents 
were purchased from Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO) 
unless otherwise specified. High resolution electrospray ionization mass spectra (ESI-
HRMS) were collected with a Waters LCT Premier XE liquid chromatograph/mass 
spectrometer (Milford, MA). Low resolution electrospray ionization mass spectra (ESI-
LRMS) were obtained on a Waters Acquity Ultra Performance LC connected to a single 
quadrupole detector (SQD) mass spectrometer. UV-Vis absorption spectra were acquired 
on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent Technologies, 
Santa Clara, CA). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker 
DRX 500 MHz instrument (Billerica, MA). Matrix assisted laser desorption/ionization 
with time-of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker 
Ultraflex III instrument (Billerica, MA). Analytical HPLC was performed on an Agilent 
1100 Series HPLC system equipped with a photodiode array detector (Santa Clara, CA). 
Preparative HPLC was performed on a Varian Prostar HPLC (Agilent Technologies, 
Santa Clara, CA). HPLC columns were purchased from W. R. Grace & Compnay 
(Columbia, MD). Fluorescence spectra were collected with a Varian Cary Eclipse 
fluorescence spectrophotometer with a Peltier multicell holder (Agilent Technologies, 
Santa Clara, CA). Protein purification was conducted on a BioCad Sprint fast protein 
liquid chromatography (FPLC) system (Agilent Technologies, Santa Clara, CA). 
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Synthesis of 3-(t-Butyldisulfanyl)propane-1,2-diol (2)   3-Mercaptopropane-1,2-
diol (1, 960 µL, 90% aq., 10 mmol, 1 equiv) was mixed with 2-methylpropane-2-thiol 
(tBuSH, 3.4 mL, 30 mmol, 3 equiv), and chilled to 0 °C on ice. A solution of iodine 
(2.7918 g, 11 mmol, 1.1 equiv) in ethanol (50 mL) was added dropwise over 2 h, until the 
reaction changed from colorless to red. The reaction was allowed to proceed for another 2 
h on ice, and then quenched with saturated NaS2O3 (1 mL). The crude mixture was 
concentrated by rotary evaporation, and then purified by flash chromatography in 2:3 
ethyl acetate/petroleum ether. The product was isolated as a yellow oil (1.7391 g, 8.9 
mmol, 89% yield). Rf 0.23 in 2:3 ethyl acetate/petroleum ether; 
1
H NMR (500 MHz, 
CDCl3): δ 2.78 (m, 1H), 3.52 (dd, J = 11.3, 4.7 Hz, 1H), 3.48 (dd, J = 11.3, 5.7 Hz, 1H), 
2.85 (dd, J = 13.2, 5.4 Hz, 1H), 2.73 (dd, J = 13.4, 7.4 Hz, 1 H), 1.29 (s, 9H). ESI
+
-
LRMS calculated for C6H13O2S2
+
 181.04, found [M − CH3]
+
 181.10. 
 
Synthesis of 1,2-Bis-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propane (3)   
2 (1.0144 g, 5.2 mmol, 1 equiv), imidazole (2.1105 g, 31 mmol, 6 equiv) and 4-dimethyl-
aminopyridine (DMAP, 0.0379 g, 0.3 mmol, 0.06 equiv) were dissolved in anhydrous 
N,N-dimethylformamide (DMF, 15 mL) on ice under argon. tert-Butyl-dimethylsilyl 
chloride (TBSCl, 2.3359 g, 16 mmol, 3 equiv) was added, and the reaction was allowed 
to proceed overnight (≥ 12 hr). Upon completion, the reaction was quenched with 0.5 N 
NaOH (10 mL), and extracted with ethyl acetate (30 mL × 3). The organic layers were 
concentrated by rotary evaporation and purified by flash chromatography in 1:19 ethyl 
acetate/hexanes. The product was isolated as a clear oil (2.1758 g, 5.1 mmol, 99% yield). 
Rf 0.74 in 1:19 ethyl acetate/hexanes; 
1
H NMR (500 MHz, CDCl3): δ 3.87 (m, 1H), 3.58 
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(dd, J = 10.0, 5.1 Hz, 1H), 3.51 (dd, J = 10.1, 6.3 Hz, 1H), 2.97 (dd, J = 13.1, 5.0 Hz, 
1H), 2.71 (dd, J = 13.1, 6.7 Hz, 1H), 1.31 (s, 9H), 0.87 (s, 18H), 0.04 (m, 12H); ESI
+
-
LRMS calculated for C19H44O2S2Si2Na
+
 447.22, found [M + Na]
+
 447.27. 
 
Synthesis of 2-((t-Butyldimethylsilyl)oxy)-3-(t-butyldisulfanyl)propan-1-ol (4)   3 
(0.8676 g, 2 mmol, 1 equiv) was dissolved in tetrahydrofuran (THF, 9 mL) on ice, and 
then a solution of trifluoroacetic acid (TFA, 1.8 mL, 24 mmol, 12 equiv) in water (1.8 
mL) was added dropwise. The reaction was allowed to proceed for 3 h on ice until all 
reactant was consumed, and then quenched with saturated NaHCO3 (30 mL) and 
extracted with ethyl acetate (30 mL × 3). The organic layers were concentrated by rotary 
evaporation and purified by flash chromatography in 1:15 ethyl acetate/hexanes. The 
product was isolated as a clear oil (0.3889 g, 1.3 mmol, 61% yield). Rf 0.25 in 1:15 ethyl 
acetate /hexanes; 
1
H NMR (500 MHz, CDCl3): δ 3.95 (m, 1H), 3.68 (dd, J = 11.3, 3.8 Hz, 
1H), 3.60 (dd, J = 11.3, 4.2 Hz, 1H), 2.85 (dd, J = 13.4, 7.2 Hz, 1H), 2.77 (dd, J = 13.4, 
5.7 Hz, 1H), 1.85 (s, 1H), 1.31 (s, 9H), 0.88 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H). ESI
+
-
LRMS m/z calculated for C13H30O2S2SiNa
+
 [M + Na]
+
 333.14, found 333.10. 
 
Synthesis of 2-((t-butyldimethylsilyl)oxy)-3-(t-butyldisulfanyl)propanal (5)  Dess-
Martin periodane was freshly prepared according to Ireland et al.
282
 4 (1.8736 g, 6 mmol, 
1 equiv) was dissolved in CH2Cl2 (40 mL) under argon. Dess-Martin periodane (3.8379 
g, 9 mmol, 1.5 equiv) was slowly added, and then the reaction was allowed to proceed for 
3 h at room temperature. Upon completion, the reaction mixture was diluted with CH2Cl2 
(50 mL) and ethyl acetate (50 mL), filtered, concentrated by rotary evaporation, and then 
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purified by flash chromatography in 1:19 ethyl acetate/hexanes. The product was isolated 
as a pale yellow oil (1.2183 g, 4.0 mmol, 65% yield). Rf 0.27 in 1:19 ethyl acetate/ 
hexanes; 
1
H NMR (500 mHz, CDCl3): δ 9.65 (d, J = 1.1 Hz, 1H), 4.23 (ddd, J = 7.9, 4,4, 
1,1 Hz, 1H), 2.99 (dd, J = 13.3, 4.4 Hz, 1H), 2.81 (dd, J = 13.4, 7.9 Hz, 1H), 1.32 (s, 9H), 
0.92 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H). ESI
-
-LRMS calculated for C13H27O2S2Si
-
 307.13, 
found [M − H]+ 307.21. 
 
Synthesis of 2-((t-butyldimethylsilyl)oxy)-3-(t-butyldisulfanyl)propanoic acid (6)   
5 (0.2479 g, 0.8 mmol, 1 equiv) was dissolved in 2-methyl-2-propanol (tBuOH, 4 mL) on 
ice. 2-Methyl-2-butene (4.8 mL, 45 mmol, 58 equiv) was added, followed by a solution 
of NaClO2 (0.2110 g, 2.3 mmol, 3 equiv) and NaH2PO4 (0.2053 g, 1.7 mmol, 2.2 equiv) 
in water (4 mL). The reaction was vigorously stirred for 2 h under nitrogen, and then 
diluted with ethyl acetate (10 mL) upon completion. The crude mixture was extracted 
against 0.1N HCl (10 mL × 3), concentrated by rotatory evaporation, and then purified by 
flash chromatography in 1:19 methanol/CH2Cl2. The product was isolated as a clear oil 
(0.0782 g, 0.24 mmol, 31% yield). Rf 0.16 in 1:19 methanol /CH2Cl2; 
1
H NMR (500 
MHz, CDCl3): δ 9.28 (s, 1H), 4.46 (dd, 1H, J = 7.8, 3.9 Hz), 3.11 (dd, 1H, J = 13.4, 3.8 
Hz), 2.91 (dd, 1H, J = 13.4, 7.7 Hz), 1.31 (s, 9H), 0.91 (s, 9H), 0.14 (s, 3H), 0.12 (s, 3H). 
ESI
−
-HRMS calculated for C13H27O3S2Si
−
 323.1171, found [M − H]− 323.1168. 
 
L-Cystine and L-Cysteine Routes towards TBS-ChB-OH    Various routes using L-
cystine or protected Cys as starting material were proven unsuccessful at various stages 
of synthesis, due to solubility or reactivity limitations. 
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Figure 2-15.  Attempted Synthesis towards TBS-ChB-OH from Cys
S-tBu
 or Cystine. 
 
 
Synthesis of α-N-Fmoc-L-thioleucine-benzotriazolide (S1)    Thioleucine (LeuS or 
L
S
) precursor was synthesized using a similar procedure as previously described in J. Am. 
Chem. Soc. 2012, 134, 6088−6091. 1H NMR (500 MHz, CDCl3): δ 8.78 (d, J = 8.3 Hz, 
1H), 8.15 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 7.3 Hz, 2H), 7.69 (d, J = 7.5 Hz, 1H), 7.65 (t, J 
= 9.1 Hz, 2H), 7.55 (t, J = 7.6 Hz, 1H), 7.40 (t, J = 7.3 Hz, 2H), 7.33 (t, J = 7.2 Hz, 2H), 
6.39 (t, J = 8.8 Hz, 1H), 5.78 (d, J = 9.6 Hz, 1H), 4.49 (d, J = 7.0 Hz, 1H), 4.41 (t, J = 7.2 
Hz, 1H), 4.25 (t, J = 6.5 Hz, 1H), 1.92 (s, 1H), 1.85 (t, J = 10.1 Hz, 1H), 1.15 (d, J = 6.2 
Hz, 3 H), 0.98 (d, J = 6.4 Hz, 3H). ESI
+
-LRMS calculated for C27H26N4O2SNa
+
 493.17, 
found [M + Na]
+
 493.26. 
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Synthesis of α-N-Fmoc-L-thiovaline-benzotriazolide (S2)    Thiovaline (ValS or 
V
S
) precursor was synthesized by Solongo Batjargal using a similar procedure as detailed 
in J. Am. Chem. Soc. 2012, 134, 9172−9182. 
 
Peptide Synthesis and Purification   Peptides were synthesized using standard 
Fmoc solid phase peptide synthesis (SPPS) procedure on either Rink Amide or 2-
chlorotrityl chloride resin (100 - 200 mesh; 0.6 mmol substitution/g). For ChB and C
b
PGo 
latent thioesters, the linkers were first installed, and then the remaining sequences were 
completed using the standard procedure. For coupling, 5 equiv of amino acid and 5 equiv 
of HBTU were dissolved in DMF, and then added to the resin. 10 equiv of N,N-
diisopropylethylamine (DIPEA) was then added, and the mixture was stirred for 30 min. 
For deprotection, 20% piperidine in DMF was stirred with the resin for 20 min. 
Thioleucine (Leu
S
 or L
S
) and thiovaline (Val
S
 or V
S
) were introduced as activated 
benzotriazole precursors
283,115
; 3 equiv of the precursor was dissolved in DMF, and 
stirred with the resin for 1 h in the presence of 10 equiv DIPEA. For N-terminally 
acetylated peptides, an acetylation cocktail of 1:1:8 acetic anhydride/N-
methylmorpholine/DMF was stirred with the resin twice, each for 10 min, after the last 
deprotection. Upon completion of SPPS, resins were rinsed thoroughly with CH2Cl2 and 
dried under vacuum. 
 
For cleavage, resins were treated with a cleavage cocktail (38:1:1 trifluoroacetic 
acid/triisopropylsilane/H2O unless otherwise specified) for 30 min. The solution was then 
collected by filtration, and dried by rotary evaporation. For purification, the crude 
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residues were brought up in 1:10 CH3CN/H2O, and then purified by reverse phase HPLC 
with acidified (with 0.1% trifluoroacetic acid) CH3CN/H2O gradients. Individual 
fractions were charac-terized by MALDI-TOF MS, and dried by lyophilization. When 
necessary, the isolated products were subjected to multiple rounds of purification until 
99.5% pure by MALDI-TOF MS and analytical HPLC. Solvent radients, retention times 
and MALDI-TOF MS results are listed in Table 2-1 through Table 2-3. 
 
Table 2-1.  Peptide Purification Methods and Retention Time. 
Peptide Gradient 
Retention 
Time 
Column 
Ac-GL
S
KXAG-ChB-NH2 (7) 1 20.9 min Vydac C18 semi-prep 
CAX-NH2 (8) 2 18.5 min Vydac C18 semi-prep 
Ac-GL
S
KXAG-C
b
PGo (11) 1 19.2 min Vydac C18 semi-prep 
Ac-MDV
S
FMKGL-C
b
PGo (13) 5 21.0 min Vydac C18 semi-prep 
αS9-140C9 (14) 6 24.4 min Vydac C4 prep 
    
* X = 7-methoxycoumarinylalanine;  L
S
 = thioleucine;  V
S
 = thiovaline. 
 
Table 2-2.  HPLC Gradients for Peptide Purification and Characterization. 
No. 
Time 
(min) 
%B  No. 
Time 
(min) 
%B  No. 
Time 
(min) 
%B 
1 0:00 2  2 0:00 2  3 0:00 2 
 5:00 2   5:00 2   6:00 2 
 10:00 30   10:00 15   30:00 50 
 30:00 50   25:00 30   40:00 100 
 35:00 100   30:00 100   45:00 100 
 40:00 100   35:00 100   50:00 2 
 45:00 2   40:00 2     
           
4 0:00 2  5 0:00 2  6 0:00 5 
 5:00 2   5:00 2   5:00 5 
 10:00 20   10:00 40   15:00 35 
 25:00 50   25:00 55   30:00 50 
 30:00 100   30:00 100   35:00 100 
 35:00 100   35:00 100   40:00 100 
 40:00 2   40:00 2   45:00 2 
           
* Solvent A: 0.1% trifluoroacetic acid in water;  Solvent B: 0.1% trifluoroacetic acid in acetonitrile  
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Table 2-3.  MALDI-TOF MS Characterization of Purified Peptides. 
Peptide 
[M + H]
+
 [M + Na]
+
 
Calc’d Found Calc’d Found 
Ac-GL
S
KXAG-ChB-NH2 (7) 939.37 939.23 961.36 961.20 
CAX-NH2 (8) 437.14 436.99 459.13 458.96 
Ac-GL
S
KXAG-C
b
PGo (11) 1093.44 1093.36 1115.43 1115.34 
Ac-MDV
S
FMKGL-C
b
PGo (13) 1357.58 1357.38 1379.56 1379.50 
αS9-140C9 (14) 13552.2 13552.8 - - 
     
* X = 7-methoxycoumarinylalanine;  L
S
 = thioleucine;  V
S
 = thiovaline. 
 
 
Synthesis of Peptide-ChB Latent Thioester (7)   Rink amide resin (25 µmol, 0.6 
mmol/g substitution, 1 equiv) was swollen in dimethylformaide (DMF) for 1 h, and then 
deprotected twice with 2 mL of 20% piperdine in DMF for 20 min each. For ChB 
installation, TBS-ChB-OH (6, 0.0089 g, 27.5 μmol, 1.1 equiv) and PyBOP (0.0143 g, 
27.5 μmol, 1.1 equiv) were dissolved in 2 mL of DMF, and then added to the resin. 
DIPEA (43.5 μL, 250 μmol, 10 equiv) was added, and then the reaction was allowed to 
proceed for 90 min with stirring. Upon completion, the resin was thoroughly rinsed with 
DMF and CH2Cl2, and then stirred in tetrahydrofuran (THF) for 1 h for equilibration. For 
TBS deprotection, 2 mL of 1.0 M tetra-n-butylammonium (TBAF) in THF was added. 
The reaction was allowed to proceed for 4 h, and then thoroughly rinsed with THF. 
 
For coupling of the next residue Gly, Fmoc-Gly-OH (0.0516 g, 125 μmol. 5 equiv) 
and dicyclohexylcarbodiimide (DCC, 0.0129 g, 62.5 μmol, 2.5 equiv) were dissolved in 2 
mL of THF, and then pre-activated for 30 min. Dicyclohexylurea (DCU) side product 
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was removed by filtration, and then the clear solution was added to the resin. Catalytic 
amount of 4-dimethylaminopyridine (DMAP, 0.0003 g, 2.5 µmol, 0.1 equiv) was added, 
and then the reaction was allowed to proceed for 45 min. Upon completion, the resin was 
thoroughly rinsed with THF, and then stirred in DMF for 1 h for equilibration. The rest of 
the sequence was elongated using standard SPPS protocol, cleaved with 3:7 trifluoro-
acetic acid/CH2Cl2 (3 mL), and purified by reverse phase HPLC (Table 2-1 to Table 2-3). 
 
Test Ligation of Peptide-ChB Latent Thioester    A ligation buffer (20 mM  TCEP, 
200 mM Na2HPO4, pH 6.8) was freshly prepared and degassed by argon purging. 7 (10 
nmol, ε325 = 12,000 M
-1
 cm
-1
, 1 equiv) and 8 (100 nmol, ε325 = 12,000 M
-1
 cm
-1
, 10 equiv) 
was each dissolved in 10 µL of ligation buffer and then combined. The reaction was 
allowed to proceed at 37 ˚C for various amount of time under argon atmosphere. Upon 
completion, 5 µL of the reaction mixture was removed, diluted into 795 uL of H2O, and 
analyzed by reverse phase HPLC on a Luna C8 analytical column using gradient 3. 
Fractions were collected for MALDI-TOF MS analysis, and UV-Vis absorption profiles 
were extracted from data acquired by photodiode array detector on analytical HPLC. 
 
 
Figure 2-16.  UV-Vis Absorption Spectra for Intermediate 9a and 9b. 
 
(9a) 
9a 
(9b) 
9b 
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Denaturant Tolerance of ChB Ligation    Reactions were conducted similarly to the 
standard ChB ligation procedure, except that a ligation buffer containing 6 M Gdn∙HCl 
was used. The presence of denaturant resulted in slower reaction kinetics, but otherwise 
no additional complications were observed. 
 
 
Figure 2-17.  Denaturant Tolerance of ChB Ligation between 7 and 8. 
 
Synthesis of Peptide-C
b
PGo Latent Thioester (11)    Ac-GL
S
KXAG-C
b
PGo 11 (X = 
7-methoxycoumarinylalanine) was synthesized on Rink amide resin (100 μmol, 0.6 
mmol/g).  The resin was deprotected with 20% piperidine in dimethylformamide (DMF), 
thoroughly rinsed, and then dried on vacuum.  Bromoacetic acid (0.0695 g, 500 μmol, 5 
equiv) was pre-activated with dicyclohexylcarbodiimide (DCC, 0.0516 g, 250 μmol, 2.5 
equiv) for 30 min in anhydrous DMF (6 mL); dicyclohexylurea (DCU) side product was 
removed by filtration, and then the clear solution was added to the resin. The reaction 
was allowed to proceed with stirring for 30 min, and then thoroughly rinsed with DMF.  
Subsequently, Fmoc-Pro-OH (0.1687 g, 500 μmol, 5 equiv) was dissolved in anhydrous 
DMF (6 mL) with diisopropylethylamine (DIPEA, 174.3 μL, 1 mmol, 10 equiv), and 
coupled to the resin for 30 min.  
  
9a 
9b 
9c 
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The next two residues were introduced as a dipeptide, to avoid premature diketo-
piperazine (DKP) formation on resin (Figure 2-18).  To accomplish this, Fmoc-Gly-
Cys(tButhio)-OH was synthesized on 2-chlorotrityl resin at 125 μmol scale using 
standard SPPS, and cleaved with 1:1:8 acetic acid/trifluoroethanol/CH2Cl2.  The crude 
product (0.0537 g, 110 μmol, 1.1 equiv) was dissolved in anhydrous DMF (6 mL) with 
PyBOP (0.0572 g, 110 μmol, 1.1 equiv) and DIPEA (174.3 μL, 1 mmol, 10 equiv), and 
then coupled to the resin for 1 h.  The rest of the peptide was elongated and acetylated 
with standard SPPS. For cleavage, the resin was treated with 30:70 trifluoroacetic 
acid/CH2Cl2 (6 mL) for 30 min, dried by rotary evaporation, and then purified by reverse 
phase HPLC (Table 2-1 through Table 2-3). 
 
 
Figure 2-18.  Necessity of Fmoc-Xaa-Csb-OH in Preventing DKP Formation in SPPS. 
 
Ligation between Peptide-C
b
PGo and Cys    A 2x ligation buffer (100 mM TCEP, 
400 mM Na2HPO4, pH 8.4) was freshly prepared and degassed by argon purging. Ac-
GL
S
KXAG-C
b
PGo 11 (100 nmol, ε325 = 12,000 M
-1
 cm
-1
) was dissolved in argon-purged 
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water (30 μL), and mixed with 20 μL of 5x Cys stock (50 mM in argon-purged water).  
50 μL of 2x ligation buffer was added, and then the reaction was allowed to proceed at 37 
˚C for 10 h.  At appropriate time points, a 4 μL sample was removed from the reaction 
mixture, quenched with 796 μL of 0.1% trifluoroacetic in water, and analyzed by reverse 
phase HPLC on a Luna C8 analytical column using gradient 4. Fractions were collected 
for MALDI-TOF MS analysis, and UV-Viv absorption profiles were extracted from data 
acquired by photodiode array detector on analytical HPLC. 
 
Kinetic Characterization of C
b
PGo Ligation    To obtain a kinetic profile of C
b
PGo 
ligation, HPLC chromatograms of samples taken at various time points were integrated 
for areas under the curve based on absorbance at 325 nm (λmax for Mcm, 7-methoxycou-
marinylalanine). Peak identities were assigned based on MALDI MS, and then LC area 
percentages (LCAP) were calculated using equation S1: 
LCAP = Area of individual peak at 325 nm / Area of all peaks at 325 nm    (S1) 
 
For data fitting, LCAP for each peak was averaged from three independent trials, and 
plotted against the time point at which they were obtained. Since all Mcm-containing 
peptides originate from the reactant peptide 11, their total concentration will stay the 
same as initial concentration of 11 (1 mM) and their individual concentrations (in terms 
of molarity) will also be proportional to their LCAPs. With Cys in large excess (10 equiv) 
and the rapid conversion of C
b
PGo to its reduced form, the reaction can be assumed as a 
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pseudo-first-order reaction of the reduced reactant 11a. Therefore, LCAPs were fitted to a 
single exponential decay function S2 using Microcal Origin 6.0 Pro ((Northampton, MA).  
LCAP = LCAP0 + A ∙ exp [ -t / τ ]      (S2) 
 
The fitting parameters were then converted into pseudo first order rate constant k1’, 
second order rate constant k2, and half-life t1/2 using equations S3 through S5. 
k1’ = 1 / τ           (S3) 
k2 = k1 / [Cys]    (S4) 
t1/2  =  τ · ln2      (S5) 
 
With an R-value of 0.9998, the experimental pseudo first order rate constant k1’ was 
calculated to be (1.53 ± 0.06) × 10
-4
 s
-1
, corresponding to a second order rate constant k2 
of (1.53 ± 0.06) × 10
-2
 s
-1 
and a reaction half-life t1/2 of (75 ± 1) min. 
 
Diketopiperazine (DKP) Thioester Intermediate    The DKP thioester intermediate 
S3 could be observed when 0.1 mM peptide-C
b
PGo 11 was incubated with ligation buffer 
in the absence of Cys (Figure 2-19).  Briefly, 11 (10 nmol, ε325 = 12,000 M
-1
 cm
-1
) was 
dissolved in 50 μL of argon-purged water, and then 50 μL of 2x argon-purged ligation 
buffer stock (100 mM TCEP, 400 mM Na2HPO4, pH 8.4) was added. The reaction was 
allowed to proceed at 37 ˚C for 45 min, and then quenched with 900 μL of 0.1% 
trifluoroacetic acid in water and analyzed by reverse phase HPLC on a Vydac C18 
analytical column using gradient 4. Fractions were collected for MALDI-TOF MS. 
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Denaturant Tolerance of C
b
PGo Ligation    Three Cys stocks (10 mM Cys, 20 mM 
TCEP, 200 mM Na2HPO4, pH 8.0) were prepared with various additives: A) none; B) 6 
M Gdn·HCl; C) 6 M Gdn·HCl and 50 mM 4-mercaptophenylacetic acid (MPAA). For 
each condition, 11 (20 nmol, ε325 = 12,000 M
-1
 cm
-1
) was dissolved in the corresponding 
Cys stock (20 μL), and allowed to react at 37 ˚C for 2 h. Upon completion, the reaction 
was diluted into 780 μL of 0.1% trifluoroacetic acid in water, and analyzed by reverse 
phase HPLC (Figure 2-20). The results showed that the presence of Gdn·HCl led to 
slower kinetics, whereas the addition of MPAA could partially “rescue” the reactivity. 
 
 
Figure 2-19.  Diketopiperazine (DKP) Intermediate in C
b
PGo Ligation. 
 
(S3) 
S3 
(S4) 
(S5) 
S4 S5 
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Figure 2-20.  Effects of Denaturant and Thiol Additive on C
b
PGo Ligation. 
 
Synthesis of Fmoc-Leu-Cys(S-tBu)-OH (S6)   Fmoc-Leu-OH (1.0602 g, 3 mmol, 
1.5 equiv) was dissolved in 20 mL of tetrahydrofuran (THF), and chilled to 0 °C on ice. 
N-Methylmorpholine (NMM, 769 µL, 7 mmol, 3.5 equiv) and isobutyl chloroformate 
(IBCF, 290 µL, 2.2 mmol, 1.1 equiv) were added, and then the reaction was stirred for 15 
min on ice. S-t-butylmercapto-L-cysteine (0.4186 g, 2 mmol, 1 equiv) was added, and the 
reaction was allowed to proceed at room temperature overnight (≥ 14 hr) under an argon 
atmosphere. Upon completion, solvent was removed by rotary evaporation. The residue 
was brought up in 40 mL of ethyl acetate, and extracted against 40 mL each of 1 M HCl 
and brine. The crude product was purified by flash chromatography in 40:60 ethyl 
acetate/petroleum ether with 0.1% acetic acid. A white foam was yielded as the final 
product (0.7643 g, 1.29 mmol, 70% yield). Rf 0.5 in 4:6 ethyl acetate/petroleum ether 
with 0.1% acetic acid. 
1
H NMR (500 MHz, CDCl3): δ 10.38 (s, 1H), 7.73 (d, J = 7.1 Hz, 
2H), 7.59 (t, J = 6.8 Hz, 2H), 7.41 (d, J = 7.0 Hz, 1H), 7.38 (t, J = 7.2 Hz, 2H), 7.29 (t, J 
11a 
12 
11a 
12 
11a 
12 
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= 7.2 Hz, 2H), 5.95 (d, J = 8.3 Hz, 1H), 4.86 (m, 1H), 4.45 (m, 1H), 4.38 (m, 2H), 4.21 (t, 
J = 6.5 Hz, 1H), 3.28 (dd, J = 13.4, 3.9 Hz, 1H), 3.17 (dd, J = 13.3, 6.0 Hz, 1H), 1.69 (m, 
2H), 1.59 (m, 2H), 1.26 (s, 9H), 0.94 (m, 6H). 
13
C NMR (500 MHz, CDCl3): δ 173.10, 
156.72, 144.09, 143.86, 141.48, 127.93, 126.33, 125.41, 120.17, 68.90, 67.56, 53.60, 
52.71, 48.37, 47.29, 41.89, 41.54, 30.02, 29.96, 28.08, 24.87, 23.15, 22.34, 22.29. ESI
+
-
HRMS: calculated for C28H37N2O5S2
+
 545.2144, found [M + H]
+
 545.2150. 
 
Synthesis of Ac-αS1-8V
S
3-C
b
PGo (13)    Rink amide resin (100 µmol, 0.6 mmol/g 
substitution) was swollen in anhydrous DMF for 1 h, and then deprotected twice with 6 
mL of 20% piperidine in anhydrous DMF, each for 20 min. BrCH2COOH (0.0695 g, 500 
µmol, 5 equiv) was dissolved in 6 mL of anhydrous DMF, and pre-activated with 
diisopropylcarbodiimide (DIC, 78 μL, 500 µmol, 5 equiv) for 20 min. The mixture was 
then transferred to the resin, and the coupling reaction was allowed to proceed for 45 
min. For Pro installation, Fmoc-Pro-OH (0.1687 g, 500 µmol, 5 equiv) was dissolved in 6 
mL of anhydrous DMF and transferred to the resin. DIPEA (174 μL, 1 mmol, 10 equiv) 
was added, and then the reaction was allowed to proceed for 4 h. A second coupling was 
repeated with fresh Fmoc-Pro-OH/DIEPA/DMF overnight (≥ 8 h). The resin was then 
deprotected with 6 mL of 20% piperidine in anhydrous DMF for 20 min. 
 
To install the next two amino acids as dipeptide, Fmoc-Leu-Cys(S-tBu)-OH (0.1634 
g, 300 µmol, 3 equiv) was dissolved in 6 mL of anhydrous DMF, and pre-activated with 
PyBOP (0.1561 g, 300 µmol, 3 equiv) and DIPEA (174 μL, 1 mmol, 10 equiv) for 3 min. 
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The mixture was then transferred to the resin, and the coupling reaction was allowed to 
proceed for 4 h. The rest of the sequence was assembled using standard SPPS procedure. 
 
For cleavage, the resin was treated with 6 mL of 1:1:2:20 1,2-ethanedithiol/triiso-
propylsilane/thioanisole/trifluoracetic acid for 30 min. The solution was then collected by 
filtration, concentrated by rotary evaporation, and then precipitated with 10 mL of cold 
diethyl ether. The pellets were collected by centrifugation at 4 krpm for 20 min, and then 
brought up in 50:50 H2O/CH3CN for reverse phase HPLC purification. 
 
Over-expression and Purification of αS9-140C9 or αS9-140C9W94     Expression and 
purification were performed by Solongo Batjargal as detailed in J. Am. Chem. Soc. 2012, 
134, 9172−9182. Briefly, a plasmid encoding for HTag-αS9−140C9 or HTag-αS9−140C9W94 
were transformed into E. coli BL21 DE3 cells, and over-expressed with isopropyl-β-D-
thiogalactopyranoside (IPTG) induction. After lysis of the cells, target protein was pulled 
down by Ni-NTA resin, and treated with Factor Xa to remove the HTag. The crude was 
then dialyzed against water, and further purified by reverse phase HPLC on a Vydac C4 
prep column using gradient 6 (Tables Table 2-1 through Table 2-3). 
 
Ligation between Ac-αS1-8V
S
3-C
b
PGo and αS9-140C9 or αS9-140C9W94     Latent 
thioester Ac-αS1-8V
S
3-C
b
PGo 13 (90 nmol, 1.5 equiv) and expressed protein fragment αS9-
140C9 or αS9-140C9W94 (60 nmol, 1 equiv) were dissolved in 60 μL of freshly degassed 
ligation buffer (6 M Gdn·HCl, 200 mM Na2HPO4, 20 mM TCEP, 1% v/v thiophenol, and 
1% v/v benzylmercaptan, pH 8.0). The reaction was allowed to proceed for 24 h at 37 °C, 
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and then quenched with 940 µL of 0.1% trifluoroacetic acid in water. The crude was 
dialyzed against water, and purified by reverse phase HPLC. Fractions were collected, 
characterized by MALDI-TOF MS, and then lyophilized until further use. 
 
 
Figure 2-21.  HPLC Chromatogram of Ligation between αS1-8V
S
3-CbPGo and αS9-140C9. 
Peaks a, b,and c correspond to hydrolyzed Ac-αS1-8V
S
3-C
b
PGo, αS9-140C9, and the ligation 
product, Ac-αS1-140V
S
3C9. UV absorbance monitored at 215 and 277 nm. 
 
 
Figure 2-22.  HPLC Chromatogram of Ligation between αS1-8V
S
3-CbPGo and αS9-140C9W94. 
Peaks a, b, and c correspond to hydrolyzed Ac-αS1-8VS3-C
b
PGo, αS9-140C9W94, and ligation 
product, Ac-αS1-140VS3C9W94. UV absorbance monitored at 215 and 270 nm. The large peak 
at 20 min is excess thiophenol additive. 
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Trypsin Digest Analysis of Ac-αSVS3C9    Ligated Ac-αSV
S
3C9 15 (20 μg) was 
dissolved in 18 μL of digestion buffer (25 mM NH4HCO3, pH 7.5), and treated with 2 μL 
of sequencing-grade modified trypsin (0.1 μg/μL). The digestion was allowed to proceed 
at 37 °C for 4 h, and then analyzed by MALDI-TOF MS. 
 
UV-Vis Absorption Spectroscopy Analysis    αS9-140C9 contains four Tyr with a 
molar absorption of 5,340 M
-1
 cm
-1
 at 273 nm; Ac-αSVS3C9 contains four Tyr and one 
thioamide with a molar absorption of 15,368 M
-1
 cm
-1
 at 273 nm.  Therefore, the molar 
absorption ratio (Ac-αSVS3C9: αS9-140C9) at 273 nm is 2.88.  The absorption spectra of the 
two proteins were normalized by assuming that the molar absorption of Ac-αSVS3C9 (140 
residues) at 218 nm is 1.07 times that of αS9-140C9 (131 residues).  The experimental 
absorbance ratio (Ac-αSVS3C9: αS9-140C9) at 273 nm is 2.84, indicating 2.84/2.88 = 99 % 
thioamide incorporation. 
 
 
Figure 2-23.  Normalized UV-Vis Absorption Spectra of αS Ligation.   
αS9-140C9 (green line), αSV
S
3C9 red line), and difference spectrum (blue line). 
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Aggregation of Ac-αS1-140V
S
5C9W94    Aggregation experiments were performed 
according to literature precedence.
284,285
 First, 350 μL samples for aggregation assays 
were prepared (97 μM WT αS with 3 μM αSW94 or 3 μM Ac-αSV
S
3C9W94) in phosphate-
buffered saline (pH 7.0) containing 1 mM β-mercaptoethanol. Aggregation was seeded 
by the addition of approximately 10% (wt/wt) pre-formed WT αS fibrils. The samples 
were incubated at 37 °C for 4−6 days with continuous shaking at 1,100 rpm. Periodically, 
40 μL aliquots were removed to monitor changes in Trp fluorescence and ThT binding.  
 
For fluorescence spectroscopy, the 40 μL aliquots were diluted to 120 μL with 
phosphate buffered saline prior to loading the sample into quartz cuvettes. To selectively 
monitor changes in Trp fluorescence in the presence of tyrosine, the excitation 
wavelength was 295 nm and emission data was collected from 315 to 385 nm. ThT 
binding was determined by directly adding 1 mL of ThT solution (20 μM in phosphate 
buffered saline) to the cuvette after monitoring Trp fluorescence. The samples were 
incubated within the cuvettes for two minutes prior to collecting ThT fluorescence data. 
The excitation wavelength was 446 nm and emission data was collected from 460 to 600 
nm. For all experiments, the temperature was 37 °C, the excitation and emission slit 
widths were 5 nm, the scan rate was 120 nm/min with an averaging time of 0.5 s, and the 
data interval 1.0 nm. Examples of primary spectra are shown below. 
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Figure 2-24.  Examples Fluorescence Spectra from αS Aggregation Experiments. 
Left: Trp fluorescence, excited at 295 nm. Right: ThT fluorescence, excited at 436 nm. In both 
cases, red, green, and blue indicate data at 0, 8, and 72 h respectively. Solid lines: 1:30 
αSW94/WT mix. Broken lines 1:30 Ac-αSV
S
3C9W94/WT mix. With Rebecca F. Wissner. 
 
PAGE Gel Analysis of Aggregation Experiments    Immediately following the 
assembly of the aggregation reaction, a 10 μL aliquot from each sample was removed for 
PAGE gel analysis and stored at - 80 °C. After 96 hours of aggregation, an additional 10 
μL aliquot was removed from each sample. Each aliquot was diluted to 30 μL with 
MilliQ water and centrifuged for 45 min at 13,200 rpm to determine the loss of soluble 
protein post-aggregation. 15 μL of the resultant supernatant was removed from the 
centrifuged samples and run on an 18% SDS-PAGE gel. The gel was stained with 
Coomassie blue and scanned. 
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Figure 2-25.  PAGE Gel Analysis of Aggregation Experiments. 
Gel band intensity of soluble fraction before aggregation (Pre) and after 4 days of aggre-
gation (Post) shows a loss of soluble monomer due to fibrillization. With Rebecca F. Wissner. 
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Chapter 3 .  Chemoselective Desulfurization and Deselenization for Traceless 
Incorporation of Thioamides into Peptides and Proteins 
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3.1  Introduction 
While traditional native chemical ligation (NCL), as developed by Kent
128
, was 
proven successful in incorporating thioamides into peptides and proteins, one inherent 
limitation of this method is the necessity of a Cys at the ligation site (Figure 3-1A). This 
greatly restricts the scope of thioamide incorporation – Cys is among the least abundant 
amino acids (2.4% frequency in the human proteome
286
) and does not exist in the native 
sequences of many protein targets, including α-synuclein, a Parkinson’s disease protein 
of interest to our laboratory For these systems, thioamide incorporation via NCL would 
leave an artifact of residual Cys in the ligated product, undermining the utility of the 
thioamide as a minimalist probe and introducing complications during biophysical 
studies. In fact, it has been clearly demonstrated that Cys mutations in αS can alter its 
aggregation and cellular toxicity.
287
 
  
To circumvent the Cys limitation in NCL, various groups have developed traceless 
methods by either masking or “erasing” the side chain thiol. Masking techniques utilize 
alkyl halides to convert Cys into Lys/Glu/Gln analogs, or homocysteine (Hcs) into Met 
after ligation
130
 (Figure 3-1C). The former is not truly traceless since it results in a 
thioether linkage (and an extra methylene group as in the case of Glu/Gln) that is 
chemically and electrostatically different from the native residue. Hcs methylation does 
yield a native Met, and has previously been utilized by our group for the synthesis of 
thioamide-containing proteins
269,288
, granting access to another 2.1% of potential ligation 
sites (Met abundance out of all 20 natural amino acids).
286
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Figure 3-1.  Comparison of Traditional and Traceless Native Chemical Ligation (NCL). 
A)  Traditional NCL utilizes an N-terminal Cys as the nucleophile, and leaves a residual Cys 
in the ligated product.  B) Traceless NCL via desulfurization/deselenization requires a Cys or 
β-thiol/selenol analog as the nucleophile; the thiol/selenol is chemically removed after NCL.  
C) Traceless NCL via masking uses either Cys or homocysteine (Hcs) as the nucleophile; the 
thiol is subsequently masked into a functionalized thioether to mimic the natural side chain.    
* Conditions are different for Ser as compared to all other amino acids. 
 
The true paradigm shift, though, would come from adopting recently developed 
desulfurization /deselenization methods, where the N-terminal residue is decorated with a 
thiol or selenol at its β- or γ-carbon as the NCL handle, and then chemically “erased” 
after ligation to become the native amino acid
218,202
 (Figure 3-1B). These methods are 
extremely versatile – with nearly identical reaction conditions, it has thus far been 
concretely demonstrated on 12 amino acids
219
 and theoretically possible for 19 out the 20 
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amino acids (except for Gly which does not have a β-carbon). In addition, the β-selenol 
analogs offer a second level of selectivity against native Cys residues, where the mild 
deselenization conditions using tris(2-carboxyethyl)phosphine (TCEP) are fully 
compatible with side chain thiols.
216
 However, it is unclear whether such methods would 
be amenable to the incorporation of thioamides into peptides and proteins, particularly in 
the case of desulfurization. Since both the thioamide and Cys contain a sulfur atom, 
characterizing and fine-tuning the chemoselectivity would seem quite challenging. 
 
Upon a closer examination at the reactions utilized – namely desulfurization by 
Raney nickel, desulfurization by VA-044, and deselenization by TCEP – we hypothesize 
that Raney nickel would be too harsh but the latter two should be feasible for thioamide-
containing peptides and proteins. Raney nickel is well-established for its broad substrate 
scope where thiols, thioethers and thionoesters (thiocarbonyl esters) are all effectively 
desulfurized, largely because of the high nickel-sulfur affinity.
289
 The only well-
characterized precedence of Raney nickel/thioamide reactions was published by 
Kornfield, where he reported a reductive desulfurization into amine (Figure 3-2).
290,291
 
Although the exact reaction conditions would be different in our traceless NCL (for 
example, it will be conducted in aqueous solution instead of organic solvents), one would 
assume that Raney nickel could lead to complications with thioamides.    
 
On the other hand, radical initiated desulfurization and deselenization do not depend 
on metal-sulfur affinity, therefore as long as thioamide could tolerates an environment 
with certain concentrations of radicals, it is possible to conduct traceless ligation while 
104 
 
leaving the thioamide intact. Based on our prior knowledge that thioamide can function 
as an acceptor for photoinduced electron transfer (PET)
115,114
 − where a single electron is 
transferred from thioamide to a paired fluorophore, generating a transient thioamide 
radical cation in the process (Figure 3-3) − we believed that the thioamide could be stable 
towards ambient radicals in desulfurization/deselenization reactions. If our hypothesis 
was valid, we would greatly expand the scope of potential ligation sites and remove the 
possibility of complications from thiol side chains in biophysical assays. 
 
 
Figure 3-2.  Raney Nickel Desulfurization of Cys and Thioamide. 
A)  Mechanism for Cys desulfurization.   B)  Proposed mechanism for reductive thioamide 
desulfurization as reported by Kornfield.  * Raney nickel is denoted as Ni(H) to represent that 
the reagent contains H2 as part of the formulation; it is generally understood that the 
hydrogen in the resulting C−H bond comes from the Raney nickel reagent. 
 
 
Figure 3-3.  Transient Thioamide Radical Cation in Photo-induced Electron Transfer (PET).  
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3.2  Results and Discussion 
We began by establishing the compatibility of the thioamide with various desulfuri-
zation/deselenization methods. First, we tested Raney nickel desulfurization on model 
peptide 1. Upon treatment with Raney nickel, peptide 1 is fully consumed; surprisingly, 
instead of a secondary amine from reductive desulfurization
290
, cleavage at the thioamide 
bond was observed, yielding peptide 1a with an N-terminal amine at the cleavage site 
(Figure 3-4). We reasoned that since the reaction was conducted in an aqueous solution 
(instead of organic solvents as in the previous study), water could serve as an excellent 
nucleophile to attack the thiocarbonyl group that is activated by nickel-sulfur binding 
(Figure 3-5). While Raney nickel has been a useful reagent in other contexts, it is evident 
that such method would not be a viable option for the incorporation of thioamides. 
 
We next sought to explore the compatibility of the thioamide with radical initiated 
desulfurization/deselenization. We chose to start with TCEP induced deselenization, to 
take advantage of our prior knowledge that the thioamide per se is stable towards 
TCEP.
283
 Without attempting to synthesize a complex Sec-containing peptide in this 
initial trial, we designed a one-pot ligation-deselenization reaction, where a thioamide-
containing CPGo thioester 2a (CPGo = Cys-Pro-Gla latent thioester; see Chapter 2) was 
ligated to selenocystine, and then treated with TCEP for deselenization. We were 
delighted to find that both the ligation and deselenization proceeded smoothly and 
chemoselectively, where peptide 2d was generated as the final product (Figure 3-6). 2d 
exhibited the characteristic thioamide π-π* absorption at 272 nm, giving us confidence  
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Figure 3-4.  Non-Selective Desulfurization of Cys and Thioamide by Raney Nickel. 
A) Schematic representation of the test reaction.  B) HPLC chromatogram monitored at 325 
nm, and MALDI-TOF mass spectra for major peak in each chromatogram;  [1 + H]
+
: expected 
1262.96, found 1262.56;  [1a + H]
+
: expected 988.53, found 988.46;  [1b + H]
+
: expected 
1230.63, found 1230.62.  C) UV-Vis absorption spectra of isolated peptides. The star sign 
indicates thioamide absorption at 272 nm, which was absent in 1a. Conditions: 0.1 mM 
peptide 1, 0.1% w/v Raney nickel, 100 mM Na2HPO4, 10 mM TCEP, pH 5.8, 12 h. TCEP = 
tris(2-carboxyethyl)phosphine;  Mcm = 7-methoxycoumarinylalanine. 
(1) 
(1a) 
(1b) 
1 1a 1b 
1 
1a 
1b 
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Figure 3-5.  Proposed Mechanism for Raney Nickel Induced Thioamide Bond Cleavage. 
 
that the thioamide remained intact throughout the process. It is interesting to note that due 
to the unique activity of selenol
292,293
, two ligation intermediates were isolated − namely 
homodimer 2b via a Sec diselenide bond and monomer 2c that was sequestered at Sec 
through a hemiselenide bond to a −SPh group from ambient thiophenol used in the 
ligation – instead of free selenol. In subsequent deselenization, both species were reduced 
into selenol upon treatment with dithiothreitol (DTT) and converted into Ala. 
 
The positive results from selective deselenization prompted us to further investigate 
the possibility of selective desulfurization with VA-044 as radical initiator  This is a more 
challenging method for two reasons:  1) there is a smaller energy difference  between a 
C=S double bond (standard bond enthalpy 137 kcal∙mol-1) and C−S single bond (65 
kcal∙mol-1), than with a C−Se single bond (56 kcal∙mol-1)77, requiring the method to be 
more stringently discriminating against the thioamide; 2) mechanistically, deselenization 
of Sec does not require ambient radicals and is simply initiated by spontaneous cleavage 
of the Se−X (X = Se, S, H) bond, whereas desulfurization of Cys requires high  
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Figure 3-6.  Selective Deselenization of Sec in the Presence of Thioamide. 
A) Schematic representation of the test reaction; a reduced version of CPGo instead of the 
tBuS-protected C
b
PGo was used to eliminate the need for TCEP as a reducing reagent in 
ligation.  B) HPLC chromatogram monitored at 325 nm, and UV-Vis absorption spectra of 
isolated peptides. The star sign indicates thioamide absorption at 272 nm; 2c also contained 
a peak around 260 nm that is characteristic of −SPh group. Ligation Conditions: 0.2 mM 
peptide 2a, 2 mM selenocystine, sat. PhSH, 200 mM Na2HPO4, pH 8.0, 12 h. Deselenization 
Conditions: 0.2 mM ligated peptide (without purification), 20 mM TCEP, 20 mM DTT, 200 mM 
Na2HPO4, pH 8.0, overnight. MALDI MS:  [2a + H]
+
, expected 1005.42, found 1005.35; [2b + 
H]
+
, expected 1795.55, found 1795.41; [2c + H]
+
, expected 1007.29, found 1007.25; [2d + 
H]
+
, expected 819.37, found 819.19. TCEP = tris(2-carboxyethyl) phosphine;  DTT = 
dithiothreitol;  Mcm = 7-methoxycoumarinylalanine. 
 
(2a) 
(2b) 
(2c) 
(2d) 
2a 
2b 2c 
2d 
2a 
2b 2c 
2d 
B) 
A) 
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concentrations of ambient radicals that are initiated by VA-044 and propagated by thiol 
additives to sever the C−S bond (Figure 3-7).  
 
 
Figure 3-7.  Proposed Mechanisms for TCEP Deselenization and VA-044 Desulfurization. 
 
We carried out our initial test on peptide 3, using an intermediate VA-044 
concentration and short reaction time to minimize potential thioamide complications. We 
were excited to find that Cys can be selectively desulfurized in the presence of a 
thioamide, generating 3a as the major product in 80% yield in 10 min (Figure 3-8). The 
nearly identical UV-Vis absorption profiles of isolated product as compared to the 
reactant demonstrated that the thioamide remained intact in Cys desulfurization 
(normalized A272 nm = 0.48 for both product and reactant). These results gave us 
confidence that the thioamide was indeed compatible with the radical initiated 
desulfurization/deselenization methods. Given that β-thiol analogs are much easier to 
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handle than β-selenol compounds in terms of synthetic efforts and air-sensitivity, we 
decided to pursue VA-044 desulfurization as the primary method for traceless NCL 
incorporation of thioamides, and reserve TCEP deselenization for situations where 
additional selectivity against Cys is needed. 
  
 
Figure 3-8.  Selective Desulfurization of Cys in the Presence of Thioamide. 
A) Schematic representation of the test reaction.  B) HPLC chromatogram monitored at 325 
nm. 3a’ denotes a genuine product standard synthesized via solid phase peptide synthesis 
(SPPS) for comparison. MALDI-TOF MS: [3 + H]
+
, expected 1482.62, found 1482.66; [3a + 
H]
+
, expected 1450.64, found 1450.70; [3a’ + H]
+
, expected 1450.64, found 1450.74. C) UV-
Vis absorption of isolated peptides. Star indicates thioamide absorption. Conditions: 0.1 mM 
peptide 3, 10 mM VA-044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH (v/v) pH 7.0. 
 
(3a) 
(3) 
3a 
3 
3a’ 
3a’ 3a 3 
* * * 
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To optimize the VA-044 desulfurization reaction, we systematically varied individual 
components of the reaction to identify their optimal concentration. We found that high 
TCEP concentration was necessary to avoid disulfide bond formation (Figure 3-22), 
which was likely an off-pathway product from collisional quenching of thiol radicals 
(Figure 3-9). A high concentration of TCEP serves the dual function of ensuring the 
prompt scavenging of thiol radical for on-pathway desulfurization, and reducing the 
disulfide bonded side product to reverse the off-pathway reaction. We also found that the 
reaction was tolerant to a wide range of VA-044 concentrations, and no complications 
were observed with as high as 1000 equivalents of VA-044 (Figure 3-23). We reasoned 
that since the majority of reactive radicals were propagated from the thiol additive 
present at 10% (v/v), the reaction was relatively insensitive to VA-044 excess as long as 
it was above a critical concentration (empirically 10 equivalents for this test reaction). In 
addition, we showed that dissolved oxygen – which may function as collisional radical 
quencher – was well-tolerated (Figure 3-24). Only minor alterations in reaction kinetics 
were observed with no additional complications, eliminating the need to keep the reaction 
buffer degassed and making it easier for other research groups to adopt our methodology.  
 
 
Figure 3-9.  Proposed Mechanism for Off-Pathway Disulfide Bond Formation. 
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Upon a closer examination of the robustness of chemoselectivity against the 
thioamide, we observed that after prolonged exposure to the radical environment, a 
thioamide-to-oxoamide conversion side product 3b gradually accumulated over time 
(Figure 3-26). Although 3b only represented a 6% side reaction after 2 h, it became 
significant after 18 h (17% side product formation). We hypothesize that this is due to the 
amide-to-imine equilibrium, where the stable C=S bond is converted to a labile C−S bond 
as part of the transformation (Figure 3-10). Since this equilibrium is intrinsic to the 
thioamide bond, we turned to “suicide scavengers” in order to suppress the side reaction.  
 
 
Figure 3-10.  Proposed Mechanism for Radical Initiated Thioamide Desulfurization. 
 
After screening a few thiocarbonyl-containing small molecules as candidates, we 
identified thioacetamide as the most effective “suicide scavenger”. Its utility as a 
desulfurization chaperon can be clearly demonstrated on model peptide 3a’ (we use a 
prime symbol to denote the genuine peptide standards in order to distinguish them from 
species identified in desulfurization reactions) – when we treated 3a’ with VA-044 in the 
absence of thioamide, side product 3b was generated at 16% by 18 h; in the presence of 
thioacetamide, 3a’ was fully stable for the same time frame (Figure 3-11B). When we 
applied this additive to the Cys/thioamide peptide 3, the protective effect was equally 
profound – by suppressing thioamide side reaction, the yield of desired product 3a was  
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Figure 3-11.  Thioacetamide as Chaperon to Suppress Thioamide Side Reaction. 
A) Schematic representation of the test reaction.  B) Treatment of control peptide 3a’ with 
VA-044 in the absence and presence of thioacetamide. HPLC chromatograms monitored at 
325 nm. MALDI-TOF MS: [3a + H]
+
, expected 1450.64, found 1450.74; [3b + H]
+
, expected 
1434.67, found 1434.87.  C) Desulfurization of peptide 3 in absence and presence of 
thioacetamide. MALDI-TOF MS: [3a + H]
+
, found 1450.46; [3b + H]
+
, found 1434.44.  D) UV-
Vis absorption spectra of isolated 3b compared to a genuine standard 3b’.  3a’, 3b’ denotes 
the genuine standards synthesized by solid phase peptide synthesis. Star sign indicates the 
absence of thioamide absorption at 272 nm. Conditions: 0.1 mM peptide 3a’ or 3, 10 mM VA-
044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH (v/v) pH 7.0, 18 h. 
(3a) 
(3) 
3a 
3b 
(3b) 
3a 
3a 
3b 
3a 
3a’ + VA-044 
3 + VA-044 
3b 3b’ 
* * 
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improved from 58% to 88% after an 18 h reaction (Figure 3-11C). It is worth noting that 
the residual peak at 21.8 min represented a 2% Cys-to-Ser conversion side reaction rather 
than thioamide-to-oxoamide conversion, which is rigo-rously characterized in Materials 
and Methods (Figure 3-30). As a further validation, we demonstrated that the supper-
ssion was effective over a wide range of thioacetamide concentrations (Figure 3-27), and 
that the oxygen and denaturant tolerance of VA-044 desulfurization was unaltered by the 
addition of thioacetamide (Figure 3-28). 
 
Having established a robust method for selective Cys desulfurization on thioamide-
containing peptides, we next sought to investigate its application in traceless native 
chemical ligation (NCL) – joining two peptide fragments using Cys as a ligation handle, 
and subsequently “erasing” it into an Ala after ligation. There are two general ways to 
achieve ligation-desulfurization – with or without an intermediate purification step on the 
ligated Cys peptide. The latter is obviously advantageous in terms of purification efforts, 
but chemically more challenging as it requires all reagents used in ligation to be compa-
tible with desulfurization. A particular reagent of concern is the aromatic thiol, typically 
thiophenol (PhSH) or 4-mercaptophenylacetic acid (MPAA), that is a common additive 
to accelerate ligation by converting alkyl thioesters into reactive aryl thioesters
136
, but 
also a radical quencher that would sequester the reactivity of tBuS∙ radicals294 (Figure 
3-12). 
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Figure 3-12.  Effects of Aromatic Thiols on One-Pot Ligation Desulfurization. 
 
To solve this problem, we attempted using CF3CH2SH as a non-aromatic substitute 
for aromatic thiols as advocated in a prior study from Payne’s group;294 unfortunately, 
this method did not yield successful ligation in our test reactions, presumably due to the 
high volatility of CF3CH2SH (boiling point 34 °C). Upon a closer examination of 
properties of the various thiols
295
, we hypothesized – contrary to previous claims by other 
groups
294
 – that PhSH can be effectively removed by lyophilization if the pH was kept 
sufficiently low to maintain it in the thiol-free form (Figure 3-13). The thiol-free residue 
can then be brought up in fresh buffer and desulfurized, without the need of additional 
purification steps for PhSH removal. 
 
 
Figure 3-13.  Schematic Representation of Thiol/Thiolate Equilibrium of PhSH. 
See Materials and Methods for theoretical calculations of residual PhSH concentrations from 
a saturated PhSH solution after lyophilization at different pH. 
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Using thioester 4a and Cys-containing peptide 4b, we demonstrated that one-pot 
ligation-desulfurization can be successfully performed in the presence of aromatic thiol 
PhSH, by adopting the simple procedure of acidification and lyophilization (Figure 3-14). 
Both ligation product 4c and desulfurization product 4d perfectly matched the genuine 
peptide standards − 3 and 3a’, respectively − in MALDI-TOF MS, UV-Vis absorption 
and HPLC retention time. Notably, the presence of 7-methoxycoumarin and thioamide 
chromophores deriving from the two fragments was clearly exemplified. With thio-
acetamide present as a desulfurization chaperon, no thioamide-to-oxoamide conversion 
was observed. 
 
With an effective strategy for one-pot ligation-desulfurization, one constraint still 
remains − VA-044 initiated desulfurization would indiscriminately desulfurize all Cys in 
the sequence, limiting its application to proteins without endogenous Cys. To remove this 
constraint, we turned to selective deselenization, where Sec can be selectively converted 
into Ala by TCEP while leaving Cys intact
216
. Having previously demonstrated the 
compatibility of the thioamide with deselenization (see Figure 3-6), we synthesized a 
Sec/Cys/thioamide-containing peptide 5, and subjected it to the standard deselenization 
procedure. Much to our surprise, while the thioamide was unaffected throughout the 
reaction, both selective deselenization on Sec and non-selective desulfurization on Cys 
took place, giving a mixture of 55% Ala/Cys product 5a and 12% Ala/Ala product 5b 
(Figure 3-15).  
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Figure 3-14.  One-Pot Ligation-Desulfurization of Thioamide-Containing Peptides. 
A) Schematic representation of the test reaction.  B) HPLC chromatograms monitored at 325 
nm (4b at 272 nm) and UV-Vis absorption spectra of major peak in each chromatogram. 
MALDI-TOF MS: [4c + H]
+
, expected 1482.62, found 1482.47; [4d + H]
+
, expected 1450.64, 
found 1450.82. Star sign indicates thioamide absorption at 272 nm. Ligation: 1 mM thioester 
4a, 1 mM peptide 4b, 40 mM TCEP, 200 mM Na2HPO4, pH 7.0, overnight. Desulfurization: 
0.1 mM reaction crude 4c, 10 mM VA-044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH 
(v/v) pH 7.0, 2 h. See Figure 3-8 for genuine standards 3 and 3a’. See Materials and 
Methods for residual PhSH characterization. 
(4a) 
4a 
(4b) 
(4c) 
(4d) 
4b 
4c 
4c 
4d 
A) 
B) 
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Figure 3-15.  Selective Deselenization of Sec in the Presence of Cys and Thioamide.  
A) Schematic representation of the test reaction.  B) HPLC chromatograms monitored at 325 
nm. MALDI-TOF MS: [5 + H]
+
, expected 1148.37, found 1148.56; [5a + H]
+
, expected 
1070.48, found 1070.74; [5b + H]
+
, expected 1038.50, found 1038.73. C) UV-Vis absorption 
spectra of reactant and isolated products. Star sign indicates thioamide absorption at 272 nm. 
Conditions: 0.1 mM peptide 5, 40 mM TCEP, 40 mM DTT, with or without 10 mM MPAA, 200 
mM Na2HPO4, pH 7.0, 18 h. TCEP = tris(2-carboxyethyl) phosphine; DTT = dithiothreitol; 
MPAA = 4-mercaptophenylacetic acid; Mcm = 7-methoxycoumarinylalanine. 
 
 
 
5 
(5) 
(5a) 
(5b) 
5a 
5b 
5a 
5 5a 5b 
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After examining the reaction mechanism, we realized that the side reaction originates 
from homolytic cleavage of Se−S bond as the first step of the deselenization reaction, 
which also generates a sulfur radical that can proceed with desulfurization (Figure 3-16). 
Since these intramolecular Se−S bonds formed spontaneously during peptide synthesis 
and purification (in fact, we used hemiselenide protected Boc-Sec(S-iPr)-OH as the 
building block, but could only isolate the intramolelar hemiselenide 5 as product), we 
would need to develop a strategy to suppress the sulfur radical. Knowing that an aromatic 
thiol is tolerated in one-pot ligation-deselenization (see Figure 3-6) but not in 
desulfurization
294,296
, we hypothesized that aromatic thiol may be able to selectively 
quench R−S∙ radicals but not R−Se∙ radicals, which is theoretically favorable based on a 
comparison of the bond dissociation energy of Se−H bond (66 kcal mol-1) and S−H bond 
(87 kcal mol
-1
)
297
 (Figure 3-17).   If this is true, we should be able to selectively suppress 
desulfurization side reaction using aromatic thiols, while allowing desired deselenization 
to proceed without complications. Indeed, using MPAA as an aromatic thiol additive, we 
were able to effectively suppress desulfurization, giving the desired product 5a in 62% 
yield (Figure 3-15). While more in-depth mechanistic studies are certainly necessary to 
fully characterize the reactivity of the various radicals involved, we have provided an 
effective empirical method for the synthesis of thioamide-containing proteins that also 
contain native Cys residues. 
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Figure 3-16.  Proposed Mechanism for Non-Selective Desulfurization. 
 
 
 
Figure 3-17.  Thermodynamics Prediction of Sulfur and Selenium Radical Quenching. 
Bond dissociation energy for aromatic thiols differs by substitution
296
, so a range is given 
instead of a single value; this difference does not alter the overall predicted trends.  
 
 
Finally, to demonstrate the possibility of expanding traceless NCL into non-Cys/Sec 
residues, we performed a proof-of-concept desulfurization reaction with a Pen-containing 
peptide 6 (Pen = penicillamine). Pen is the β-thiol analog of Val; similar to Cys, it can be 
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used as a ligation handle and subsequently “erased” into the native Val202. We chose Pen 
because it is a most sterically demanding member among all β-thiol analogs; the ambient 
radicals will need to access a quantanery carbon center than is one bond away from the 
peptide backbone in order to intiate desulfurization. Upon treatment with VA-044 in the 
presence of thioacetamide, 6 was converted to desired 6a in 73% yield, with its thioamide 
intact (Figure 3-18). This clearly showed the feasibility of β-thiol and β-selenol analogs 
for thioamide incorporation via traceless NCL, lifting the last restriction on semi-
synthesis of thioamide-containing peptides and proteins. 
 
 
Figure 3-18.  Selective Deselenization of Sec in the Presence of Cys and Thioamide. 
A) Schematic representation of the test reaction.  B) HPLC chromatograms monitored at 325 
nm, and UV-Vis absorption of isolated peptides. MALDI-TOF MS: [6 + H]
+
, expected 1482.62, 
found 1482.56; [6a + H]
+
, expected 1450.64, found 1450.82. Retention time: 22.4 min for 6, 
and 22.7 min for 6a; the difference is small but reproducible; identities of the peptides were 
confirmed by mass spectrometry. Star sign indicates thioamide absorption at 272 nm. 
Conditions: 0.1 mM peptide 6, 10 mM VA-044, 40 mM TCEP, 200 mM Na2HPO4, 10% tBuSH 
(v/v), pH 7.0, 18 h. TCEP = tris(2-carboxyethyl) phosphine; Mcm = 7-methoxycoumarinyl-
alanine. With D. Miklos Szantai-Kis. 
 
6 
(6) 
(6a) 
6a 
6 
6a 
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3.3  Conclusion 
We have devised a method for the traceless incorporation of thioamide into peptides 
and proteins using chemoselective desulfurization/deselenization in combination with 
native chemical ligation (NCL). We demonstrated that Cys can be selectively converted 
into Ala using VA-044 as a radical initiator in the presence of a backbone thioamide, and 
discovered that a small molecule, thioacetamide, can be used as an additive to improve 
the robustness of this chemoselectivity. We also showed that by acidifying the ligation 
mixture, PhSH can be effectively removed by lyophilization, enabling one-pot ligation-
desulfurization that had not previously been achieved. For sequences with additional 
native Cys, we showed the utility of selective deselenization, where Sec was converted 
into Ala in the presence of Cys and thioamides, and identified aromatic thiols as additives 
to enhance the chemo-selectivity. To expand into ligation sites other than Cys/Sec, we 
demonstrated selective desulfurization of β-thiol analogs, using conversion of 
penicillamine into Val as a proof-of-concept example. In conclusion, we have greatly 
expanded the scope of thioamide incorporation − it is now possible to achieve NCL at 
nearly any amino acid site in a target protein, which should greatly advance the adoption 
of the thioamide as a minimalist probe. 
 
3.4  Future Directions 
With the methodology for thioamide incorporation in place, we are now capable of 
performing “positional scanning” experiments, where a combinatorial library of target 
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proteins can be generated, with thioamide and fluorophores at various positions. 
Specifically, there are 15 good ligation sites in α-synuclein, where the junction is between 
a small amino acid Gly or Ala and an “erasable” Ala or Val handle (Figure 3-19). This 
would not only enable us to incorporate a thioamide at the N- or C-terminal region, but 
also allow us to perform a tandem ligation to incorporate thioamide directly into the fibril 
core (residues 65 to 95) without worrying about the perturbation of residual Cys.  
 
1      6      11     16      21     26     31 
MDVFM  KGLSK  AKEG|V VA|A|AE KTKQG |VAEA|A GKTKE 
 
35     41     46     51      56     61     66 
G|VLYV GSKTK  EG|VVH G|VATV  AEKTK  EQVTN  VGG|AV 
 
71     76     81     86      91     96     101 
VTG|VT A|VAQK TVEG|A GSIA|A |ATGFV  KKDQL  GKNEE 
 
105    111    116    121     126    131    136 
G|APQE GILED  MPVDP  DNEAY   EMPSE  EGYQD  YEPEA 
 
Figure 3-19.  α-Synuclein Sequence and Potential Traceless NCL Sites. 
 
Of particular interest would be tandem ligation between αS1-66, αS67-89 and αS90-140. 
We can synthesize the middle fragment αS67-89 using standard SPPS, with thioamides at 
any Val, Ala, Glu, Gln or Lys sites. The C-terminal fragment αS90-140 would contain a 
fluorophore at F94 position, which has been previously shown to be at a rigid position 
just outside the fibril core
47
. By generating fibrils using these doubly labeled proteins, we 
can extrapolate thioamide-fluorophore distances from fluorescence spectroscopy both in 
the mature fibril and during the aggregation process, and start to decode the biophysical 
process that is the very basis of Parkinson’s disease.   
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3.5  Materials and Methods 
General Information    VA-044 was purchased from Wako Pure Chemical Industries 
(Osaka, Japan). Fmoc protected amino acids and peptide synthesis reagents were 
purchased from EMD Millipore (Billerica, MA). All other reagents and solvents were 
purchased from Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO) 
unless otherwise specified. High resolution electrospray ionization mass spectra (ESI-
HRMS) were collected with a Waters LCT Premier XE liquid chromatograph/mass 
spectrometer (Milford, MA). Low resolution electrospray ionization mass spectra (ESI-
LRMS) were obtained on a Waters Acquity Ultra Performance LC connected to a single 
quadrupole detector (SQD) mass spectrometer. UV-Vis absorption spectra were acquired 
on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent Technologies, 
Santa Clara, CA). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker 
DRX 500 MHz instrument (Billerica, MA). Matrix assisted laser desorption/ionization 
with time-of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker 
Ultraflex III instrument (Billerica, MA). Analytical HPLC was performed on an Agilent 
1100 Series HPLC system (Santa Clara, CA). Preparative HPLC was performed on a 
Varian Prostar HPLC system (Agilent Technologies, Santa Clara, CA). HPLC columns 
were purchased from W. R. Grace & Compnay (Columbia, MD). 
 
 
Figure 3-20.  Synthesis Scheme of Thioalanine Precursors for Thioamide Incorporation.   
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Synthesis of N-Boc-1,2-phenylenediamine (S1)   1,2-Phenylenediamine (5.9478 g, 
55 mmol, 1.1 equiv) was dissolved in anhydrous tetrahydrofuran (THF, 50 mL). A 
solution of of di-tert-butyldicarbonate (Boc2O, 10.9125 g, 50 mmol, 1 equiv) in 
anhydrous THF (50 mL) was added dropwise over 4 h on ice. Upon completion, the 
reaction was quenched by slow addition of H2O (100 mL), and extracted with ethyl 
acetate (100 mL×3). The organic layers were combined, dried by rotary evaporation, and 
then purified by flash chromatography with 2:8 ethyl acetate/petroleum ether. A white 
flake was isolated as the final product (6.9823 g, 33.5 mmol, 67% yield). Rf 0.18 in 2:8 
ethyl acetate/petroleum ether.  
1
H-NMR (500 MHz, CDCl3): δ 7.27 (d, J = 7.6 Hz, 1H), 
6.99 (t, J = 8.3 Hz, 1H), 6.77 (t, J = 7.6 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.60 (s, 1H), 
3.76 (s, 2H), 1.54 (s, 9H). 
13
C-NMR (500 MHz, CDCl3): δ 154.16, 140.23, 126.17, 
124.82, 119.44, 117.53, 80.48, 28.48. ESI
+
-HRMS: calculated for C11H17N2O2
+
: 209.12; 
found [M + H]
+
: 209.14. 
 
Synthesis of α-N-Fmoc-L-alanine-(N-Boc)-2-aminoanilide (S2).  In an argon 
atmosphere, Fmoc-Ala-OH (1.5567 g, 5mmol, 1 equiv) was dissolved in 50 mL of dry 
tetrahydrofuran (THF) and chilled in a 1:3 NaCl : ice bath (-10 °C).  With stirring, N-
methylmorpholine (NMM, 1.10 mL, 10 mmol, 2 equiv) and isobutylchloroformate 
(IBCF, 0.65 mL, 5 mmol, 1 equiv) were slowly added.  The reaction was stirred at -10°C 
for 15 min, and N-Boc-1,2-phenylenediamine (S1, 1.0413g, 5 mmol, 1 equiv) was added.  
The reaction was allowed to proceed at -10°C for 2 h, and then at room temperature 
overnight (≥ 14 h).  Upon completion, the solvent was removed by rotary evaporation.  
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The residue was brought up in 40 mL of ethyl acetate, and extracted against 40 mL each 
of 1 M Na2HPO4, brine, 5% NaHCO3, and brine.  The aqueous layers were combined and 
extracted against 100 mL of ethyl acetate. The organic layers were combined, dried by 
rotary evaporation, and purified by flash chromatography in ethyl acetate/petroleum ether 
(35:65 v/v).  A pale yellow solid was yielded as the final product (1.7944 g, 3.6 mmol, 
77% yield).  Rf 0.23 in 35:65 ethyl acetate/petroleum ether.  
1
H-NMR (500 MHz, 
CDCl3): δ 8.73 (s, 1H), 7.70 (d, J = 7.6 Hz, 2H), 7.52 (t, J = 8.0 Hz, 2H), 7.48 (d, J = 7.4 
Hz, 1H), 7.33 (t, J = 8.0 Hz, 2H), 7.31 (m, 1H), 7.22 (m, 2H), 7.12 (s, 1H), 7.10 (t, J = 
7.5 Hz, 1H), 7.01 (t, J = 7.6 Hz, 1H), 5.87 (d, J = 7.1 Hz, 1H), 4.38 (m, 1H), 4.35 (t, J = 
6.4 Hz, 2H), 4.14 (t, J = 6.7 Hz, 1H), 1.44 (s, 9H), 1.41 (d, J = 7.1 Hz, 3H).  
13
C-NMR 
(500 MHz, CDCl3): δ 171.83, 156.25, 154.11, 143.72, 141.28, 131.39, 128.81, 127.79, 
127.11, 126.57, 125.40, 125.08, 124.20, 80.75, 68.62, 51.08, 47.09, 28.32, 22.11.  ESI
+
-
HRMS: calculated for C29H31N3O5Na
+
: 524.2161; found [M + Na]
+
: 524.2148. 
 
Synthesis of α-N-Fmoc-L-thioalanine-(N-Boc)-2-aminoanilide (S3).  In an argon 
atmosphere, S2 (1.6593 g, 3.3 mmol, 1 equiv) and Lawesson’s reagent (1.0036 g, 2.5 
mmol, 0.75 equiv) were refluxed in 30 mL of CH2Cl2 for 18 h.  Upon completion, the 
solvent was removed by rotary evaporation. The crude product was purified by flash 
chromatography in ethyl acetate/petroleum ether (35:65 v/v) to yield a pale yellow foam 
(1.5214 g, 2.9 mmol, 89% yield).  Rf 0.43 in 35:65 ethyl acetate/petroleum ether.  
1
H-
NMR (500 MHz, CDCl3): δ 10.09 (s, 1H), 7.69 (d, J = 7.3 Hz, 2H), 7.61 (d, J = 7.4 Hz, 
1H), 7.51 (d, J = 7.6 Hz,1H), 7.49 (d, J = 7.1 Hz,1H), 7.33 (t, J = 7.4 Hz, 2H), 7.30 (m, 
1H), 7.23 (m, 2H), 7.22 (m, 1H), 7.05 (t, J = 7.6 Hz, 1H), 6.91 (s, 1H), 6.04 (d, J = 6.4 
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Hz, 1H), 4.67 (m, 1H), 4.31 (d, J = 6.1 Hz, 2H), 4.14 (t, J = 7.0 Hz, 1H), 1.50 (d, J = 6.6 
Hz, 3H), 1.42 (s, 9H).  
13
C-NMR (500 MHz, CDCl3): δ 205.90, 155.94, 153.83, 143.61, 
143.56, 141,22, 141.20, 132.95, 129.64, 128.49, 127.78, 127.14, 125.11, 125.07, 124.65, 
123.59, 120.01, 81.07, 67.27, 55.58, 46.99, 28.26, 22.42.  ESI
+
-HRMS: calculated for 
C29H31N3O4SNa
+
: 540.1933; found [M + Na]
+
: 540.1914. 
 
Synthesis of α-N-Fmoc-L-thioalanine-benzotriazolide (S4)  In argon atmosphere, 
S3 (1.0861 g, 2.1 mmol, 1 equiv) was dissolved in 10 mL of CH2Cl2 and chilled to 0 ˚C 
on ice.  10 mL of an ice cold TFA/CH2Cl2 (50:50 v/v) solution was slowly added, and the 
reaction was allowed to proceed at 0 ˚C for 2 h.  Upon completion, the solvent was 
removed by rotary evaporation.  The residue was dissolved in glacial AcOH (9.5 mL) and 
water (0.5 mL), and then chilled to 0 ˚C on ice.  With stirring, NaNO2 (0.2202 g, 3.2 
mmol, 1.5 equiv) was added in small portions over 5 min.  The reaction was allowed to 
proceed at 0 ˚C for 30 min, and then quenched with 30 mL of ice cold water.  The 
precipitate was collected by filtration, dried on vacuum for 30 min, and then purified by 
flash chromatography in ethyl acetate/petroleum ether (35:65 v/v).  A yellow foam was 
yielded as the final product (0.6286 g, 1.5 mmol, 69% yield).  Rf 0.54 in 35:65 ethyl 
acetate/petroleum ether.  
1
H-NMR (500 MHz, CDCl3): δ 8.75 (d, J = 8.3 Hz, 1H), 8.12 
(d, J = 8.0 Hz, 1H), 7.74 (d, J = 7.1 Hz, 2H), 7.64 (m, 2H), 7.61 (m, 1H), 7.52 (t, J = 7.4 
Hz, 1H), 7.38 (t, J = 6.7 Hz, 1H), 7.30 (t, J = 6.8 Hz, 1H), 6.31 (m, 1H), 5.91 (d, J = 8.8 
Hz, 1H), 4.47 (dd, J = 10.3, 7.0 Hz, 1H), 4.34 (dd, J = 10.3, 7.0 Hz, 1H), 4.22 (t, J = 6.6 
Hz, 1H), 1.66 (d, J = 6.6 Hz, 3H).  
13
C-NMR (500 MHz, CDCl3): δ 210.01, 155.61, 
147.18, 144.03, 143.88, 141.41, 132.46, 131.68, 127.83, 127.32, 127.20, 125.32, 125.22, 
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120.92, 120.11, 116.31, 67.16, 57.27, 47.33, 23.10.  ESI
+
-HRMS: calculated for 
C24H20N4O2SNa
+
: 451.1205; found [M + Na]
+
: 451.1195. 
 
 
 
 
Figure 3-21.  Crystal Structure of Thioalanine Precursor.   
Crystal was grown in 35:65 ethyl acetate/petroleum ether; data were acquired on a Bruker 
Kappa APEX II Duo CCD diffractometer (Billerica, MA). Graphics were generated using 
Schrödinger PyMOL (Cambridge, MA). C=S bond length observed: 1.6 Å. 
 
Peptide Synthesis and Purification   Peptides were synthesized using standard 
Fmoc solid phase peptide synthesis (SPPS) procedure on either Rink Amide or 2-
chlorotrityl chloride resin (100 - 200 mesh; 0.6 mmol substitution/g). For coupling, 5 
equiv of amino acid and 5 equiv of HBTU were dissolved in dimethylforamide (DMF), 
pre-activated for 1 min in the presence of 10 equiv of N,N-diisopropylethylamine 
(DIPEA), and then stirred with the resin for 30 min at room temperature. For 
deprotection, 20% piperidine in DMF was stirred with the resin for 20 min. Thioalanine 
(denoted Ala
S
 or A
S
) was introduced through activated benzotriazole precursors (S4); 2 
equiv of the precursor was dissolved in dry CH2Cl2, and stirred with the resin for 45 min 
in the presence of 2 equiv DIPEA. For N-terminally acetylated peptides, an acetylation 
cocktail of 1:1:8 acetic anhydride/N-methylmorpholine/DMF was stirred with the resin 
twice, each for 10 min, after the last deprotection. Upon completion of SPPS, resins were 
rinsed thoroughly with CH2Cl2 and dried under vacuum. 
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For cleavage, resins were treated with a cleavage cocktail (12:1:1:26 trifluoroacetic 
acid/triisopropylsilane/H2O/CH2Cl2) for 30 min. The solution was then collected by 
filtration, and dried by rotary evaporation. For purification, the crude residues were 
brought up in 1:10 CH3CN/H2O, and then purified by reverse phase HPLC with acidified 
(with 0.1% trifluoroacetic acid) CH3CN/H2O gradients. Individual fractions were charac-
terized by MALDI-TOF MS, and dried by lyophilization. When necessary, the isolated 
products were subjected to multiple rounds of purification until 99.5% pure by MALDI-
TOF MS and analytical HPLC. Solvent radients, retention times and MALDI-TOF MS 
results are listed in Table 3-1 through Table 3-3. 
 
Table 3-1.  Peptide Purification Methods and Retention Time.   
Peptide Gradient 
Retention 
Time 
Column 
Ac-LA
S
AKAGCAKXAG-NH2 (1) 1 23.1 min Vydac C18 Semi-prep 
Ac-LA
S
AKAGAAKXAG-NH2 (1b) 1 22.3 min Vydac C18 Semi-prep 
Ac-GL
S
KXAG-CPGo (2a) 4 22.0 min YMC-Pack Pro C8 Semi-prep 
Ac-XTTEAVDACTA
S
AK-NH2 (3) 5 16.0 min Vydac C18 Semi-prep 
Ac-XTTEAVDAATA
S
AK-NH2 (3a’) 6 21.6 min Vydac C18 Semi-prep 
Ac-XTTEAVDAATAAK-NH2 (3b’) 6 19.9 min Vydac C18 Semi-prep 
Ac-XTTEAVDASTA
S
AK-NH2 (S7’) 6 19.7 min Vydac C18 Semi-prep 
Ac-XTTEAVDACTAAK-NH2 (S8’) 6 21.2 min Vydac C18 Semi-prep 
Ac-XTTEAVDA-SC2H4COOCH3 (4a) 7 17.6 min YMC-Pack Pro C8 Semi-prep 
CTA
S
AK-NH2 (4b) 8 12.8 min Vydac C18 Semi-prep 
UTA
S
ACVFKX-NH2
Se−S
 (5)** 9 24.5 min YMC-Pack Pro C8 Semi-prep 
Ac-XTTEAYDAATA
S
AK-NH2 (6) 10 34.6 min Vydac C18 Prep 
    
* X = 7-methoxycoumarinylalanine;  Y = penicillamine;  U = selenocysteine;  Go = glycolic acid. 
**  The “Se-S” superscript denotes that 5 was isolated as an intramolecular hemiselenide species. 
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Table 3-2.  HPLC Gradients for Peptide Purification and Characterization. 
No. 
Time 
(min) 
%B  No. 
Time 
(min) 
%B  No. 
Time 
(min) 
%B 
1 0:00 2  2 0:00 2  3 0:00 2 
 5:00 2   5:00 2   8:00 2 
 10:00 15   10:00 20   10:00 10 
 25:00 30   25:00 50   30:00 50 
 30:00 100   30:00 100   35:00 100 
 35:00 100   35:00 100   40:00 100 
 40:00 2   40:00 2   45:00 2 
           
4 0:00 2  5 0:00 2  6 0:00 2 
 10:00 2   5:00 2   5:00 2 
 15:00 20   10:00 25   10:00 20 
 30:00 50   25:00 40   25:00 35 
 35:00 100   30:00 100   30:00 100 
 40:00 100   35:00 100   35:00 100 
 45:00 2   40:00 2   40:00 2 
           
7 0:00 2  8 0:00 2  9 0:00 2 
 5:00 2   5:00 2   5:00 2 
 10:00 25   10:00 10   10:00 20 
 30:00 45   20:00 20   40:00 50 
 35:00 100   25:00 100   45:00 100 
 40:00 100   30:00 100   50:00 100 
 45:00 2   35:00 2   55:00 2 
           
10 0:00 5         
 5:00 5         
 15:00 22         
 45:00 28         
 50:00 100         
 55:00 100         
 60:00 5         
 60:00 5         
           
* Solvent A: 0.1% trifluoroacetic acid in water;  Solvent B: 0.1% trifluoroacetic acid in acetonitrile 
 
Table 3-3.  MALDI-TOF MS Characterization of Purified Peptides. 
Peptide 
[M + H]
+
 [M + Na]
+
 
Calc’d Found Calc’d Found 
Ac-LA
S
AKAGCAKXAG-NH2 (1) 1262.59 1262.63 1282.58 1284.62 
Ac-LA
S
AKAGAAKXAG-NH2 (1b) 1230.62 1230.78 1252.61 1252.77 
Ac-GL
S
KXAG-CPGo (2a) 1005.41 1005.35 1027.40 1027.33 
Ac-XTTEAVDACTA
S
AK-NH2 (3) 1482.62 1482.42 1504.61 1504.41 
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Table 3-3 (cont’d).  MALDI-TOF MS Characterization of Purified Peptides. 
Peptide 
[M + H]
+
 [M + Na]
+
 
Calc’d Found Calc’d Found 
Ac-LA
S
AKAGCAKXAG-NH2 (1) 1262.59 1262.63 1282.58 1284.62 
Ac-LA
S
AKAGAAKXAG-NH2 (1b) 1230.62 1230.78 1252.61 1252.77 
Ac-GL
S
KXAG-CPGo (2a) 1005.41 1005.35 1027.40 1027.33 
Ac-XTTEAVDACTA
S
AK-NH2 (3) 1482.62 1482.42 1504.61 1504.41 
Ac-XTTEAVDAATA
S
AK-NH2 (3a’) 1450.64 1450.80 1472.63 1472.79 
Ac-XTTEAVDAATAAK-NH2 (3b’) 1434.67 1434.81 1456.66 1456.80 
Ac-XTTEAVDASTA
S
AK-NH2 (S7’) 1466.64 1466.74 1488.63 1466.72 
Ac-XTTEAVDACTAAK-NH2 (S8’) 1466.64 1466.80 1488.63 1466.81 
Ac-XTTEAVDA-SC2H4COOCH3 (4a) 1095.41 - 1117.40 1117.45 
CTA
S
AK-NH2 (4b) 508.23 508.37 530.22 530.34 
UTA
S
ACVFKX-NH2
Se−S
 (5)** 1148.37 1148.46 1170.36 1170.44 
Ac-XTTEAYDAATA
S
AK-NH2 (6) 1482.62 1482.56 1504.61 1504.55 
     
* X = 7-methoxycoumarinylalanine;  Y = penicillamine;  U = selenocysteine;  Go = glycolic acid. 
**  5 was isolated as an intramolecular hemiselenide species. 
 
Raney Nickel Desulfurization    Peptide 1 (10 nmol, ε325 = 12,000 M
-1
 cm
-1
)
 
was 
dissolved in desulfurization buffer (100 µL, 100 mM Na2HPO4, 10 mM TCEP, pH 5.8), 
and then Raney nickel (0.1 mg) was added. The reaction was allowed to proceed at room 
temperature for 12 h, and then supernatant was recovered by centrifugation at 13.2 krpm 
for 20 min. The crude was analyzed by analytical RP-HPLC on a Luna C8 analytical 
column using gradient 2. Individual fractions were collected manually, and then analyzed 
by MALDI-TOF and UV-Vis absorption spectroscopy. 
 
Synthesis of Reduced Ac-GL
S
KXAG-CPGo (2a)    Ac-GL
S
KXAG-C
b
PGo (S5) with 
a side chain tBuS− protecting group was synthesized as we described previously283. To 
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generate the reduced 2a, S5 (200 nmol, ε325 = 12,000 M
-1
 cm
-1
) was mixed with 100 µL 
of reduction buffer (40 mM TCEP, 200 mM Na2HPO4, pH 6.8) and 20 µL of CH3CN. 
The reaction was allowed to proceed at 37 ˚C for 1 h. Upon completion, CH3CN (80 μL) 
was added, and the supernatant was recovered by centrifugation at 13.2 krpm for 20 min. 
The crude was diluted into H2O (800 μL), and then purified by reverse phase HPLC 
(Table 3-1). Isolated product was characterized by MALDI MS (Table 3-3), quantified by 
UV-Vis absorption, split into 20 nmol aliquots, and then lyophilized until further use. X = 
7-methoxycoumarinylalanine; Go = glycolic acid. 
 
One-Pot Ligation Deselenization with Selenocystine    A phosphate buffer stock 
(200 mM Na2HPO4, pH 8.0) and a 5 M NaOH solution were freshly degassed using the 
freeze-pump-thaw method. 2% (v/v) PhSH was added to the buffer stock, and pH was 
quickly adjusted back to 8.0 using the degassed 5 M NaOH solution under an argon 
atmosphere. A 1.1x L-selenocystine stock (2.2 mM) was prepared by dissolving L-seleno-
cystine (0.0007 g, 2.2 µmol) in the above buffer (1 mL). To thioester 2a (20 nmol, ε325 = 
12,000 M
-1
 cm
-1
), 10 µL of CH3CN and 90 uL of the 1.1x L-selenocytine stock (final 
concentration 2 mM, 10 equiv) was added. The reaction was allowed to proceed at 37 °C 
for 12 h under an argon atmosphere. 
 
For deselenization, a 50 µL aliquot of the ligation reaction was removed, and directly 
added to 50 µL of 2x deselenization buffer stock (40 mM TCEP, 40 mM DTT, 200 mM 
Na2HPO4, pH 8.0) that had been freshly degassed by freeze-pump-thaw method. The 
reaction was allowed to proceed at 37 °C overnight (≥ 14 h) under an argon atmosphere. 
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Upon completion, both ligation and deselenization crudes were diluted with argon-purged 
H2O, and then analyzed by reverse phase HPLC on a Luna C8 column using gradient 2. 
Individual fractions were recovered, and analyzed by MALDI-TOF MS and UV-Vis 
absorption spectroscopy. 
 
VA-044 Desulfurization of Cys/Thioamide-Containing Peptide    Peptide 3 (10 
nmol, ε325 = 12,000 M
-1
 cm
-1
) was dissolved in 80 µL of argon-purged 1.25x buffer stock 
(50 mM TCEP, 125 mM Na2HPO4, pH 7.0). 10 µL of tBuSH was added, followed by 10 
µL of freshly prepared 10x VA-044 stock (100 mM in argon-purged water). The reaction 
was allowed to proceed at 37 °C for 10 min under argon atmosphere, and then quickly 
quenched by chilling to 0 °C on ice. Excess tBuSH was removed by a stream of argon, 
and then the crude mixture was diluted into H2O for analysis by reverse phase HPLC on a 
Luna C8 analytical column using gradient 3. Fractions were collected, and then analyzed 
by MALDI-TOF MS and UV-Vis absorption spectroscopy. Yield was quantified by 
integrating peak areas in HPLC chromatogram. 
 
TCEP Dosage Dependence    The reactions were conducted similarly to the standard 
procedure, except that 1.25x buffer stocks of various TCEP concentration were used, and 
that a 2 h reaction time was adopted. At low TCEP concentrations, side product S6 was 
observed, with a disulfide bond between Cys and ambient tBuSH (Figure 3-22). The side 
product was not observed at high TCEP concentrations. 
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Figure 3-22.  TCEP Dosage Dependence and Generation of Disulfide Bonded Side Product. 
MALDI-TOF MS: [S6 + H]
+
, expected 1570.65, found 1570.74.  
 
VA-044 Dosage Dependence    Reactions were conducted similarly to the standard 
procedure, except that 10x VA-044 stocks at various concentrations were used for 2 h or 
18 h (Figure 3-23). Above 0.1 mM, no distinction was observed at the range of VA-044 
concentrations tested. At very low VA-044 concentration, however, the reaction was 
significantly slower and messier − at 2 h, while all other conditions showed complete 
reaction, minimal product formation was observed at 0.01 mM VA-044. At 18 h, the 
reaction was still not complete, with additional side peaks in the chromagram. 
(S6) 
3a 
S6 
S6 
3a 
3a 
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Figure 3-23.  VA-044 Dosage Dependence on Chemoselective Cys Desulfurization. 
 
Oxygen Tolerance    Reactions were conducted similarly to the standard procedure, 
except that an undegassed buffer stock was used with 5 min or 10 min reaction time. 
While both reactions completed within 10 min, the undegassed condition resulted in a 
slightly slower kinetics – 80% complete (as measured by reactant consumed) by 5 min as 
compared to 89% complete for the degassed condition (Figure 3-24). 
3a 
3a 
3a 
3a 
3a 
3 
3a 
3 
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Figure 3-24.  Oxygen Tolerance on Chemoselective Cys Desulfurization. 
 
Denaturant Tolerance    Reactions were conducted similarly to the standard proce-
dure, except that a 1.25x buffer stock with denaturant was used with 2 h reaction time. 
No difference was found as compared to denaturant free conditions (Figure 3-25). 
 
 
Figure 3-25.  Denaturant Tolerance on Chemoselective Cys Desulfurization. 
3a 
3 
3a 
3a 
3 
3a 
3a 
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Prolonged Reaction with Cys/Thioamide-Containing Peptide    Reactions were 
conducted similarly to the standard procedure, except that longer reaction times were 
adopted. Side products, particularly 3b, accumulated over time (Figure 3-26). 
 
Figure 3-26.  Accumulation of Non-Selectively Desulfurized Side Product over Time. 
 
Thioacetamide Dosage Dependence    Reactions were conducted similarly to the 
standard procedure, except that buffers with various concentrations of thioacetamide 
were used with 18 h reaction time. Suppression of thioamide-to-oxoamide conversion 
was effective over the wide range of concentrations tested; at very high concentration, 
thioacetamide may quench ambient radicals, leading to slower kinetics (Figure 3-27). 
 
Oxygen and Denaturant Tolerance in the Presence of Thioacetamide    Reactions 
were conducted similarly to the control reactions without thioacetamide for 18 h. No 
distinction was found with the addition of thioacetamide (Figure 3-28). 
3a 
3a 
3a 
3b 
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Figure 3-27.  Thioacetamide Dosage Dependence on Thioamide Protection. 
 
 
Figure 3-28.  Oxygen and Denaturant Tolerance in the Presence of Thioacetamide. 
 
Characterization of Cys-to-Ser Conversion Side Products   We were surprised to 
find a residual peak at 21.8 min even in the presence of thioacetamide, which should 
3a 
3a 
3a 
3a 
3a 
3a 
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suppress thioamide-to-oxoamide conversion and abolish side product 3b. Upon a closer 
examination of the MALDI-TOF MS and UV-Vis absorption spectra (Figure 3-30), we 
realized that the residual peak represents a separate side product S7 where a Cys-to-Ser 
conversion took place with thioamide intact. The conversion could result from quenching 
of alkyl radical by water or dissolved oxygen in the reaction solution (Figure 3-29); in 
fact, a similar conversion had been reported for oxygen-related complications in Sec 
deselenization.
221,222
 We believe both water and oxygen contribute to the Cys side 
reaction observed here – a 2% conversion still took place in argon purged buffer, as 
compared to 3% in non-degassed buffer. 
 
 
Figure 3-29.  Proposed Mechanism for the Cys-to-Ser Conversion Side Reaction. 
 
To prove the identity of the residual peak, we synthesized three control peptides − 
Ala/oxoamide peptide 3b’, Ser/thioamide peptide S7’, and Cys/ oxoamide peptide S8’ 
(prime symbol denotes the genuine peptide standards to distinguish them from species 
identified in desulfurization reactions). We showed that 3b’ and S7’ both eluted at 21.8 
min under the gradient used, but had vastly different UV-Vis absorption profiles. While 
S8’ shares the same expected mass with S7’, it eluted at a different retention time, and of 
140 
 
 
Figure 3-30.  Characterization of Cys-to-Ser Conversion Side Reaction. 
A) Sequence of all side products involved.  B) MALDI-TOF mass spectra and UV-Vis 
absorption spectra for the 21.8 min peak isolated from reactions with or without 
thioacetamide. The retention times may be similar, but peak identities were vastly different.  
C) HPLC chromatrogram monitored at 325 nm and UV-Vis absorption spectra for genuine 
peptide standards synthesized by solid phase peptide synthesis (SPPS). Only S7’ matches 
the profile observed in reaction with thioacetamide as additive. Mcm = 7-
methoxycoumarinylalanine. 
 
  
(3b) 
(S7) 
(S8) 
[3b+H]
+
 
[3b+Na]
+
 
[S7+H]
+
 
[S7+Na]
+
 
3b 
S7 
3b’ 
S7’ 
S8’ 
3b’ 
S7’ 
S8’ 
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course, did not exhibit thioamide absorption at 272 nm (Figure 3-30). Therefore, we 
conclude that the 2% residual peak corresponded to Cys-to-Ser conversion side product 
S7, and that thioamide-to-oxoamide conversion was fully suppressed by thioacetamide. 
 
Synthesis of Ac-Mcm-TTEAVDA-SC2H4COOCH3 Thioester (4a)    Protected 
precursor Ac-Mcm-T
tBu
T
tBu
E
OtBu
AVD
OtBu
A-OH (S9) was synthesized on 2-chlorotrityl 
chloride resin using standard solid phase peptide synthesis (SPPS) procedure, and cleaved 
with 1:1:8 acetic acid/trifluoroethanol/CH2Cl2. Lyophilized crude S9 (20 µmol, 1 equiv) 
was mixed with dimethylformamide (DMF, 1 mL), tetrahydrofuran (THF, 1 mL), N,N-
diisopropylethylamine (DIPEA, 34.8 µL, 200 µmol, 10 equiv) and methyl 3-mercapto-
propionate (43.3 µL, 400 µmol, 20 equiv). PyBOP (0.0520 g, 100 µmol, 5 equiv) was 
added, and then the reaction was allowed to proceed at room temperature for 4 h. Upon 
completion, the reaction was quenched with 0.1% trifluoroacetic acid in water (10 mL). 
The precipitate was collected by centrifugation at 13.2 krpm for 20 min, and then cleaved 
with 3 mL of 1:1:38 triisopropylsilane/methyl 3-mercaptopropionate/trifluoroacetic acid 
for 30 min. The crude mixture was dried by rotary evaporation, and then brought up in 
50:50 acetonitrile/water for purification by reverse phase HPLC. The purified product 
was quantified by UV-Vis absorption (ε325 = 12,000 M
-1
 cm
-1
) and lyophilized. Mcm = 7-
methoxycoumarinylalanine. 
 
Theoretical Prediction of PhS
-
 Concentration at Various pH    Knowing that the 
pKa of thiophenol is 6.6 and that its solubility is 0.08% (7.3 mM), we can theoretically 
predict the concentration of PhS
-
 at any given pH by solving the acid-base equilibrium. 
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Assuming that the protonated form PhSH can be fully removed by lyophilization (typical 
vacuum: 0.024 mBar << vapor pressure of PhSH: 1.8 mBar), the concentration of PhS
-
 
would provide a good estimation for residual aromatic thiol/thiolate after lyophilization. 
pKa = −log
[H+] ∙ [PhS−]
[PhSH]
= 6.6 
[PhS−] + [PhSH] = 0.726 M 
⇒ [PhS−] =
0.726 × 10−6.6
[H+] + 10−6.6
 
When lyophilization is conducted at pH 7, as much as 5.2 mM of 7.3 mM total PhSH 
would remain in the PhS
-
 form, which would overwhelm the 0.1 mM peptide. When 
lyophilization is carried out at pH 1, however, the residual PhS- concentration is only 18 
nM, an insignificant amount with respect to the 0.1 mM peptide. 
 
One-Pot Ligation-Desulfurization    A phosphate buffer stock (40 mM TCEP, 100 
mM Na2HPO4, pH 7.0) was freshly prepared and degassed by argon purging. 2% PhSH 
(v/v) was added, and then pH was quickly adjusted back to 7.0 under argon atmosphere. 
Thioester 4a and peptide 4b (50 nmol each) were each dissolved in 25 µL of the above 
buffer, and then combined. The reaction was allowed to proceed at 37 °C overnight. 
 
For desulfurization, 10 µL of the ligation crude was removed, acidified with 100 µL 
of 1% trifluoroacetic acid in water, and then quickly frozen and lyophilized. The crude 
residue was brought up in 80 µL of freshly degassed 1.25x desulfurization buffer (50 mM 
TCEP, 125 mM Na2HPO4, pH 7.0), and then tBuSH and VA-044 were added to proceed 
with the standard desulfurization procedure. Upon completion, all crude reaction samples 
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were diluted into H2O, and analyzed by reverse phase HPLC on a Luna C8 analytical 
column using gradient 3. Individual fractions were collected, and then analyzed by 
MALDI-TOF MS and UV-Vis absorption spectroscopy. 
 
 
Figure 3-31.  Synthetic Scheme for Sec-Containing Peptides. 
 
Synthesis of N,N’-di-Boc-L-selenocystine (S10)    L-Selenocystine (0.1670 g, 0.5 
mmol, 1 equiv) was dissolved in argon-purged H2O (4 mL) and 1,4-dioxane (4 mL), and 
chilled to 0 °C on ice. Trimethylamine (900 μL, 6 mmol, 12 equiv) was added, followed 
by Boc anhydride (0.2728 g, 1 mmol, 2 equiv). The reaction was allowed to proceed on 
ice for 2 h, and then at room temperature overnight (≥ 12 hr) under argon atmosphere. 
Upon completion, the reaction was diluted with H2O (18 mL), acidified with 3 M 
hydrochloric acid (3 mL), and then quickly extracted with ethyl acetate (30 mL × 3). The 
organic layers were combined, concentrated by rotary evaporation, and then purified by 
flash chromatography in 0.1% acetic acid in ethyl acetate. A pale yellow foam was 
isolated as the product (0.2383 g, 0.45 mmol, 89% yield). Rf 0.15 in ethyl acetate with 
0.1% acetic acid. 
1
H-NMR (500 MHz, CDCl3): δ 8.93 (s, 2H), 5.65 (d, J = 6.9 Hz, 1H), 
4.57 (m, 2H), 3.48 (m, 2H), 3.40 (dd, J = 12.7, 5.6 Hz, 2 H), 1.44 (s, broad, 18 H). 
13
C-
NMR (500 MHz, CDCl3): δ 174.95, 155.84, 81.18, 54.01, 33.34, 28.66. ESI
-
-HRMS: 
calculated for C16H27N2O8Se2
-
, 535.0098; found [M - H]
-
 535.0095. 
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Synthesis of Boc-Sec(S-iPr)-OH (S11)    S10 (0.1681 g, 0.31 mmol, 1 equiv) was 
dissolved in argon-purged tetrahydrofuran (THF, 5 mL). Triethylamine (439 μL, 3.2 
mmol, 10 equiv) was added, followed by 2-propanethiol (599 μL, 6.3 mmol, 20 equiv). 
The reaction was allowed to proceed at room temperature for 3 h under argon 
atmosphere. Upon completion, the reaction mixture was dried by rotary evaporation. The 
residue was brought up in H2O (10 mL), acidified with 3 M hydrochloric acid (1 mL), 
and quickly extracted with ethyl acetate (10 mL × 3). Organic layers were combined, 
concentrated by rotary evaporation, and then purified by flash chromatography in 5:5 
ethyl acetate/ petroleum ether with 0.1% acetic acid. A white foam was isolated as the 
final product (0.2005 g, 0.59 mmol, 93% yield). Rf in 0.27 in 5:5 ethyl acetate/petroleum 
ether with 0.1% acetic acid. 
1
H-NMR (500 MHz, CDCl3): δ 5.43 (d, J = 6.9 Hz, 1H), 4.63 
(dd, J = 11.3, 6.9 Hz, 1H), 3.33 (dd, J = 12.5, 4.2 Hz, 1H), 3.24 (dd, J = 12.1, 6.5 Hz, 
1H), 3.03 (septet, J = 6.7 Hz, 1H), 1.46 (s, 9H), 1.32 (d, J = 6.6 Hz, 6H). ESI
+
-HRMS: 
calculated for C11H21NO4SSeNa 366.0254, found [M + Na]
+
 366.0252. 
 
Synthesis of Sec-Containing Peptide    Peptide 5 was synthesized using standard 
solid phase peptide synthesis (SPPS) procedure on Rink amide resin. Sec was introduced 
as Boc-Sec(S-iPr)-OH (S11) using standard HBTU activation method. The peptide was 
cleaved with 12:1:1:26 trifluoroacetic acid/2-propanethiol/triisopropylsilane/CH2Cl2, and 
then purified by reverse phase HPLC. 5 was isolated as the primary product, with an 
intramolecular hemiselenide bond between Sec and Cys. 
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Deselenization of Sec/Cys/Thioamide-Containing Peptide    Deselenization buffer 
(40 mM TCEP, 40 mM DTT, 200 mM phosphate, pH 7.0) was freshly prepared and 
degassed by the freeze-pump-thaw method. Peptide 6 (10 nmol, ε325 = 12,000 M
-1
 cm
-1
) 
was dissolved in 100 µL of the above buffer, and then the reaction was allowed to 
proceed at 37 ˚C for 18 h. Upon completion, the reaction was chilled to 0 ˚C on ice, and 
then 100 µL of argon-purged CH3CN was added.  The supernatant was recovered by 
centrifugation at 13.2 krpm for 20 min, diluted into argon-purged H2O (650 μL), and then 
analyzed by reserve phase HPLC on a Luna C8 analytical column using gradient 3. 
Fractions were collected and analyzed for MALDI-TOF MS and UV-Vis absorption. 
 
4-Mercaptophenylacetic Acid (MPAA) as Deselenization Additive    Reaction was 
conducted similarly to the standard procedure, except that a buffer stock containing 10 
mM MPAA was used. MPAA was chosen over PhSH for its low volatility. 
 
Synthesis of Pen-Containing Peptide    Fmoc-Pen(Trt)-OH was purchased from 
Sigma-Aldrich (St. Louis, MO), and incorporated into peptide 6 sequence using standard 
solid phase peptide synthesis (SPPS) procedure.  
 
Desulfurization of Pen/Thioamide-Containing Peptide    Reaction was conducted 
using standard desulfurization procedure with thioacetamide. Briefly, Peptide 6 (10 nmol, 
ε325 = 12,000 M
-1
 cm
-1
) was dissolved in 80 µL of argon-purged 1.25x buffer stock (50 
mM TCEP, 125 mM thioacetamide, 125 mM Na2HPO4, pH 7.0). tBuSH and VA-044 
stock were then added, and the reaction was allowed to proceed at 37 °C for 18 h. The 
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crude was analyzed by reverse phase HPLC on a Luna C8 analytical column using 
gradient 3, and characterized by MALDI-TOF MS and UV-Vis absorption spectroscopy. 
 
3.6  Acknowledgement 
This work was supported by funding from the University of Pennsylvania, the 
National Institute of Health (5R01NS081033-03 to E.J.P.), and the Searle Scholars 
Program (10-SSP-214 to E.J.P.). Instruments were supported by the National Science 
Foundation and National Institutes of Health include: HRMS (NIH RR-023444), X-ray 
diffractometer (NSF CRIF-0091925), and MALDI-TOF MS (NSF MRI-0820996). We 
thank Patrick J. Carroll for X-ray crystallography data acquisition, and Rakesh Kohli for 
assistance with HRMS analysis. 
 
 
147 
 
 
 
 
 
Chapter 4 .  Chemoenzymatic Incorporation of Selenocysteine onto the Protein N-
terminus by Aminoacyl Transferase (AaT) 
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4.1  Introduction 
Having established a robust method for thioamide incorporation through traceless 
native chemical ligation (NCL), we have one last challenge to address – the installation 
of “erasable” ligation handles onto expressed protein fragments.  For short peptides, 
ligation handles such as selenocysteine (Sec) and β-thiol/selenol amino acid analogs can 
be conveniently introduced by solid phase peptide synthesis (SPPS). However, SPPS has 
an inherent length limit (typically 70 aa)
270
, beyond which synthesis and purification 
would become prohibitively difficult. Therefore, when an expressed protein C-terminal 
fragment is required for ligation sites that are far from the C-terminus, a new approach 
for Sec/analog attachment must be developed. 
 
The conventional way to generate N-terminal Xaa protein fragments is through fusion 
protein expression. As demonstrated in our preparation of αS9-140C9,
283
 a construct with 
an N-terminal purification tag and a protease recognition sequence can be expressed, 
after which the N-terminal Cys is revealed by proteolysis (Figure 4-1A). To apply this 
method to N-terminal Sec/analog fragments, however, we would also need to adopt 
unnatural amino acid (Uaa) mutagenesis
272
 for translational insertion of Sec/analog into 
the fusion protein. This would be overwhelmingly complex in terms of 
validation/optimization efforts – at the bare minimum, we will need to evolve an 
orthogonal synthetase-tRNACUA pair for the analogs, ensure that all analogs are 
metabolically stable and nontoxic for cellular expression, and identify a protease that 
would tolerate a β-branched side chain at the cleavage site. If the unnatural side chains 
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are not readily tolerated by the ribosome, we would also need to evolve a modified 
ribosome for ligation handle incorporation. 
 
 
Figure 4-1.  Methods for Sec and β-Thiol Analog Installation onto Expressed Proteins. 
A)  Fusion protein expression with unnatural amino acid (Uaa) mutagenesis. A TAG codon is 
introduced into the fusion protein construct at the desired site of ligation; a specifically 
evolved synthetase (RS) charges tRNACUA with an unnatural amino acid, and “reads through” 
the TAG codon which would otherwise be interpreted as a “stop” codon. B) Post-translational 
enzymatic modification. Target protein is produced by regular cellular expression, and then 
N-terminally modified by an appropriate enzyme to install the Sec/analog. 
 
In contrast, post-translational enzymatic modifications present a much simpler and 
arguably more versatile option (Figure 4-1B). Rather than evolving an entire cellular 
expression machinery for these ligation handles, we just need to identify (or evolve) an 
appropriate enzyme that could transfer synthetic moieties like Sec and β-thiol analogs 
site-specifically onto the N-termini of expressed proteins. If viable, this strategy would 
have two major advantages: 1) with minimal deviation from regular recombinant protein 
production procedure, very little optimization is necessary for target protein expression 
and handling; 2) conducting the modification ex vivo with a single enzyme gives us 
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nearly full control over key variables, where we can quickly screen substrates, optimize 
reaction conditions and evolve the enzyme for incorporation of our desired analogs.  
 
A naturally-existing enzyme that performs exactly this type of modifications is E. coli 
aminoacyl transferase (AaT), a component of the prokaryotic N-end degradation pathway 
(Figure 4-2). AaT recognizes an N-terminal Lys or Arg on an expressed protein, and then 
attaches a Leu or Phe onto the N-terminus from a tRNA donor
258
. In E. coli, this serves as 
a means to tag proteins for degradation; the L/F-K/R motifs are recognized by an 
“adapter protein” ClpS, which then transports the tagged proteins to a proteolytic 
complex for degradation.
256
 From a protein engineering perspective, this unique N-
terminal amide bond formation capability presents an excellent opportunity for selective  
 
 
Figure 4-2.  Aminoacyl Transferase (AaT) as a Protein Engineering Tool. 
A) Biological function of AaT in the E. coli N-end degradation pathway. AaT transfers a Leu or 
Phe onto the exposed Arg or Lys on the protein N-terminus, which results in an N-terminal 
L/F-R/K motif that is recognized as a degradation signal.  B) AaT as a protein engineering 
tool. When AaT is used in isolate without the other components of the N-end degradation 
pathway, the enzyme can be repursposed for transfer of natural or unnatural amino acids 
onto the protein N-terminus. 
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protein N-terminal modification − when used in isolation (i.e. in the absence of other 
components of N-end degradation pathway), AaT can be adapted as a tool to incorporate 
a variety of natural or synthetic amino acids site-specifically onto the protein N-terminus. 
 
AaT was discovered in the 1960s from E. coli cell lysate for its ability to transfer Leu 
or Phe onto proteins
257,258
. It was later established that the AaT modification was specific 
to the protein N-terminus
259
, and that the anticodon of the tRNA was unneccesary for the 
AaT recognition of aminoacylated tRNA as its substrate
263
. In early protein engineering 
studies 
264,265,267
, AaT has been used by Sisido and Tirrell for the proof-of-concept 
incorporation of unnatural amino acids such as acridone and fluorinated leucine. In our 
own group, we were able to greatly simplify the substrate synthesis and screening process 
by adopting a minimal adenosine donor (Figure 4-3)
268
 – while full-length aminoacyl-
tRNA is the natural substrate, only the last adenosine on the acceptor stem is essential for 
AaT recognition and activity
261. This allows us to take an efficient “chemoenzymatic” 
approach, where adenosine donors of unnatural amino acids are chemically synthesized 
through simple organic transformations, and then directly screened for activity as AaT 
substrates without being limited by the RS specificity in the tRNA-charging step. Using 
this approach, we were able to identify novel AaT substrates such as benzo-phenone or 
disulfide protected amino acids in our previous work
268,269
. 
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Figure 4-3.  Aminoacyl Adenosine Donors as Minimal AaT Substrates. 
Top: Fully Enzymatic Approach. Desired amino acid is charged onto a tRNA by its corres-
ponding synthetase (RS), which is then utilized by AaT as a substrate. Bottom: Chemo-
enzymatic Approach. An amino acid/adenosine conjugate is directly used as donor for AaT 
mediated protein N-terminal modification. Adapted from Wagner et al.
268
 
 
By examining the known substrate scope and crystal structures of AaT,
261, 264-265, 267-
269
 we hypothesized that the AaT-mediated N-terminal modification strategy would be 
applicable to hemiselenide protected selenocysteine (Sec) using wildtype AaT without 
additional directed evolution. AaT is a somewhat “promiscuous” enzyme; it has equal 
preference between its natural substrates Leu and Phe, and has been shown to tolerate a 
variety of unnatural substrates in reconstituted ex vivo systems (Figure 4-4). In the crystal 
structure with a Phe-adenosine substrate bound, there is a small void space next to the ε-
carbon of Phe that could tolerate side chain extension (Figure 4-5); with the precedence 
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Figure 4-4.  Selected Natural and Unnatural Substrates of AaT. 
See Introduction chapter for a complete summary of known AaT substrates. We have shown 
previously that un-protected Cys and homocysteine (Hcs) are not viable substrates
269
. 
 
 
 
 
 
Figure 4-5.  Crystal Structure and Contact Scheme of AaT Substrate Binding Pocket. 
Crystal structure adapted from Watanabe et al. (PDB: 2Z3K)
261
; residues in direct contact 
with substrate Phe side chain (within 5 Å) are highlighted in purple; certain non-contact 
segments are omitted for clarity. A small void space is present next to the ε-carbon (pink 
dotted circle). 
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of disulfide protected homocysteine and polyaromatic amino acids, we also expect good 
conformational flexibility of this binding pocket for Sec(SR) side chains 
 
It is worth noting that while the Sec amino acid can be naturally incorporated with a 
special cellular machinery
298
, a post-translational modification approach is still necessary 
for traceless ligation. The Sec amino acid is encoded by the UGA stop codon, which is 
re-interpreted as a Sec codon by a special elongation factor EFsec, a selenocysteine inser-
tion sequence (SECIS) in the 3’-untranslated region of the mRNA, and a SECIS/EFsec-
binding protein SBP2
245
. Current attempts to recombinantly express Sec-containing 
proteins had limited success, where Trp mis-incorporation (Trp codon: UGG) and low 
yields due to chain termination were cited as the most common complications
252
. In 
addition, all natural and recombinant Sec-proteins are expressed with a Sec-Xaan-Cys 
motif (n = 2 ~ 4) to sequester the highly reactive selenol side chain as an intramolecular 
hemiselenide with the adjacent Cys during expression and handling
251,252
. If we choose 
the recombinant expression approach with Sec/Cys motifs, it would completely defeat the 
purpose of ligation site expansion through traceless NCL by re-introducing the need for a 
native Cys residue (or a non-native Cys mutation). Another approach is the metabolic 
replacement of the Cys sulfur with selenium by supplying nutrients with a certain 
percentage of selenites in the E. coli growth media
240
; this results in global replacement 
of all Cys, which is also undesirable for our applcations. In comparison, the AaT post-
translational modification approach directly incorporates a single Sec with hemiselenide 
protection in a site-specific manner, enabling the expansion of traceless NCL to 
expressed protein fragments without the Cys complication.  
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4.2  Results and Discussion 
To screen hemiselenide protected Sec derivatives for activity as AaT substrates, we 
first needed to chemically synthesize the corresponding “minimal” adenosine (Ade) 
donors. Using a similar strategy as previously applied to other amino acids
268,269
, we 
developed a 6-step synthesis of H-Sec(SR)-Ade donors 6 from L-selenocystine 1 (Figure 
4-7). Hemi-selenides have unique thiol exchange properties – similar to the well-known 
disulfide exchange, the Se−S bond is in constant equilibrium with other thiol or selenol 
species in their surrounding environment, and can be readily substituted by supplying 
large excess of the desired thiol (Figure 4-6)
226,220
. Taking advantage of this property, we 
were able to greatly simplify and streamline our synthesis − an H-Sec(S-tBu)-Ade donor 
6c was first prepared in bulk, and then derivatized through a simple one-step 
hemiselenide exchange to generate a library of adenosine donors 6a-e. We note that these 
exchange reactions are highly versatile – interconversion among the H-Sec(SR)-Ade 
donors can be achieved by simply incubating one donor with excess of the desired thiol 
(Figure 4-14). 
 
 
Figure 4-6.  Thiol Exchange Equilibrium of Hemiselenides. 
 
To assess the chemoenzymatic activity of our Sec-adenosine donor library, we subject 
these donors to an in vitro transfer assay using a model peptide LysAlaAcm 7. If the 
hemiselenide protected Sec amino acids are viable substrates for AaT, we should observe 
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transfer of the Sec(SR) cargo from adenosine donor onto the N-terminus of LysAlaAcm. 
Indeed, the formation of Sec(SR)-LysAlaAcm products 8a-e was clearly observed for all  
 
 
Figure 4-7.  Synthesis of Hemiselenide-Protected Sec-Ade Donors from L-Selenocystine. 
A) Synthesis scheme from L-selenocystine 1 to desired adenosine donors 6a-e. B) MALDI-
TOF MS and UV-Vis absorption characterization using 6b as an example. Selenium isotopic 
pattern can be clearly observed in final product by MALDI-TOF MS; presence of adenosine is 
also evident in UV-Vis absorption. See Figure 4-12 for characterization of other products. 
Conditions: a) (Boc)2O, DIPEA, 1:1 H2O/1,4-dioxane; b) tBuSH, DIPEA, THF; c) ClCH2CN, 
DIPEA, THF; d) (DMT)-A, DIPEA, catalytic NBu4Ac, THF; e) TFA, tBuSH, TIPS, THF; f) RSH, 
H2O. Boc = tert-butoxy carbamate; DIPEA = N,N-diisopropylethylamine, THF = tetrahydro-
furan; DMT = 4,4'-dimethoxytrityl; (DMT)-A = 5’-O-DMT-adenosine; NBu4Ac = tetrabutyl-
ammonium acetate; TFA = trifluoroacetic acid; TIPS = triisopropylsilane; Et = ethyl; iPr = 
isopropyl; Ph = phenyl; Bz = benzyl.   
157 
 
 
Figure 4-8.  Screening of Hemiselenide Protected Sec-Ade Donors as AaT Substrates. 
A) Schematic representation of the AaT activity assay for substrate screening. B) Transfer 
efficiencies of various amino acids by wildetype AaT. The natural substrate Phe is also tested 
as H-Phe-Ade donor for positive control. C) HPLC and MALDI-TOF MS characterization of 
the transfer reactions. Chromatogram monitored at 325 nm; integrity of selenium in isolated 
products can be clearly observed in the MALDI-TOF spectra. See Table 4-4 for a complete 
characterization of all test reactions. Acm = 7-aminocoumarin.* Data on protected Cys were 
acquired by Tomohiro Tanaka and Anne M. Wagner.   
7 
7 
8c 
8b 
8c 
8b 
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Sec-Ade donors tested (Figure 4-8). The isopropyl protected Sec(S-iPr) and t-butyl 
protected Sec(S-tBu) exhibited the highest transfer efficiencies, presumably due to the  
better steric accommodation of the small, branched side chains by the AaT substrate 
binding pocket (see Figure 4-5). As a further validation, we also synthesized the Cys 
counterparts H-Cys(S-iPr)-Ade 6f and H-Cys(S-tBu)-Ade 6g of the two most effective 
Sec-Ade donors, and observed nearly identical transfer efficiencies as the Sec substrates 
6b and 6c. This gave us confidence that selenium in the hemiselenide side chains did not 
interfere with our AaT-mediated chemoenzymatic transformation. Lastly, we showed that 
the reaction was tolerant of ambient oxygen – nearly identical transfer efficiencies were 
observed in degassed or non-degassed reaction buffers (Figure 4-15). 
 
To demonstrate the utility of this chemoenzymatic strategy in incorporating Sec onto 
the N-termini of expressed protein fragments, we generated αS6-140 9 (a truncated version 
of αS with an N-terminal Lys) through cellular expression and successfully transferred 
Sec(S-iPr) onto its N-terminus from adenosine donor 6b (Figure 4-9). The integrity of 
Sec can be further confirmed in a subsequent deselenization test – when 10 was treated 
with tris(2-carboxyethyl)phosphine (TCEP), a 155 Da mass shift was clearly observed, 
corresponding to the characteristic deselenization of Sec into an Ala (Figure 4-16). 
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Figure 4-9.  Chemoenzymatic Incorporation of Sec(S-iPr) onto Express αS6-140. 
A) Schematic representation of the AaT chemoenzymatic modification reaction. αS6-140 was 
prepared through cellular expression, and then subject to AaT mediated N-terminal modifi-
cation using 6b as adenosine donor. B) MALDI-TOF MS characterization. [9 + H]
+
, expected 
13828.95, found 13824.14; [10 + H]
+
, expected 14053.92, found 14049.13. 
 
 
  
9 10 
9 
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4.3  Conclusion 
We have developed an efficient chemoenzymatic approach to incorporate hemi-
selenide protected selenocysteine (Sec) site-specifically onto the N-termini of expressed 
proteins with E. coli aminoacyl transferase (AaT). Using minimal adenosine donors, we 
identified that small, branched side chain protecting groups were preferred as AaT 
substrates, with the isopropyl protected Sec(S-iPr) and t-butyl protected Sec(S-tBu) being 
the most effective. As a proof-of-concept example, we successfully transferred Sec(S-iPr) 
onto the N-terminus of an expressed protein, αS6-140, from the corresponding adenosine 
donor. Combining this chemoenzymatic approach with solid phase peptide synthesis 
(SPPS) for short peptides, we are now capable of generating N-terminal Sec peptide and 
protein fragments of any size (given an appropriate N-terminus, see discussion below), 
enabling thioamide incorporation at any desired regions in the protein sequence through 
traceless native chemical ligation. 
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4.4  Future Directions 
To fully realize our vision of efficiently installing any traceless ligation handle at any 
desired position, we need to achieve three additional milestones: 1) quantitative transfer 
efficiency of the desired ligation handle; 2) ability to utilize β-thiol analogs as AaT subs-
trates; 3) expansion of the N-terminal recognition residue to those other than Lys or Arg. 
 
To achieve quantitative transfer efficiency, we would need to either evolve a more 
efficient AaT for our desired substrates, or reinstate the fully enzymatic route for AaT-
mediated N-terminal modification (see Figure 4-3). We chose the second approach 
because it is more feasible − by re-introducing a RS into the reaction, the charged tRNA 
substrate can be continuously regenerated. It does not require either the AaT or the RS to 
achieve quantitative transfer/aminoacylation efficiency; with the appropriate reaction 
time, the substrate regeneration process per se is sufficient to drive the transfer reaction 
to completion. The hurdle is, of course, to identify/generate a synthetase that would 
recognize our desired ligation handle. As a preliminary trial, we screened S. cerevisiae 
phenylalaninyl synthetase (PheRS), E. coli methioninyl synthetase (MetRS), E. coli 
leucyl synthetase (LeuRS) and their rationally designed mutants, but unfortunately were 
not able to identify a positive candidate. (See Materials and Methods for details.) With 
the vast number of potential variables, we will next resort to directed evolution to 
generate a viable synthetase. 
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For the second goal of expanding AaT substrate scope to β-thiol analogs, we will 
utilize directed evolution and computational design to evolve an appropriate AaT mutant. 
In wildtype AaT, there are tight van der Waals contacts between the β-carbon of the 
substrate and nearby residues, precluding the incorporation of β-branched substrates. 
Rationally designed mutations have been attempted by other members in our group, but 
did not yield much success. Work is currently underway in our group to use a 
combination of surface display screening and in silico design to generate a mutant AaT 
for β-branched substrates. 
 
To expand the selection of N-terminal recognition residues, we can either mutate the 
AaT peptide recognition pocket or explore other transferases with different recognition 
properties. For E. coli AaT, the preference for N-terminal Arg or Lys is dictated by the 
presence of a negatively charged Glu156 residue in the peptide binding pocket, with the 
assistance of Tyr42, Tyr120 and Gln188 as hydrogen bonding partners
261
. Conceivably, 
these residues can be mutated through directed evolution to alter the steric and electro-
static selectivity of the binding pocket, thus expanding the scope of N-terminal residue 
recognition. Another option is to adopt other transferases – for example, arginyl trans-
ferase (ATE-1) in S. cerevisiae and H. sapiens recognizes an N-terminal Asp, Glu, and 
Cys, and then transfers an Arg onto the N-terminus of these proteins
299,300
. Using a 
similar minimal adenosine donor strategy, we can quickly characterize the substrate 
promiscuity of these enzymes, and if necessary, evolve them for our desired ligation 
handles. 
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4.5  Materials and Methods 
General Information    L-Selenocystine was purchased from Sigma-Aldrich (St. 
Louis, MO). 5′-O-(4,4′-Dimethoxytrityl) adenosine ((DMT)-A) was purchased as a 
custom order from ChemGenes Corporation (Wilmington, MA). Lysylalanylamino-
methylcoumarin (LysAlaAcm) was purchased from Bachem (Torrence, CA). The pEG6 
plasmid, containing His10-tagged E. coli AaT, was a gift from Alexander Varshavsky 
(California Institute of Technology). QuikChange® site-directed mutagenesis kits were 
purchased from Stratagene (La Jolla, CA). DNA oligomers were purchased from 
Integrated DNA Technologies (Coralville, IA). Bradford reagent assay kits were 
purchased from BioRAD (Hercules, CA). Amicon Ultra centrifugal filter units (3k Da 
MWCO) were purchased from EMD Millipore (Billerica, MA). All other reagents and 
solvents were purchased from Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. 
Louis, MO) unless otherwise specified.  
 
High resolution electrospray ionization mass spectra (ESI-HRMS) were collected 
with a Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA). 
Low resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on a 
Waters Acquity Ultra Performance LC connected to a single quadrupole detector (SQD) 
mass spectrometer. Nuclear magnetic resonance (NMR) spectra were obtained on a 
Bruker DRX 500 MHz instrument (Billerica, MA). UV-Vis absorption spectra were 
acquired on a Hewlett-Packard 8452A diode array spectrophotometer (Agilent Techno-
logies, Santa Clara, CA). Matrix assisted laser desorption/ionization with time-of-flight 
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detector (MALDI-TOF) mass spectra were acquired on a Bruker Ultraflex III instrument 
(Billerica, MA). Analytical HPLC was performed on an Agilent 1100 Series HPLC 
system (Santa Clara, CA). Preparative HPLC was performed on a Varian Prostar HPLC 
system (Agilent Technologies, Santa Clara, CA). HPLC columns were purchased from 
W. R. Grace & Compnay (Columbia, MD). 
 
Synthesis of N,N’-di-Boc-L-Selenocystine (2)    2 was synthesized by Boc protect-
tion of L-selenocystine 1 as described in Chapter 3. 
 
Synthesis of Boc-Sec(S-tBu)-OH (3c)    Tetrahydrofuran (THF) and triethylamine 
(Et3N) were freshly degassed by the freeze-pump-thaw method. 2 (0.2072 g, 0.4 mmol, 1 
equiv) was dissolved in 6.5 mL of degassed THF, and then Et3N (541 μL, 4 mmol, 10 
equiv) and 2-methyl-2-propanethiol (tBuSH, 1.1 mL, 10 mmol, 25 equiv) were added. 
The reaction was allowed to proceed at room temperature under an argon atmosphere for 
4 h. Upon completion, the reaction mixture was concentrated by rotary evaporation. The 
residue was brought up in 10 mL of H2O, acidified with 1 mL of 3 M HCl, and then 
extracted with ethyl acetate (10 mL × 3). The organic layers were combined and concen-
trated by rotary evaporation, and then purified by flash chromatography in 5:5 ethyl 
acetate/petroleum ether with 0.1% acetic acid. A pale yellow crystalline solid was 
isolated as the final product (0.2523 g, 0.7 mmol, 91% yield). Rf = 0.25 in 5:5 ethyl 
acetate/ petroleum ether with 0.1% acetic acid. 
1
H-NMR (500 MHz, CDCl3): δ 11.16 (s, 
1H), 5.44 (d, J = 7.1 Hz, 1H), 4.64 (d, J = 3.7 Hz, 1H), 3.30 (dd, J = 11.9, 4.1 Hz, 1H), 
3.22 (dd, J = 12.1, 5.8 Hz, 1H), 1.44 (s, 9H), 1.34 (s, 9H). 
13
C-NMR (500 MHz, CDCl3): 
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δ 175.61, 155.69, 82.52, 53.78, 46.57, 34.39, 30.84, 28.61. ESI−-HRMS: calculated for 
C12H22NO4SSe
−: 356.0435; found [M − H]−: 356.0442. 
 
Synthesis of Boc-Sec(S-tBu)-OCH2CN (4c)    Tetrahydrofuran (THF) and diisopro-
pylethylamine (DIPEA) were freshly degassed by the freeze-pump-thaw method. 3c 
(0.2194 g, 0.64 mmol, 1 equiv) was dissolved in degassed THF (7.7 mL), and chilled to  
0 ˚C on ice. DIPEA (335 μL, 1.9 mmol, 3 equiv) was added, followed by ClCH2CN (2.0 
mL, 32 mmol, 50 equiv). The reaction was allowed to proceed on ice for 2 h, and then at 
room temperature overnight (≥ 12 hr) under an argon atmosphere. Upon completion, the 
reaction mixture was concentrated by rotary evaporation, and then purified by flash 
chromatography in 5:5 ethyl acetate/petroleum ether. The reactant was recovered in 5:5 
ethyl acetate/petroleum ether with 0.1% acetic acid, and then subject to two additional 
rounds of ClCH2CN activation. A pale yellow solid was isolated as the product (0.1396 g, 
0.35 mmol, 57% yield).  Rf = 0.74 in 5:5 ethyl acetate/ petroleum ether. 
1
H-NMR (500 
MHz, CDCl3): δ 5.39 (d, J = 6.9 Hz, 1H), 4.79 (s, 2H), 4.72 (dd, J = 12.4, 5.7 Hz, 1H), 
3.24 (dd, J = 13.2, 4.8 Hz, 1H), 3.20 (dd, J = 13.4, 5.7 Hz, 1H), 1.45 (s, 9H), 1.36 (s, 9H). 
13
C-NMR (500 MHz, CDCl3): δ 170.04, 155.29, 114.15, 81.01, 53.53, 49.48, 47.00, 
33.55, 30.83, 28.59. ESI
+
-HRMS: calculated for C14H24N2O4SSeNa
+
: 419.0520; found 
[M + Na]
+
: 419.0519. 
 
Synthesis of Boc-Sec(S-tBu)-(5’-O-DMT)Adenosine (5c)    Tetrahydrofuran (THF) 
was freshly degassed by the freeze-pump-thaw method. 4c (0.1396 g, 0.35 mmol, 2 
equiv) was dissolved in THF (4 mL). 5′-O-(4,4′-Dimethoxytrityl) adenosine (0.1006 g, 
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0.18 mmol, 1 equiv) was added, followed by catalytic amount of tetrabutylammonium 
acetate (0.0027 g, 9 µmol, 0.05 equiv). The reaction was allowed to proceed overnight (≥ 
12 h) under an argon atmosphere. Upon completion, the reaction was concentrated by 
rotary evaporation, and then purified by flash chromatography in 1:19 methanol/ethyl 
acetate. A white foam was isolated as the final product (0.1029 g, 0.11 mmol, 65% yield). 
Rf = 0.42 in 1:19 methanol/ethyl acetate. 
1
H-NMR and 
13
C-NMR sepctra (500 MHz, d
8
-
THF) are shown below (Figure 4-10). ESI
+
-HRMS: calculated for C43H53N6O9SSe
+
: 
909.2760; found [M + H]
+
: 909.2767. 
 
Synthesis of H-Sec(S-tBu)-Ade (6c)    Tetrahydrofuran (THF), CH2Cl2 and H2O 
were freshly degassed by the freeze-pump-thaw method. 5c (0.0200 g, 22 μmol, 1 equiv) 
was dissolved in degassed THF (1 mL) and chilled to 0 °C on ice. Triisopropylsilane (23 
μL, 110 μmol, 5 equiv) was added, followed by tBuSH (205 μL, 2.2 mmol, 100 equiv). 
Trifluoroacetic acid (1 mL) was added dropwise, and then the reaction was allowed to 
proceed at room temperature for 2 h under an argon atmosphere. Upon completion, the 
reaction was dried by rotary evaporation. The residue was brought up in degassed CH2Cl2 
(1 mL), and then extracted with degassed H2O (1 mL × 3) to recover the product. The 
crude was directly purified by reverse phase HPLC using a binary solvent system of 
water/acetonitrile with 0.1% trifluoroacetic acid (Table 4-1 through Table 4-3). 
 
Synthesis of Other H-Sec(SR)-Ade Donors (6a-e)   All other adenosine donors were 
derivatized from 6c through thiol exchange: H2O was freshly degassed by the freeze- 
pump-thaw method. 6c (0.0056 g, 11 µmol, 1 equiv) was dissolved in 1 mL of degassed  
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Figure 4-10.  
1
H and 
13
C NMR Characterization of Boc-Sec(S-tBu)-(5’-O-DMT)Ade (5c) 
1
H-NMR 
13
C-NMR 
168 
 
H2O. 100 µL of an appropriate thiol (ethanethiol for 6a; 2-propanethiol for 6b; thio-
phenol for 6d; benzyl mercaptan for 6e) was added, and the reaction was allowed to 
proceed at room temperature for 2 h under an argon atmosphere. Upon completion, 
excess thiol was evaporated by a stream of argon. The aqueous crude was directly 
injected onto reverse phase HPLC for purification (Table 4-1 through Table 4-3). 
 
 
Figure 4-11.  iPrSH Exchange with or without Intermediate Purification. 
HPLC analysis of crude reaction mixtures monitored at 260 nm on a YMC-Pack Pro C8 semi-
prep column using gradient 1.In one-pot deprotection/thiol exchange, 5c was deprotected, 
lyophilized, and then directly subject to thiol exchange without purification of 6c. 6b’ denotes 
the 2’-acylated isomer of 6b (see later sections); asterisk denotes the absence of 6c. 
 
We note that no major difference was observed when the thiol exchange reaction was 
conducted on either HPLC purified 6c, or crude 6c that had simply been lyophilized after 
6b 
6b 
6b’ 
6b’ 
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TFA deprotection of 5c (Figure 4-11). Therefore, all bulk preparations of the adenosine 
donors were performed in a one-pot manner without the intermediate HPLC purification 
step, both to simplify the process and to avoid material loss during purification. MALDI-
TOF MS and UV-Vis characterization of final products 6a-e are shown in Figure 4-12. 
 
 
Figure 4-12.  MALDI-TOF MS and UV-Vis Characterization of Adenosine Donor 6a-e. 
See Figure 4-7 for characterization of 6b, and Table 4-3 for a complete list of expected and 
observes m/z values. The integrity of selenium and adenosine can be clearly observed in all 
products. 6d and 6e showed additional absorption around 230 nm, which is characteristic for 
the side chain phenyl/benzyl substitution.  
 
Table 4-1.  Adenosine Donor Purification Methods and Retention Time.   
Compound Gradient 
Retention 
Time* 
Column 
H-Sec(S-Et)-Ade (6a) 1 16.2 / 18.2 min YMC-Pack Pro C8 Semi-prep 
H-Sec(S-iPr)-Ade (6b) 1 19.2 / 20.8 min YMC-Pack Pro C8 Semi-prep 
H-Sec(S-tBu)-Ade (6c) 1 21.1 / 23.4 min YMC-Pack Pro C8 Semi-prep 
H-Sec(S-Ph)-Ade (6d) 1 22.0 / 24.5 min YMC-Pack Pro C8 Semi-prep 
H-Sec(S-Bz)-Ade (6e) 1 22.7 / 25.0 min YMC-Pack Pro C8 Semi-prep 
    
* All adenosine donors are isolated as a mixture of interconverting 2’- and 3’-isomers. 
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Table 4-2.  HPLC Gradients for Purification and Characterization. 
No. 
Time 
(min) 
%B  No. 
Time 
(min) 
%B  No. 
Time 
(min) 
%B 
1 0:00 2  2 0:00 1  3 0:00 2 
 5:00 2   5:00 1   5:00 2 
 10:00 10   10:00 30   25:00 20 
 30:00 30   15:00 40   30:00 100 
 35:00 100   20:00 100   35:00 100 
 40:00 100   25:00 100   45:00 2 
 45:00 2   27:00 1     
     30:00 1     
           
* Solvent A: 0.1% trifluoroacetic acid in water;  Solvent B: 0.1% trifluoroacetic acid in acetonitrile 
 
Table 4-3.  MALDI-TOF MS Characterization of Purified Adenosine Donors. 
Compound 
[M + H]
+
 [M + Na]
+
 
Calculated Found Calculated Found 
H-Sec(S-Et)-Ade (6a) 479.05 479.02 501.04 500.98 
H-Sec(S-iPr)-Ade (6b) 493.07 492.95 515.06 514.91 
H-Sec(S-tBu)-Ade (6c) 507.09 507.12 529.08 529.09 
H-Sec(S-Ph)-Ade (6d) 527.05 527.12 - - 
H-Sec(S-Bz)-Ade (6e) 541.07 541.05 563.06 563.05 
     
 
 
Characterization of 2’- and 3’-Isomers of Adenosine Donors    As noted in our 
previous work
268, all adenosine donors were isolated as a mixture of 2’- and 3’-acylated 
isomers. To ascertain this observation in our hemiselenide protected Sec donors, we 
isolated the early and late peaks (assigned as 2’- and 3’-isomers based on the known 
thermodynamic preference for 3'-acylation of adenosine
301
) of H-Sec(S-iPr)-Ade, re-
injected them separately, and observed interconversion of the two species (Figure 4-13). 
Since these two isomers co-exist in rapid equilibrium, we reasoned that it would be 
unnecessary to obtain one pure isomer − as the 3’-isomer is consumed by AaT in chemo-
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enzymatic reaction, the 2’-isomer will convert into the 3’-isomer by equilibrating, thus 
supplementing substrates for the reaction. 
 
 
Figure 4-13.  Interconversion of 2’- and 3’-Isomers of H-Sec(S-iPr)-Ade 6b. 
Early peak (assigned as 6b’) and late peak (assigned as 6b) were isolated, brought up in 
H2O, and re-injected onto reverse phase HPLC. Chromotogram monitored at 260 nm on a 
Jupiter C18 analytical column using gradient 1. In both cases, the interconversion rapidly 
reached thermodynamic equilibrium of 1:3 6b’/6b under ambient conditions. MALDI-TOF MS: 
[6b + H]
+
, expected 493.07, found 493.06; [6b’ + H]
+
, expected 493.07, found 493.05. 
 
Versatility of Thiol Exchange on Hemiselenides    To demonstrate the versatility of 
the thiol exchange reaction in derivatizing hemiselenides, we performed thiol exchange 
on H-Sec(S-tBu)-Ade 6c and H-Sec(S-Bz)-Ade 6e, and showed that the two species could 
be interconverted simply by adding different thiols in excess (Figure 4-14).  
6b 
6b’ 
6b 
6b’ 
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Figure 4-14.  Interconversion of Adenosine Analogs as Driven by Excess of Different Thiols. 
6c was readily converted into 6e by treatment with excess BzSH; vice versa, 6e could be 
generated from 6c by treatment with excess tBuSH. HPLC chromatograms of crude reaction 
mixtures monitored at 260 nm on a YMC-Pack Pro C8 semi-prep column using gradient 1. 
MALDI-TOF MS: [6c + H]
+
, expected 507.12, found 507.08; [6e + H]
+
, expected 541.05, 
found 541.07. Star signs indicate the absence of the original adenosine donor added. 
 
Expression and Purification of E. coli Aminoacyl Transferase (AaT)    His10-
tagged E. coli amino acyl transferase (AaT) was expressed from a pEG6 plasmid (ampi-
cillin resistant) in E. coli BL21-Gold (DE3) cells using a procedure adapted from Graciet 
et al.
302
 In particular, no β-mercaptoethanol (BME) was used in our purification, to avoid 
complications with the hemiselenide side chains. For protein expression, E. coli BL21-
Gold (DE3) cells were transformed with the plasmid, and selected on an LB plate in the 
presence of ampicillin (Amp, 100 μg/mL) by overnight growth at 37 °C. 5 mL LB media 
was inoculated with a single colony, and then grown at 37 °C in the presence of Amp 
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(100 μg/mL) until OD600 ≥ 0.5. The primary culture was diluted into 1 L of LB media 
with Amp (100 mg/L), and grown at 37 °C until OD600 = 0.6. 100 mg of isopropyl β-D-
thiogalactoside (IPTG, 0.1 mM final concentration) was added to induced AaT expre-
ssion, and then the cells were grown at 25 °C for another 16 ~ 18 h.  
 
For purification, cells were harvested at 6,000 rpm using a GS3 rotor on a Sorvall 
RC-5 centrifuge. Cell pellets were resuspended in Ni-NTA binding buffer (50 mM Tris, 
10 mM imidazole, 300 mM KCl, pH 8.0 with protease inhibitor cocktail, 1 mM phenyl-
methanesulfonyl fluoride and 10 units/mL DNAse1–Grade II), and then lysed by soni-
cation. The crude was centrifuged at 13,200 rpm for 15 min, and then supernatant was 
recovered and incubated with Ni-NTA resin for 1 h on ice with gentle shaking. The resin 
was collected by filtration, rinsed with 4 volumes of wash buffer (50 mM Tris, 50 mM 
imidazole, 300 mM KCl, pH 8.0), and then eluted with 8 volumes of elution buffer (50 
mM Tris, 250 mM imidazole, 300 mM KCl, pH 8.0). Pure fractions of AaT were 
identified by SDS-PAGE, and then collected and dialyzed into a storage buffer (50 mM 
Tris, 30 % glycerol, 120 mM (NH4)2SO4, pH 8.0) at 4 °C overnight. After concentration 
determination by Bradford assay
303
, the purified enzymes were stored at -80 °C until use. 
 
AaT Activity Assay for Adenosine Donor Screening    H2O, acetone, a 10x buffer 
stock (500 mM Tris, 1.5 M KCl, 100 mM MgCl2, pH 8.0), and a LysAlaAcm 7 stock (10 
mM in water) were freshly degassed by the freeze-pump-thaw method. Sec adenosine 
donor was brought up in degassed H2O, and adjusted to 10 mM based on UV-Vis absor-
ption (ε260 = 15,400 M
-1
 cm
-1
). Under an argon atmosphere, H2O (41.6 µL), buffer stock 
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(6.25 µL), LysAlaAcm stock (0.625 µL) and Sec adenosine donor stock (6.25 µL) were 
thoroughly mixed, and then AaT (7.81 µL, 0.8 mg/mL) was added to initiate the reaction. 
The reaction was allowed to proceed at 37 ˚C for 4 h under an argon atmosphere. Upon 
completion, the reaction was quenched with 1% acetic acid in degassed H2O (187.5 μL). 
Degassed acetone (1 mL) was added, and then the mixture was kept at -20 °C for 1 h to 
precipitate the enzyme. Supernatant was recovered after centrifugation at 13,200 rpm and 
4 ˚C for 20 min, and then excess acetone was removed by rotary evaporation. The residue 
was diluted into degassed H2O (800 μL), and then analyzed by reverse phase HPLC on a 
Jupiter C18 analytical column using gradient 2.  
 
For quantification, peak identities were assigned based on MALDI-TOF MS (Table 
4-4), and then transfer efficiencies were calculated from peak areas monitored at 325 nm. 
For each adenosine donor, the transfer efficiency was reported as the average value with 
standard deviation from three independent trials. 
 
Table 4-4.  Retention Time and MALDI-TOF MS Characterization of LysAlaAcm Peptides. 
Peptide 
Retention 
Time 
[M + H]
+
 [M + Na]
+
 
Calc’d Found Calc’d Found 
LysAlaAcm (7) 11.1 min 375.20 375.29 397.19  
Sec(S-Et)-LysAlaAcm (8a) 12.6 min 586.16 586.38 - - 
Sec(S-iPr)-LysAlaAcm (8b) 13.1 min 600.17 600.14 622.16 622.11 
Sec(S-tBu)-LysAlaAcm (8c) 13.2 min 614.18 614.13 636.17 636.10 
Sec(S-Ph)-LysAlaAcm (8d) 13.4 min 634.15 634.33 656.14 656.23 
Sec(S-Bz)-LysAlaAcm (8e) 13.3 min 648.17 648.48 - - 
Phe-LysAlaAcm (8h) 12.4 min 522.26 522.33 544.25 544.31 
      
*  Retention time obtained on a Jupiter C18 analytical column using gradient 2. 
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Oxygen Tolerance    Reactions were conducted similarly as the standard procedure, 
except that non-degassed water and buffers were used (Figure 4-15). Transfer efficiencies 
were reported as the average value from three independent trials. 
 
 
Figure 4-15.  Oxygen Tolerance of Chemoenzymatic AaT Reaction with H-Sec(S-iPr)-Ade. 
 
Expression and Purification of αS6-140    Expression and purification were per-
formed by Anne M. Wagner as detailed in Angew. Chem. Int. Ed. 2013, 52, 6210-6213. 
Briefly, a pET-16b plasmid encoding for HisTag-αS6-140 was transformed into E. coli 
BL21 DE3 cells, and over-expressed with isopropyl-β-D-thiogalactopyranoside (IPTG) 
induction. After lysis of the cells, target protein was pulled down by Ni-NTA resin, and 
treated with Factor Xa to remove the HisTag. The protein was dialyzed into storage buffer 
(20 mM Tris, 150 mM KCl, 10 mM Mg2Cl2, pH 8.0), quantified by BCA assay (Pierce), 
and stored at -80 °C until use. 
 
AaT-Mediated Chemoenzymatic Transfer of Sec(S-iPr) onto αS6-140    H-Sec(S-
iPr)-Ade 6b was brought up in H2O, and adjusted to 10 mM based on UV-Vis absorption 
7 
8b 
7 
8b 
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(ε260 = 15,400 M
-1
 cm
-1
). H2O (35.2 µL), 10x reaction buffer (6.25 µL, 500 mM HEPES, 
1.5 M KCl, 100 M MgCl2, pH 8.0), αS6-140 stock (6.94 µL, 0.9 mg/mL) and 6b stock 
(6.25 µL) were thoroughly mixed. AaT stock (7.81 uL, 0.8 mg/mL) was added to initiate 
the reaction. The reaction was allowed to proceed at 37 ˚C for 4 h; an additional dose of 
6b stock (6.25 uL) was added each hour. Upon completion, the reaction was buffer-
exchanged into H2O using Amicon Ultra centrifugal filter units (3k Da MWCO). The 
resulting crude mixture was then directly analyzed by MALDI-TOF MS. 
 
Deselenization of Sec(S-iPr)-αS6-140    To confirm the presence of Sec, 50 µL of the 
above reaction crude was mixed with 150 µL of a TCEP stock (50 mM Tris, 20 mM 
TCEP, 10 mM DTT, pH 8.0). The reaction was allowed to proceed at 37 ˚C for 6 h under 
an argon atmosphere. Upon completion, the reaction was buffer-exchanged into H2O 
using Amicon Ultra centrifugal filter units (3k Da MWCO), and analyzed by MALDI-
TOF MS. TCEP = tris(2-carboxyethyl)phosphine; DTT = dithiothreitol. 
 
 
Figure 4-16.  Deselenization of Sec(S-iPr)-αS6-140 into Ala- αS6-140 11. 
MALDI-TOF MS: [11 + H]
+
, expected 13899.99, found 13893.67. 
 
Synthesis of H-Sec(S-iPr)-OH and H-Sec(S-Et)-OH (S1, S2)    Tetrahydrofuran 
(THF) was freshly degassed by the freeze-pump-thaw method. N,N’-di-Boc-L-seleno-
11 
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cystine 2 (0.0730 g, 0.14 mmol, 1 equiv) was dissolved in degassed THF (1.6 mL), and 
then ethanethiol (246 μL, 3.4 mmol, 25 equiv) or 2-propanethiol (316 μL, 3.4 mmol, 25 
equiv) was added to initiate the thiolysis. The reaction was allowed to proceed at room 
temperature for 4 h under an argon atmosphere. Upon completion, trifluoroacetic acid (2 
mL) was added dropwise to initiate the Boc deprotection. The reaction was allowed to 
proceed for 45 min under an argon atmosphere, and then the crude product was recovered 
by ether precipitation. The residue was brought up in 1:10 CH3CN/H2O, and then purified 
by reverse phase HPLC on a Vydac C8 semi-prep column using gradient 3. Retention 
time: 21.3 min for S1; 14.2 min for S2. ESI
+
-LRMS: calc’d for C6H14NO2SSe
+
 243.98, 
found [S1 + H]
+
 244.01; calc’d for C5H12NO2SSe
+
 229.97, found [S2 + H]
+
 230.02 
 
Expression and Purification of Synthetases    Expression and purification of His6-
tagged S. cerevisiae phenylalaninyl synthetase (PheRS) and E. coli leucyl synthetase 
(LeuRS, with a T252F mutation to block the editing site
304
) were conducted using a 
similar procedure as AaT expression and purification, except that different buffers were 
used. For PheRS: binding buffer, 50 mM Tris, 300 mM KCl, pH 8.0; wash buffer, 50 mM 
Tris, 20 mM imidazole, 300 mM KCl, pH 8.0; elution buffer, 50 mM Tris, 40 mM 
imidazole, 300 mM KCl, pH 8.0; storage buffer, 25 mM Tris, 50% glycerol, pH 7.6. For 
LeuRS: binding buffer, 50 mM Tris, 10 mM imidazole, 300 mM KCl, pH 8.0; wash 
buffer, 25 mM Tris, 20 mM imidazole, 300 mM KCl, pH 8.0; elution buffer, 50 mM Tris, 
100 mM imidazole, 300 mM KCl, pH 8.0; storage buffer, 50 mM Tris, 50% glycerol, pH 
7.6. E. coli methionine synthetase (MetRS) and its mutant MetRS L13G were expressed 
and purified by John B. Warner following literature precedence by the Tirrell group
264
. 
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Synthetase Activity Profiling in AaT-Mediate N-Terminal Modification    Synthe-
tase activities were tested in a fully enzymatic transfer assay using LysAlaAcm 7 as the 
model peptide and H-Sec(S-iPr)-OH S1 as the amino acid substrate; in the case of MetRS 
and its L13G mutant, H-Sec(S-Et)-OH S2 was also tested since it more closely resembles 
the natural substrate Met. For each synthetase/mutant, a positive control with its natural 
substrate and two negative controls (withholding amino acid or tRNA) were also included 
as reference points (Figure 4-17). For a typical assay: a 15 mM H-Sec(SR)-OH amino 
acid stock was freshly prepared from S1 or S2 in H2O. Milli-Q H2O (21.8 µL), 10x buffer 
stock (6.25 µL, 500 mM HEPES, 1.5 M KCl, 100 mM Mg2Cl, pH 8.0), LysAlaAcm 7 
stock (0.625 µL, 10 mM in H2O), Sec amino acid stock (4.17 µL) and ATP stock (3.13 
µL, 50 mM in H2O) were thoroughly mixed. tRNA (12.5 µL, 200 µM), AaT (7.81 µL, 
0.8 mg/mL) and synthetase (6.25 µL, 1 mg/mL) were then added to initiate the reaction. 
The reaction was allowed to proceed at 37 ˚C for 4 h under an argon atmosphere, and 
then worked up and analyzed similarly as the standard AaT assay. Unfortunately, none of 
the synthetases showed activity towards the H-Sec(SR)-OH amino acids tested. 
 
Rationally Designed LeuRS Mutants    Based on crystal structure
305
 and previous 
mutagenesis work by Schultz et al.
306
, we rationally designed five LeuRS mutants with 
various permutations of the amino acid binding pocket and tested them for activity in 
AaT-mediated N-terminal modification assays. Unfortunately, none of these mutants 
showed the desired activity. Mutants and primers are listed in Table 4-5 and Table 4-6. 
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Figure 4-17.  Synthetase (RS) Activity Profiling Assay using PheRS as an Example. 
A) Assay scheme. B) HPLC chromatograms monitored at 325 nm. MALDI-TOF MS: [7 + H]
+
, 
expected 375.20, found 375.20; [Phe-7 + H]
+
, expected 522.26, found 522.25. 
 
Table 4-5.  Rationally Designed LeuRS Mutants. 
Mutant M40 T252 Y499 Y527 H533 H537 Primers Used 
        
pWT - T252F - - - - - 
1 - T252F Y499S - - H537G 2, 4 
2 M40A T252F - - H533A H537G 1, 5 
3 - T252F - Y527T H533A H537G 3, 5 
4 - T252F Y499S Y527T H533A - 2, 3, 4 
5 - T252F Y499S Y527T H533A H537G 2, 3, 5 
*  A T252Y mutation was included in all mutants to block the editing site
304
.  
 
7 
7 
7 
Phe-7 
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Table 4-6.  Primers for LeuRS Mutagenesis. 
No. Mutation  Primer Sequence 
    
1 M40A Forward 5'- G AAG TAT TAC TGC CTG TCT GCG CTT CCC 
TAT CCT TCT GGT C -3' 
  Reverse 5'- G ACC AGA AGG ATA GGG AAG CGC AGA 
CAG GCA GTA ATA CTT C -3' 
2 Y499S Forward 5'- TTT ATG GAG TCC TCC TGG TCT TAT GCG 
CGC TAC ACT TGC -3' 
  Reverse 5'- GCA AGT GTA GCG CGC ATA AGA CCA GGA 
GGA CTC CAT AAA -3' 
3 Y527T Forward 5’-TAC TGG CTG CCG GTG GAT ATC ACC ATT 
GGT GGT ATT GAA-3’ 
  Reverse 5’-TTC AAT ACC ACC AAT GGT GAT ATC CAC 
CGG CAG CCA GTA-3’ 
4 H533/H537G Forward 5'- ATT GAA CAC GCC ATT ATG GGC CTG CTC 
TAC TTC CGC TTC -3' 
  Reverse 5'- GAA GCG GAA GTA GAG CAG GCC CAT AAT 
GGC GTG TTC AAT -3' 
5 H533A/H537G Forward 5'- C ATT GGT GGT ATT GAA GCG GCC ATT ATG 
GGC CTG CTC TAC TTC CGC -3' 
  Reverse 5'- GCG GAA GTA GAG CAG GCC CAT AAT GGC 
CGC TTC AAT ACC ACC AAT G -3' 
*  Desired mutations are highlighted in bold. 
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